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A growing number of therapeutic compounds currently being developed by 
pharmaceutical companies are poorly water soluble leading to limited and/or erratic 
bioavailability.  The rate limiting step for absorption of these compounds is dependent on 
the dissolution and apparent solubility.  Nanoparticle formation has been exploited as a 
method to improve the bioavailability of these poorly water soluble active pharmaceutical 
ingredients (API) by increasing the dissolution rates and apparent solubilities. 
The influence of hydrophilic stabilizers in powder compositions prepared by the 
spray freezing into liquid (SFL) process using either an emulsion feed dispersion or 
organic co-solvent feed solutions on enhancing the wetting and dissolution properties of 
nanostructured aggregates containing itraconazole (ITZ).  Subsequently, an in vivo 
pharmacokinetic study was conducted comparing the SFL processed powder to 
commercial Sporanox®. 
An ultra-rapid freezing (URF) technology has been developed to produce high 
surface area powders composed of solid solutions of an active pharmaceutical ingredient 
 ix
(API) and a polymer stabilizer. Rapid freezing technologies are known to enhance the 
physico-chemical properties of APIs and thus increase bioavailability.  However, the 
effect of the different freezing geometries and rates in the URF process are unknown.  
Therefore, this study investigated how solvent properties and thin film geometry of the 
droplet affect the freezing rate and thus the physico-chemical properties of micronized 
danazol powders. 
Amorphous nanoparticles containing tacrolimus (TAC) in a solid dispersion were 
prepared using the Ultra-rapid Freezing (URF) process.  The objective of this study was 
to assess the effects of combinations of polymeric stabilizers on the maximum degree and 
extent of supersaturation of TAC.  An attempt to establish if an in vitro-in vivo 
correlation exists between supersaturation and improved pharmacokinetic parameters for 
orally dosed TAC was performed. 
Enteric solid dispersions could overcome limitations of premature precipitation of 
supersaturated solutions by 1.) delaying dissolution until the compound enters the 
intestines where absorption is favored and 2.) increasing the apparent solubility at higher 
pH to increase the driving force for absorption.  The objective of the study is to 
investigate the influence of composition parameters including drug:polymer ratio and 
polymer type, and particle structure of enteric solid dispersions on the release of ITZ. 
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Chapter 1:  Advances in Drug Delivery Technologies for 
Nanoparticulates 
 
1.1  ABSTRACT 
 
A growing number of therapeutic compounds currently being developed by 
pharmaceutical companies are poorly water soluble leading to limited and/or erratic 
bioavailability.  Nanoparticle formation has been exploited as a method to improve the 
bioavailability of these poorly water soluble active pharmaceutical ingredients (API).  
Two strategies have been proposed for formation of nanoparticles, particle reduction and 
particle nucleation and stabilization.  Particle reduction technologies include milling and 
homogenization, while nucleation and stabilization technologies include solvent 
evaporation, rapid freezing, and antisolvent technologies.  Both strategies have the ability 
to enhance dissolution of the API leading to increased bioavailability.   Examples of 
nanoparticle compositions have shown enhanced uptake across biological membranes 
due to their small size.  Surface modification of nanoparticles has also proven beneficial 
by allowing for site specific targeting, increasing residence time, and protecting against 
degradation.  Examples using these nanoparticle technologies introduced within this 
chapter focus on oral and pulmonary delivery of the API.
 2
1.2  INTRODUCTION 
 
 Recent advances in synthesis and purification in the areas of medicinal and 
organic chemistry have brought about a number of new chemical entities (NCE) which 
hold promise in treating many of today’s diseases and disorders.  However, a large 
number of these NCEs display poor in vivo solubility (poorly water soluble) resulting in 
poor absorption and limited and/or erratic bioavailability.  Therefore, many of these 
NCEs are never pursued by the pharmaceutical industry and subsequently developed into 
commercial products.  Also, poorly water soluble active pharmaceutical ingredients 
(APIs) used to treat oncology patients may include solubilizing excipients which possess 
harmful side effects leading to patient non-compliance.[1, 2]  It is desired that 
nanoparticulate systems reduce variability and increase bioavailability of poorly water 
soluble APIs through enhanced absorption due to improved wetting and dissolution.   
 Hydrophobic APIs are not the only compounds which benefit from delivery as 
nanoparticulate systems.  Oral delivery of proteins, peptides, and nucleic acids has 
proven exceedingly difficult.  While being water soluble, these compounds are 
susceptible to denaturation post-administration when exposed to low pH and gastric 
enzymes.[3]  Most proteins have poor absorption across the intestinal barrier as well and 
therefore, micro- and nanoparticulate carrier systems could help increase absorption of 
these compounds.[4]  
 Nanotechnology has been employed in non-pharmaceutically related areas such as 
microchip manufacturing, and it is reported that products resulting from these 
technologies display enhanced properties such as ultradense integrated circuits and faster 
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processing speeds [5] compared to their larger counterparts.  Only recently has the 
pharmaceutical industry applied nanotechnology as a viable method for improving drug 
delivery for NCEs and non-optimized drug products.  Traditionally, nanoparticles have 
been defined as particles or structures no larger than 100 nm in diameter; however, it is 
common to see in the pharmaceutical literature the term ‘nanoparticle’ used to describe 
particles no greater than one micron in diameter.[6] 
Within the fast evolving discipline of pharmaceutical drug delivery and 
formulation research, the use of nanoparticle technologies is still in its infancy but recent 
examples of nanotechnology have shown particular promise as a method to increase the 
bioavailability of poorly water soluble APIs.  Development for these APIs in the form of 
nanoparticles, providing viable alternatives to more routine development strategies, 
including using a prodrug, salt form, or metastable drug form in order to increase 
bioavailability, has been made possible through advances in analytical characterization of 
nano-sized particles.  Specifically, microscopic techniques including scanning electron 
microscopy (SEM), transmission electron microscopy (TEM), tunneling force 
microscopy, atomic force microscopy (AFM), and particle sizing techniques including 
dynamic and laser light scattering, have allowed scientists to have a greater 
understanding of the physico-chemical properties of nanoparticles.  Z-contrast TEM or 
STEM dark-field imaging has enabled scientists to determine API domain locations 
within an excipient matrix by detecting differences in compositional changes and 
thicknesses within the sample.[7]  Advances in AFM now permit scientists to understand 
differences in surface modification of nanoparticles at near atomic levels, while at the 
same time being able to view the surfaces of the particles in 3-dimension (3-D).  Equally 
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important, researchers can now measure particle sizes down to 20 nm accurately using 
laser light scattering.[8]  Even with the increased understanding of the physical properties 
of nanoparticles, the scientific community is only now beginning to understand how these 
nanoparticles are leading to improved bioavailability and efficacy of NCEs in vivo.   
This chapter will review recently reported nanoparticle technologies and discuss 
important physical properties inherent to nanoparticles.  We will discuss the relationship 
between these properties and in vivo performance, focusing on the influence of particle 
size on uptake as a function of various routes of administration.  Finally, we will review 
the impact that surface modifications of nanoparticles have on absorption enhancement. 
1.3  NANOPARTICLE TECHNOLOGIES 
 
 Nanoparticle formation can be described by two general strategies, particle 
reduction or particle nucleation and stabilization.  For the particle reduction strategy, 
large API particles are fractured into smaller particles using a variety of processes and 
equipment.  These nanoparticles are generally stabilized using various polymers and 
surfactants which can modify the surface charge of the particle preventing aggregation 
caused by electrostatic forces.  Secondly, nanoparticles may also be formed by particle 
nucleation from solution in which the API, with or without stabilizing agents, is 
dissolved.  Particle growth is arrested using stabilizing polymers or surfactants, and 
controlled by manipulating process parameters in order to obtain particles within a 
desired size range.  This section will review recently reported strategies of nanoparticle 
formation. 
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1.3.1  Particle reduction 
1.3.1.1  Milling processes 
 
 Dry powder milling processes such as ball milling or hammer milling are able to 
reduce particle sizes of powders down to about 1 micron in diameter through particle-
substrate and particle-particle collisions.  Further particle size reduction is restricted due 
to electrostatic forces generated during the milling process which can cause aggregation 
of the particles.  Additional processing of the powder, such as blending, can become 
difficult if this occurs.  In addition, the high energy required to break up the API particles 
generates excessive amounts of heat which can lead to thermal degradation of the API.  
To overcome these limitations, a wet milling process (Nanocrystal® technology) is 
reported to form uniform nanoparticles by milling the API particles in an aqueous 
polymer medium.[9]  The milling takes place under controlled temperatures thereby 
reducing or eliminating thermal degradation due to friction.  This technology is generally 
operated in a batch or recirculation mode and takes as little as 30-60 minutes to form 
crystalline nanoparticles measuring < 200 nm in diameter.[9]   
1.3.1.2  Homogenization 
 
 High pressure homogenization is also a convenient process for reducing the 
particle size of API particles.  Typically, API suspensions can be homogenized into the 
nanometer range using a piston-gap high pressure homogenizer (HPH).  The 
homogenizer consists of a pumping mechanism which moves the fluid through a narrow 
gap consisting of a valve seat and an adjustable valve.  Briefly, the API is pre-wetted as a 
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course suspension using a rotor/stator mixer before being transferred to the HPH.  As the 
fluid is forced through the gap of the HPH, cavitation, high shear forces, and particle-
particle collisions reduce the size of the particles with each pass through the gap.  Particle 
size is controlled primarily by controlling the operating pressure (5,000-20,000 psi) and 
the number of passes (1-10 cycles) through the gap. Processed particle suspensions 
described as Disso Cubes® can undergo further processing by spray drying or 
lyophilization to form fine powders.[10] 
1.3.2  Particle nucleation and stabilization 
 
Precipitation technologies include methods in which particles are nucleated from 
a solution and particle growth is inhibited and controlled through the use of stabilizing 
polymers.[11-13].  Precipitation of API from a solution occurs when there is an increase 
in concentration above the solubility limit (e.g. supersaturation) or a decrease in solubility 
of the solute within the solvent.  When the change in solvent strength is rapid, 
supersaturation can occur leading to an increase in homogeneous nucleation rate.[14]  
Changes in solvation strength can happen through solvent evaporation, rapid freezing, or 
addition of anti-solvents.  Solvent evaporation is done through addition of heat or 
pressure reduction, while freezing is done using some type of cryogen.  Anti-solvents 
have poor API solubility but must be miscible with the solvent in which the API is 
dissolved.  Once precipitation has been initiated, particle growth proceeds by coagulation 
and/or condensation.  Coagulation results when two particles collide forming one larger 
particle, while condensation takes place as dissolved solute adsorbs to a solid particle 
causing increased growth.  The design of the particle engineering technology can have a 
 7
tremendous impact on nucleation and subsequent growth mechanisms leading to particle 
formation, which then influences the resulting physico-chemical properties of the 
powders.  The following technologies have been generally described based on their 
mechanism of particle formation: solvent evaporation, rapid freezing, or anti-solvent 
precipitation. 
1.3.2.1  Solvent evaporation 
 
Solvent evaporation from solution 
Spray-drying is one of the most common particle engineering processes due to its 
economic feasibility and scalability.  The process comprises atomizing a solution 
(organic or aqueous) containing the API of choice and stabilizing polymers.  The 
atomized cloud is then pulled downstream via vacuum into a heated zone.  The high 
surface area droplets enhance evaporation of the solvent leaving dry particles.  These 
dried particles are then collected using a cyclonic chamber.  Particle size and distribution 
is primarily dependent on the droplet size exiting the atomizing nozzle.  Therefore, 
nozzles which give a more uniform droplet size distribution, such as ultrasonic nozzles, 
will lead to particles with a narrow particle size distribution.  Solvent choice, solids 
loading and drying rate also contribute to the resulting surface morphology of the 
particles.[15] 
Aerosol flow reactors are similar to spray dryers and operate by atomizing an API 
solution via a collision-type air jet atomizer into an inert carrier gas which is passed 
through a heated tubular laminar flow chamber.  Critical parameters include the spray 
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nozzle (e.g. type, diameter), spray rate, droplet size, temperature of the chamber zones, 
solvent, and solids loading.[16]   Raula et al. reported that fast solvent removal rates lead 
to collapsed or hollow particles while poor solubility of the solute within the chosen 
solvent led to irregularly shaped particles.  Smooth, spherical nanoparticles were formed 
with a uniform particle size of about 100 nm using solvents with good API solubility and 
high evaporation rates sprayed at moderate drying temperatures (less than 120°C).[17]  
Collapsed particles resulted from high solvent evaporation rates at the surface causing a 
solid crust to encapsulate the particle preventing further outward diffusion of the solvent.  
The remaining solvent within the particle most likely ruptured through a defect or hole in 
the solidified surface and rapidly evaporated, leaving a hollow particle.  Solute/solids 
loading in the solvent also had an effect on the final surface morphology of the 
nanoparticles.[18]  Low API amounts resulted in homogeneous particles having broad 
glass transition patterns indicating miscibility while higher API loadings above the 
solubility limits of the API in the solvent resulted in crystallization of the API. 
Solvent evaporation processes such as evaporative precipitation into aqueous 
solution (EPAS) are designed to cause nucleation through the rapid removal of a 
solvent.[7, 19-24]  In EPAS, the API is dissolved in a water immiscible organic solvent 
such as dichloromethane.  Stabilizing polymers are then dissolved in the organic phase 
and/or aqueous phase.  The organic solution is then sprayed under pressure into the 
heated aqueous phase.  The pressure drop as the organic phase exits the nozzle causes 
atomization and the heat causes rapid evaporation of the organic solvent.  Properties of 
the particles can be controlled by varying a number of parameters such as stabilizing 
polymer choice, concentration, and/or location, spraying rate, and pressure drop. 
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Solvent evaporation of emulsion systems 
 One of the simplest methods to manufacture solid nanoparticles is through 
emulsification, and this topic has been reviewed extensively [25, 26].  Common 
emulsification methods such as high shear mixing with a rotor-stator mixer, high pressure 
homogenization, or sonication are used to prepare either oil-in-water (o/w) or water-in-oil 
(w/o) emulsions.  Emulsifying agents preferentially orient between the two phases at the 
interface of the droplet to prevent coalescence.  Generally, oils or water-immiscible 
organic solvents (i.e. dichloromethane) and water are the typical solvents.  The API is 
preferentially dissolved in the more soluble of the two phases (i.e. organic or oil phase for 
poorly water soluble APIs).  Particles are formed during evaporation of the solvents 
either through increased heat and/or reduced pressure depositing the API within the core 
or adsorbed onto the surface.  Mean particle size of the final particles is dependant on the 
droplet size of the internal phase and can range from nanoparticles to microparticles 
depending on the method of manufacture.  Creating multiple emulsions such as oil-in-
water-in-oil (o/w/o) or water-in-oil-in water (w/o/w) can lead to multiple layers allowing 
more flexibility and creativity in designing delivery systems according to the specific 
requirements of the clinical endpoint.  Nanoparticles loaded with antitubercular drugs 
(rifampicin, isoniazid and pyrazinamide) and encapsulated with poly (DL-lactide-co-
glycolide) (PLGA) were manufactured using a multiple emulsion system and 
administered via nebulization to guinea pigs.[27]   Compositions were tested for 
aerodynamic performance, in vivo disposition, and chemotherapeutic efficacy.  
Pharmacokinetic analysis revealed a 6- to 19-fold increase in absolute bioavailability and 
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a 12- to 32-fold increase in relative bioavailability.  For the chemotherapeutic efficacy 
studies, guinea pigs were inoculated with 1.5 × 105 viable bacilli of M. tuberculosis and 
allowed to incubate for 20 days.  One treatment group received once a day oral dosing for 
46 days while the other treatment group received every other day pulmonary dosing for 
10 days.  Control groups received no dosing or drug free PLG nanoparticles.  Studies 
revealed no tuberculosis bacilli after 30 days post-inoculation for either the oral and 
nebulized API nanoparticles while the control groups had high M. tuberculosis counts 
within the lungs demonstrating the ability of nanoparticles to both improve 
bioavailability and decrease dosing regimens.  
Fig. 1.1 shows a few of the many different carrier systems which have been 
developed using the emulsion evaporation technique to optimize drug delivery.  The API 
of choice can exist within the particle as a molecular solution or as a solid dispersion 
characterized by discrete API domains within the matrix.  In addition, the API can exist 
within the matrix core of the tablet or bead possibly encapsulated by a polymer coating.  
The API can also be adsorbed onto the surface of the core or within the polymer coating.  
Varying the design of the API carrier (API location, polymer choice, size, etc.) can result 
in immediate, delayed, or sustained release systems.  Rosca et al. [28] studied the 
evaporation step of multiple emulsions to determine the effect on surface morphologies 
of the final microparticle encapsulation efficiency and release behavior.  Results showed 
that lower encapsulation efficiency was attributed to fast solvent evaporation.  SEM 
pictures also revealed nanoparticles adsorbed to the surface of the microparticles 
contributing to the burst effect in the release profile.  Variations in double emulsion 
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composition can control the final microparticle morphology depending on the inner 
aqueous phase composition and the size of the emulsified droplet. 
 Emulsification allows for surface modification of the resulting particles which is 
useful for targeting to a specific site within the body, evading an immune response, or 
facilitating permeation through biological membranes.  The polymer used for surface 
modification must be biocompatible and functional for the intended purpose.  Examples 
of surface modified particles include PEGylated nanoparticles to evade immune 
responses, polyethyleneimine (PEI) and chitosan as gene carriers, and conjugated 
polyethylene glycol (PEG)-poly(lactide-co-glycolide) (PLGA) polymers for controlled 
API release.   
Lipid based nanoparticle carriers use a mixture of lipids, waxes, and surface 
active stabilizers rather than hydrophilic polymers.  Solid lipid nanoparticles (SLN), 
developed in the early 1990’s [29], are well tolerated by the body [30] and have been 
developed for parenteral, oral, topical, and pulmonary delivery [31, 32].  Therefore, this 
technology is useful for many lipophilic APIs which have low aqueous solubility and 
may induce toxic side effects.  The nanoparticles are prepared by either the hot 
homogenization technique or the cold homogenization technique [33].  In both 
techniques, the API is dissolved in the lipid which is heated just above its melting point.  
In the hot homogenization technique the lipid melt is dispersed into an aqueous surfactant 
solution heated to the same temperature, homogenized using a HPH and cooled to form 
the SLNs.  In the cold homogenization technique the lipid melt is cooled into 
microparticles, dispersed into a cold surfactant solution and homogenized forming the 
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SLNs.  Gasco [34] later developed a method for the preparation of SLNs by forming a 
microemulsion to further enhance absorption. 
  So called “stealth nanoparticles” are surface modified particles designed to 
escape clearance from the blood after intravenous injection.[35, 36]  Nanoparticles 
injected directly in the bloodstream are vulnerable to clearance by the reticulo-endothelial 
system (RES), often within minutes after injection.  Recognition of these particles by the 
RES is due in large part to the surface charge, hydrophobicity and size of the particles.  
Therefore, surface modification of these particles is critical to increase the circulation 
time of the particles.  Typically, these particles have been covalently grafted with a 
hydrophilic non-ionic polymer through the double emulsion (w/o/w) technique described 
above.  Examples of polymers include the polyethylene glycols (PEG), poloxamers, and 
polyvinylpyrrolidone (PVP).    
1.3.2.2  Rapid freezing to induce nucleation 
 
Freezing technologies such as Spray Freeze Drying (SFD) [37], Spray Freezing 
into Liquid (SFL) [38] and Ultra-rapid Freezing (URF) [39, 40] utilize a rapid freezing 
mechanism to form frozen nanoparticles which are then further processed to remove the 
frozen solvent yielding a dry powder.  Briefly, the API and various stabilizing/surface 
active excipients are dissolved in a common solvent.  This solution is then rapidly frozen 
either by spraying onto or directly into a cryogen.  If the freezing rate is sufficiently fast, 
phase separation between the API and stabilizing agents is prevented creating frozen 
molecularly dispersed nanoparticles.  Removal of the frozen solvent then follows, 
yielding high surface area nanoparticles of API in the matrix.  In the SFL process, an 
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API/polymer feed solution is atomized through an insulating poly ether-ether ketone 
(PEEK) nozzle submerged directly into a cryogenic liquid (liquid N2).  The fine droplets 
produced as the solution exits the nozzle ensures rapid freezing of the API in the 
amorphous state.[12, 41-48]  The frozen particles are collected and lyophilized in a 
temperature controlled tray lyophilizer yielding highly porous nano-structured amorphous 
powders.  High potency (> 90% API) compositions with sufficient stabilization are 
possible to further reduce possible excipient side effects.[49]   
1.3.2.3  Anti-solvent precipitation 
 
Anti-solvent precipitation using supercritical fluids 
Precipitation technologies which utilize supercritical fluids to form micro- and 
nano-particles have existed commercially for over 30 years with the most common 
supercritical fluid being supercritical carbon dioxide (CO2) due to its lack of toxicity, low 
critical temperature (31.1°C), and inexpensive cost.[50]  Within these technologies, the 
supercritical fluid is used either as the solvent for the API and stabilizing polymers or as a 
non-solvent/anti-solvent.  In processes such as Rapid Expansion of Supercritical 
Solutions (RESS), the API and excipients are dissolved in supercritical CO2, followed by 
rapid expansion of the solution through a nozzle.[51]  The API becomes supersaturated 
resulting in homogeneous nucleation and particle formation.  Physical processing 
parameters such as pressure and temperature of the precipitator and nozzle size can 
control the properties of the particles.  However, solubility of the solutes within the 
supercritical fluids is the major limiting factor for this technology.  On the other hand, 
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many technologies (i.e. Gas Antisolvent (GAS), Precipitation with Compressed 
Antisolvent (PCA)) have utilized the poor solvent capability of supercritical fluids as 
non-solvents or anti-solvents.[52, 53]  In these processes, the API solution containing a 
solvent miscible with the supercritical fluid is sprayed via a nozzle into the supercritical 
fluid.  Mass transfer of the supercritical fluid into the droplet causes precipitation and 
nucleation of the particles.  Solution Enhanced Dispersion by Supercritical Fluids (SEDS) 
utilizes a coaxial nozzle design and mixing chamber.  This design facilitates increased 
atomization (smaller droplets) and faster mass transfer rates resulting in faster 
precipitation rates of the particles and smaller particle sizes.  Surface coating and 
encapsulation has also been studied using these supercritical fluid technologies.  
Generally, particles are formed using the supercritical fluid processes as described above.  
The coating material or polymer is then sprayed into the particle dispersion using the 
same process and adsorbed to the surface of the newly formed particles.[54]  Tsutsumi et 
al. [55] coated RESS processed powders using a fluidized bed coater but had limited 
success coating nanoparticles which tended to agglomerate during the coating process. 
 
Anti-solvent precipitation using non-supercritical solvents 
Anti-solvent technologies utilize organic or aqueous solvents as anti-solvents to 
initiate nucleation through a rapid decrease in solvent power.  Generally, the API is 
dissolved in a water miscible organic solvent such as ethanol or acetone.  The solution is 
then added rapidly to water causing nucleation.  Stabilizing polymers can be dissolved in 
one or both phases.  The organic solvent is then removed through evaporation leaving the 
nanoparticles dispersed in the aqueous phase.  Dry powder can be made by further 
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removal of the water using lyophilization or spray drying.  Rasenack and Müller 
developed an in situ micronization technique to form nanoparticles.[56]  Briefly, the API 
is dissolved in a water-miscible organic solvent while the stabilizing agents are dissolved 
in water.  The two phases are then mixed “batch-wise” forming a dispersion of 
nanoparticles.  Subsequent studies have focused on pulmonary delivery of these enhanced 
powders [57, 58].using a dry powder inhaler (DPI).   
The anti-solvent technology, Flash NanoPrecipitation was reported recently.[59-
61]  This process comprises mixing a solvent phase composed of the API and stabilizers 
(amphiphilic block copolymers) and an aqueous anti-solvent phase via a confined 
impinging jet (CIJ) mixer.  The CIJ mixers result in rapid mixing of the two phases 
leading to supersaturation of the API inducing nucleation and minimizing particle 
growth.[62]  Additionally, the concentration of the API and the copolymer type and 
loading profoundly impact nucleation and growth kinetics which affects the resulting 
particle size.  If mixing times are sufficiently fast (Damköhler number, Da, ≤ 1), 
homogenous kinetics occur where particle size is no longer a function of jet velocity 
allowing for a more robust operation and precise particle size distribution.  Using β-
carotene and polystyrene(10)-b-poly(ethyleneoxide)(68), Johnson was able to produce 
uniform nanoparticles measuring 83 nm in diameter.[63] 
The controlled precipitation technology [64] reported by Rogers et al. is a process 
capable of forming crystalline nanoparticles of poorly water soluble APIs with enhanced 
dissolution rates.  The process consists of dissolving the API and stabilizer(s) in a water-
miscible organic solvent.  The organic phase is then added to an aqueous mixing zone 
where a decrease in solvent power causes rapid precipitation of the API which is then 
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immediately stabilized by dissolved stabilizers.  The remaining organic solvent is then 
evaporated leaving an aqueous slurry which can be dried further through conventional 
methods (e.g. lyophilization, spray drying, etc). 
Microemulsions and mini-emulsions differ from coarse emulsions based on size 
and method of polymerization [65, 66], and are thermodynamically stable systems.  
Creation of a microemulsion requires that an emulsion (o/w) be formed in the presence of 
a co-surfactant.  In the correct ratios as determined by a ternary phase diagram, a 
transparent, thermodynamically stable system is formed.  Common co-surfactants include 
lecithin, bile salts, sodium lauryl sulfate, and waxy alcohols such as cetyl alcohol.   
Further addition of water under mild agitation causes spontaneous precipitation of API 
nanoparticles.  The microemulsion template technology developed by Mumper et al. 
utilizes microemulsions as a template for the formation of nanoparticles.  The particle 
size is dependent on the internal droplet size of the microemulsion and since formation of 
microemulsions leads to a uniform particle size distribution, the resulting nanoparticles 
are very uniform.  Precipitation of the nanoparticles by this technology occurs by cooling 
rather than dilution to spontaneously form API loaded nanoparticles.  Dilution to induce 
precipitation lowers the API concentration resulting in larger final volumes which then 
must subsequently be administered to the patient.  Oyewumi et al. further developed the 
microemulsion template technology to form surface modified nanoparticles for delivery 
of APIs specifically across the blood brain barrier (BBB).[67, 68]  Successful permeation 
across the BBB was found to be dependent on surface polymer selection and the 
accompanying surface charge [69] 
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1.4  DESIRABLE ATTRIBUTES OF NANOPARTICLES – IN VITRO 
 
 It is hypothesized that enhancing the in vitro properties of poorly water soluble 
APIs through the processes described above allows for more favorable absorption in vivo. 
Most important of these is the increase in API dissolution as a result of increased surface 
area (decreased particle size).  Biopharmaceutical Classification System (BCS) Class II 
drugs are poorly water soluble but highly permeable across biological membranes.[70]  
Therefore, the rate limiting step to API absorption is hypothesized to be dissolution of the 
API.  Increasing dissolution rates through decreasing particle size can have a profound 
effect on increasing the bioavailability of this class of APIs.  Many nanoparticle 
engineering technologies also have the ability to design particles through surface 
modification which can render the particle ‘invisible’ to the bodies natural defenses.  
Modification of the surface can also enhance dissolution by creating hydrophilic surfaces 
which interact with water more easily. 
 Due to their small size, interactions between the nanoparticles and their 
surroundings are also different than those of larger particles.  For example, nanoparticles 
are influenced much more by Brownian motion which can enhance stabilization of 
nanoparticle suspensions.  
1.4.1  Dissolution enhancement 
 
 The dissolution rate of a particle is described by the Noyes-Whitney equation (Eq. 
1), which mathematically describes the in vitro dissolution rate of an API, and reveals the 
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Where dC/dt is the rate of dissolution, A is the surface area of the particle, D is the 
diffusion coefficient, Cs is the apparent solubility of the API in the dissolution medium, C 
is the solubility of the API at time t, and h is the diffusion boundary layer.  (Cs-C) 
becomes the concentration driving force for dissolution and can be neglected if the 
dissolution occurs under sink conditions (e.g. volume of medium at least greater than 
three times that required to form a saturated solution of the API).[71]  Therefore, the 
dissolution rate is directly proportional to the particle size or surface area of the API.  
Using conventional rotor/stator milling followed by HPH and spray drying, Hecq et al. 
[72] manufactured high potency nifedipine/hydroxypropyl methylcellulose nanoparticles 
with a mean particle size of 291 nm before spray drying.  After spray drying the particles 
were 3.7 microns due to agglomeration during the process.  As seen in Fig. 1.2 the spray 
dried particles have enhanced dissolution with 70% dissolved after 20 minutes and 
complete dissolution after 2 hours.  Inclusion of mannitol in the composition helped 
prevent agglomeration during the spray drying process (339 nm after spray drying) and 
led to complete dissolution within 10 minutes.  The physical mixture of the same 
composition had a mean particle size of 98.7 microns and after 2 hours less than 10% had 
dissolved.      
 Reducing the particle size can also increase the solubility of the API according to 
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Where r is the particle radius, υ is the molar volume, ρ is the density, γ is the interfacial 
tension, and S is the solubility at temperature T.  So is the solubility on a flat, solid sheet, 
M is the molecular weight of the solid, and R is the ideal gas constant.  However, 
increases in solubility due to particle size reduction are negligible until particle size is 
decreased to well below 200 nm as seen in the hypothetical model shown in Fig. 1.3 [73].  
As the particle size is decreased below 200 nm, the solubility relative to the equilibrium 
solubility (i.e. the solubility ratio, S/So) increases exponentially.  Therefore, increasing 
the intrinsic solubility allows for more API to dissolve leading to increased dissolution 
rates.  This can have a profound affect on increasing absorption of APIs in which the rate 
limiting step is dissolution. 
Many of the nanoparticle technologies have the ability to create amorphous API 
which also can facilitate dissolution by lowering the required energy needed for 
dissolution to occur.[74]  Supersaturation of the API within the surrounding medium can 
also be achieved which can further enhance the driving force for absorption across 
biological membranes.  However, stability of the amorphous API becomes a concern 
since crystalline APIs exhibit a lower thermodynamic energy state and are more stable.  
Amorphous materials exhibit a glass transition temperature (Tg) which when exposed to 
temperatures higher than the Tg, structural rearrangement into a more stable crystalline 
lattice begins.  Therefore, careful attention to particle stability must be given when 
designing amorphous nanoparticles.  In order to prevent recrystallization, high Tg 
polymers, such as PVP, cellulose polymers like hydroxypropyl methylcellulose (HPMC) 
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and ethylcellulose (EC), and carbomers, must be included in the composition, preferably 
intimately mixed within the amorphous composition such as a solid dispersion or 
solution.  Doing so will increase the overall Tg of the composition increasing its physical 
stability when exposed to higher storage temperatures. 
1.4.2  Physical stability of nanoparticles 
 
 Particles are constantly being acted upon by surrounding forces (e.g. gravitational 
forces, normal forces, electrostatic forces and particle-particle interactions).  In the solid 
state, nanoparticles behave much like larger particles, however, when they are included in 
various delivery vehicles such as a suspension or aerosol, their size can influence both the 
physical stability of the system and the amount delivered in to the body 
 Nanoparticles in a surrounding liquid environment which can be formed by 
microemulsion processes discussed earlier are extremely stable because the diffusion rate 
(Brownian motion) is higher than the sedimentation (or creaming) rate caused by 
gravity.[75]   These nanoparticlulate systems can be used to deliver spontaneously 
forming SLNs or other polymeric nanoparticles parenterally, orally, topically, or by 
inhalation.   
 Aggregation of micro- or nanoparticles can lead to suspension destabilization, and 
occurs due to electrostatic interactions between particles. As particles randomly approach 
each other, electrostatic forces will facilitate bonding or will repel the particles depending 
on the zeta potential or the surface charge of the particles compared to the dispersing 
medium.  A high net charge difference either positive or negative will lead to repulsion of 
the two particles while the opposite will lead to aggregation.  As the aggregate grows, 
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gravitational forces become more significant leading to creaming or settling of the 
suspension.  Inclusion of cationic or anionic surfactants can help prevent aggregation by 
influencing the zeta potential in either a positive or negative direction, respectively.   
 Ostwald ripening, which occurs as a result of high polydispersity, is the primary 
mechanism for suspension destabilization (e.g. physical separation) of 
microemulsions.[76]  In suspensions, there exists a certain amount of solubility of the 
API within the dispersing liquid.  Fluctuations in temperature can increase the propensity 
for Ostwald ripening to occur.  As the temperature of the system increases, solubility 
increases and the smaller particles, having a higher surface area-to-volume ratio dissolve 
first.  When the temperature decreases, the dissolved substances will precipitate and 
preferentially adsorb onto the surface of larger particles causing particle growth over 
time.  As temperatures continue to increase and decrease, particle growth will continue 
causing suspension destabilization. 
1.5  BENEFITS OF USING NANOPARTICLES - IN VIVO 
 
We have discussed the advantages that nanoparticles have in vitro focusing on 
dissolution enhancement of poorly water soluble APIs and an increase in solubility with a 
decrease in particle size.  Improved physical stability occurs through addition of non-
ionic surfactants to the surface of the particles in order to reduce electrostatic attraction 
while physical separation is minimized by Brownian motion in nanoparticle dispersions.  
However, those advantages have little consequence if there is little or no improvement to 
in vivo properties including increased API absorption and efficacy and reduced variability 
and toxicity.  It is essential to understand the role of particle size and surface modification 
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in API absorption through a variety of biological membranes.  Nanoparticles as carrier 
systems are more easily absorbed across biological membranes because of their smaller 
size.  Likewise, permeation can be facilitated by modifying the surface properties which 
is of particular importance to APIs which display poor absorption characteristics like 
proteins and peptides.  Targeting specific sites within the body to deliver treatment is 
possible using surface modified nanoparticles especially on the cellular level.  
Nanoparticles also have the ability to avoid clearance by the immune system or adhering 
onto mucous membranes thereby increasing the residence time allowing more time for 
treatment to occur.  Encapsulated nanoparticles offer protection to APIs susceptible to 
degradation mechanisms. 
1.5.1  Influence of size on uptake across biological membranes 
 
 Nanoparticles have the ability to facilitate transport across biological membranes 
through a number of different ways.  As stated earlier, nanoparticles can enhance 
dissolution of poorly water soluble APIs which can then easily permeate biological 
membranes like the GI tract where the API is taken up into systemic circulation.  
Undissolved nanoparticles have also shown the ability to aid absorption across 
membranes through a number of different pathways.  All mucous membranes are coated 
with a mucous gel layer of entangled glycoproteins.[77]  Small nanoparticles have the 
ability to diffuse through this entangled polymer layer much more efficiently than larger 
sized particles (greater than one micron) of the same material as depicted in Fig. 1.4 
Adsorption isotherms show a linear increase in adsorption sites for nanoparticles while a 
Langmuir type isotherm for micron size particles suggests that a monolayer of particles 
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forms before saturation occurs.  Therefore, more adsorption sites exist for smaller 
particles leading to a faster diffusion rate across the gel layer.  Once particles arrive at the 
surface of the gastrointestinal wall, different pathways are available for translocation 
across the gastrointestinal wall.  Specifically for nanoparticles smaller than 200 nm 
endocytosis by the absorptive cells facilitates translocation.[77]  For larger particles, 
transcellular uptake becomes much more difficult; however, addition of hydrophilic 
polymers can increase transcellular uptake.  Paracellular uptake through tight junctions is 
unlikely with nanoparticles but is possible if the tight junctions are disrupted.[77]  
Nanoparticles are also preferentially taken up by the M cells of the Peyer’s patches 
located in the follicle-associated epithelium of the gastrointestinal tract as shown by 
Pappo and Ermak [78].  However, uptake by the M cells is size specific with 34% of 50 
nm particles absorbed, 10% of 300 nm particles absorbed, and less than 5% of 1 micron 
particles absorbed [79].  In a study reported by Loper [80, 81] to investigate the 
absorption of a poorly water soluble API, particles of varying mean particle size (0.1-5 
micron) were manufactured using the wet milling technique previously described.  When 
delivered orally to fasted dogs the bioavailability significantly improved as particle size 
was decreased as seen in Fig. 1.5 showing a direct correlation between nanoparticle size 
and increased absorption.  Vaughn et al. [82] studied the increase in oral absorption of 
danazol using the EPAS and SFL technologies to produce nanoparticles.  The enhanced 
danazol formulations from both processes form supersaturated solutions during in vitro 
dissolution studies.  SFL processed powders displayed a concentration 33% greater than 
the apparent solubility of danazol for 90 minutes while EPAS processed powders showed 
a 27% higher concentration than the apparent solubility for up to 60 minutes.  This 
 24
phenomenon was attributed to the small particle size of the processed powders which 
were found in a previous study using STEM [7] to be 30 nm for the SFL danazol domains 
and 100 nm EPAS danazol domains.  When these powders were orally administered to 
mice, the SFL powders showed a two-fold increase in Cmax and a 3.8-fold increase in 
AUC after 24 hours compared to the crystalline physical mixture.  The EPAS powders 
also showed about a two-fold increase in Cmax while having a 2.2-fold increase in AUC.  
The enhanced pharmacokinetic parameters were a direct result of the ability of the 
amorphous danazol nanoparticles to supersaturate allowing more drug to be absorbed. 
 Delivering nanoparticles to their site of action can be particularly challenging 
when the dose delivered is dependent on particle size which is the case for pulmonary 
delivery.  The lungs consist of a series of bifurcating tubes terminating in the alveolar 
sacs in the deep lung.  Gas exchange occurs in the deep lungs which are the most 
favorable site for APIs to enter systemic circulation.  Optimum delivery of APIs to the 
lungs requires particles to be in the range of 1-5 microns (mass median aerodynamic 
diameter, MMAD).  Due to inertial forces, particles larger than 5 microns will impact on 
the back of the throat and subsequently swallowed by the patient.  Particles smaller than 
one micron are eventually exhaled by the patient as a result of longer settling times.[83]  
However, a small fraction of these inhaled nanoparticles can settle into the deep lung 
through diffusional processes.    Therefore, nanoparticles are generally delivered to the 
deep lung via inclusion within nebulized liquid droplets [84] or solid microparticles [85].  
Nanoparticles have been dispersed within a non-chlorofluorocarbon (CFC) propellant and 
delivered to the deep lung via a pressurized metered dose inhaler (pMDI).[86]  These 
inhaled nanoparticles can result in enhanced uptake of API across the epithelial 
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membrane making nanoparticle delivery to the lung an attractive strategy for increased 
drug delivery.[87]  Sham et al. [85] created gelatin and polybutylcyanoacrylate (PBCA) 
nanoparticles through a two step desolvation method and emulsion polymerization 
process, respectively.  The nanoparticles were then added to a dissolved lactose aqueous 
solution and spray dried to form nanoparticle loaded lactose microparticles within the 
respirable size range.  Dailey et al. [84] investigated the properties of different nebulizers 
on the delivery of nanoparticles to the lungs.  The biodegradable PLGA based 
nanoparticles were prepared using an anti-solvent mixing technique and nebulized using 
a jet, ultrasonic, or piezo-electric crystal nebulizer.  Aggregation of the suspension during 
nebulization was examined by filtration separation (> 0.8 micron) pre- and post-
nebulization including the remaining suspension within the nebulizer reservoir.  
Aggregation was determined to be a function of particle surface charge with hydrophobic 
particles exhibiting the greatest affinity for aggregation.   Differences in nebulizer 
performance were also noted.  Results revealed that both jet and ultrasonic nebulizers 
produced excellent respirable fractions while the piezo-electric crystal nebulizer emitted 
droplets with large MMADs and decreased API output. 
 McConville et al. [88] developed itraconazole (ITZ) compositions using the SFL 
and EPAS technologies and dosed the compositions to mice.  Dosing of the mice 
consisted of administration of the nanoparticle suspension administered via an ultrasonic 
nebulizer to the mice contained within a restraint-free dosing chamber [88].  
Characterization of the nebulized suspensions showed high respirable fractions between 
71-85% and MMADs between 2.7-2.82 µm for all compositions tested.  In vivo 
pharmacokinetic studies showed high ITZ within the lung for both EPAS (Cmax = 16.8 
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µg/g, AUC = 99.7 µg*h/ml) and an SFL composition (Cmax = 13.4 µg/g, AUC = 85.8 
µg*h/ml).  In a later study, Vaughn et al. [89] studied the effect of single and multiple 
dosing via ultrasonic nebulizer of SFL processed ITZ nanoparticles on both the lung and 
serum concentrations compared to the orally administered Sporonox® solution.  The 
studies showed that administration of ITZ nanoparticles to the lungs is an effective 
treatment for invasive fungal infections.  It was also estimated that ITZ absorption into 
systemic circulation after pulmonary dosing over 12 days achieved high enough steady 
state concentrations of ITZ to act as a prophylaxis against certain strains of fungi, namely 
A. fumigatus.   
1.5.2  Effect of surface modification on delivery of nanoparticles 
 
Along with particle size, the surface characteristics of particles play an important 
role in how particles are absorbed within the body.  Nanoparticulate systems can be 
designed to facilitate transport across biological membranes, target specific tissues or 
sites within the body, avoid uptake by the immune system, increase residence time within 
the body, or protect against premature degradation or metabolic processes. 
1.5.2.1  Transport across biological membranes  
 
Delivery of APIs across the BBB can be extremely difficult due to the built in 
defenses of the body to protect the brain against foreign substances.  The structure of the 
blood brain barrier is much like that of the GI tract; however, tight junctions between 
endothelial cells are sealed by claudins making paracellular transport virtually 
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impossible.  While reducing particle size can help increase transport across the BBB, the 
addition of surface modification of the particles is critical to increasing transport across 
the BBB.  The endothelial cells of the BBB also contain a host of different transporters, 
receptors, and enzymes which serve to remove substances back into the blood or 
metabolize the substance before it can gain access to the brain.  Surface modification can 
limit the rate of basolateral to apical transport by disguising recognition of the API by the 
transporters.  The template microemulsion produced nanoparticles with various surface 
bound polymers to examine their effect on permeation across the BBB. [69, 90, 91]  
Studies revealed that low concentrated anionic formulated nanoparticles showed 
improved uptake [69] while thiamine coated nanoparticles facilitated binding to BBB 
thiamine transporters resulting in increased permeation [91].  
1.5.2.2  Site specific targeting 
 
 Nowhere is targeted nanoparticle drug delivery more valuable than in the area of 
cancer therapy.  Traditional chemotherapy consists of parenteral administration of 
chemotherapeutic agents.  These agents, many of which cause severe side effects, destroy 
both tumor and healthy cells alike.  Because many of these compounds are poorly water 
soluble, solubilizing agents and adjuvants are often included in the formulation.  These 
excipients can also cause serious life threatening side effects themselves.  One of the 
most commercially successful chemotherapeutic products, Taxol® (paclitaxel, PAC) 
includes the adjuvant Cremophor EL which is known to cause hypersensitivity, 
nephrotoxicity, neurotoxicity, and cardiotoxicity.[92]  Therefore, there is a tremendous 
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need in this area for delivery systems which can both eliminate the use of toxic excipients 
and enhance absorption leading to decreased dose.   
 Nanoparticles composed of biodegradable materials have the ability to move 
through capillaries to target tumors and evade immune responses which can prematurely 
eliminate the API from the body.[93]  Tumor pore sizes within several tumor models 
range from 380-780 nm [94, 95] so nanoparticle delivery offers a tremendous advantage 
to deliver the therapeutic agent directly into the tumor.  Tumors also contain many API 
resistant mechanisms including P-glycoprotein transport mechanisms and outward 
interstitial flow which prevent APIs from remaining within the tumor.  Yoo et al. [96] 
investigated the in vivo application of controlled release doxorubicin (DOX) conjugated 
PLGA nanoparticles and found that a single injection of the nanoparticles had similar 
activity to daily injections of free DOX over 12 days.  Chen et al. [97] developed a SLN 
formulation of PAC and found that the SLN compositions had increased half-lives (10.06 
and 4.88 hr) compared to the commercial product containing Cremophor EL (1.36 hr).  
Likewise, Fundaro et al. (2000)[98] found increased circulation (24 hr) of DOX loaded 
stealth SLNs in rats compared to the commercially available solution formulation (4 hr).  
Little success has been made to reduce the toxicity of new nanoparticle 
formulations with many of the compositions having similar cytotoxicity as the 
commercial product when delivered parenterally.[99]   It is hypothesized that localized 
delivery of the chemotherapeutic agent to the tumor site should increase efficacy thereby 
reducing the required amount needed for tumor size reduction.  However, efflux 
mechanisms within the tumor continue to make success more difficult.  One strategy is to 
develop “smart nanoparticles” which preferentially bind to tumors and deliver their 
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payload.    These strategies include targeting the tumor-specific cells, targeting the tumor 
vasculature, or targeting through vessel formation, and have been reviewed in detail.[100]  
Current therapies utilize antibodies [101, 102], transferrin [103], or oligonucleotides 
[104] to actively target tumor sites which have been shown to bind to specific tumor 
antigens .  At least four current cancer therapies utilize antibodies for targeting with 
Rituxan® being the most successful.   
 One strategy to specifically target microorganisms causing bacterial, viral, and 
fungal infections is to preferentially target macrophages of the immune system in which 
the microorganisms may reside.[105, 106]  The hydrophobic surfaces attract more plasma 
protein markers to adsorb to the surface of the particles and undergo endocytosis by the 
macrophages.  Makino et al. [107] investigated the effect of both particle size and surface 
charge on the rate of uptake of polystyrene nanoparticles  by alveolar macrophages.  
They found that 200 nm particles had considerably higher uptake as seen in Fig. 1.6a 
Likewise, Fig. 1.6b shows the amount of uptake of particles with varying functional 
groups.  Therefore, both size and surface properties have an affect on particle uptake by 
macrophages.  From this information, one can design particles to either avoid or reside 
within the lymphatic system depending on the intended use of the API. 
1.5.2.3  Increasing residence time 
 
As mentioned earlier, surface modification plays an important role in increasing 
the residence time of an API within the body.  For intravenously delivered nanoparticles, 
clearance from the bloodstream occurs rapidly and is a function of the physico-chemical 
properties of the particles, primarily size, surface charge, and surface hydrophobicity.  
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Addition of hydrophilic polymers such as PEG prevents recognition by various markers 
of the complement system within the blood avoiding uptake by the circulating 
macrophages.  Bocca et al. [108] examined the phagocytic uptake of stealth SLNs versus 
non-stealth SLNs using cultured murine macrophages.  The stealth SLNs included 
addition of PEG 2000 to the lipid nanoparticle.  In all cases, the stealth SLNs showed less 
than 5% of the dose taken up by the macrophages while the non-stealth SLNs showed on 
average 35-40% of the dose taken up after 90 minutes.  PEGylated nanoparticles have 
also been shown to have potential as carriers for proteins and peptides which have 
difficulty crossing biological membranes.    
Mucoadhesive polymers have the ability to increase residence times of 
nanoparticle systems in non-parenteral delivery systems.  Some mucoadhesive polymers 
include chitosan, cellulose based polymers such as HPMC, carbomers, and sodium 
alginate.  Many routes of administration have been employed mucoadhesive polymers to 
increase residence time including oral, nasal, transdermal, ocular, and vaginal drug 
delivery.  The mechanism of polymer attachment is not well understood, however, it is 
believed that physical entanglement between the mucoadhesive polymer and mucin, a 
glucosylated glycoprotein found in abundance in mucus membranes, is responsible.  It is 
also possible that electrostatic, hydrophobic, H-bonding or van der Waals’ forces could 
contribute to further bonding interactions [109]. 
1.5.2.4  Protection against enzymatic and chemical degradation 
 
Surface modified nanoparticles have also been used as protective carriers for 
delivery of APIs susceptible to enzymatic or chemical degradation, the most common 
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example being oral delivery of proteins, peptides, and nucleic acids.  While water soluble 
compounds lie outside the scope of this review, it is worth briefly mentioning the use of 
nanoparticulate carriers that are able to increase absorption of these compounds by 
providing protection against degradation while facilitating permeation across biological 
membranes.  Traditionally, the protein is loaded into the core of the nanoparticles and 
encapsulated in a protective shell through emulsification or phase separation 
methods.[110]  The polymeric shell consists of polymers which can facilitate absorption 
across the GI tract as well as provide protection against degradation.  Takeuchi et al. 
[111] recently designed chitosan-coated liposomes for delivery of calcitonin.  In vivo 
studies showed the chitosan-coated liposomes had a prolonged pharmacological effect 
compared to the non-coated liposomes.  The authors concluded that the prolonged 
pharmacological effect was due to the retentive properties of chitosan as well as its ability 
to avoid uptake by enterocytes.   
1.6  CONCLUSION 
 
 Recently, nanoparticle research directed to pharmaceutical applications has 
resulted in many effective delivery systems which have improved the absorption and 
bioavailability of many poorly water soluble APIs.  The in vitro properties inherent to 
nanoparticles are becoming more fully understood through the development of more 
accurate analytical techniques and equipment such as the TEM and AFM.  At the same 
time, new particle engineering technologies are being developed to control the physico-
chemical properties of nanoparticles to develop systems with superior in vitro properties.  
These technologies include those designed to reduce the particle size of existing particles 
 32
such as milling, as well as technologies designed to nucleate and stabilize nanoparticles. 
Significant research in formation and delivery of nanoparticles has been accomplished 
particularly in the areas of enhancing the properties of poorly water soluble APIs.  This 
includes the effect of size on dissolution rate enhancement as well as addition of surface 
modifiers for dissolution enhancement, stabilization, and drug targeting.  Only now are 
researchers beginning to understand how these nanoparticles, with their enhanced 
physico-chemical properties in combination with human physiology, are able to enhance 
absorption and bioavailability of these particles.  Currently, work is being conducted to 
develop nanoparticles which have the ability to target specific sites within the body 
which can lead to increased efficacy, decreased dose requirements and decreased side 
effects.  Research is also focusing on increasing the residence time within the body to 
allow for more API release.  Nanoparticles are being designed to avoid unwanted 
metabolism and clearance through the use of surface modification (i.e. stealth and 
mucoadhesive particles). 
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1.8  DISSERTATION OBJECTIVES AND OUTLINE 
 
 Many new chemical entities (NCE) being developed today display poor water 
solubility and as a result suffer from poor oral bioavailability.  Therefore, a need exists to 
modify the physical properties of these NCEs allowing the body to more easily absorb the 
chemicals and acquire the desired therapeutic effect.  In chapter 1, several techniques for 
improving the bioavailability of these poorly water soluble compounds through 
nanoparticle formation and nanoparticle delivery systems are introduced.  In addition, the 
desirable in vitro and in vivo properties of these systems are described in great detail to 
assess the importance of size reduction and surface modification on the improvement of 
these compounds.  The overall objective of this dissertation was to formulate, 
characterize, and evaluate nanoparticle delivery systems developed from rapid freezing 
processes through in vitro and in vivo analysis.  Active pharmaceutical ingredients (API) 
were selected based on a need within the pharmaceutical industry for bioavailability 
improvement. Formulations were produced using the rapid freezing technologies spray 
freezing into liquid (SFL) or ultra-rapid freezing (URF).  In vivo studies were performed 
using well established animal models to assess the improvement of the processed 
powders compared to the bulk material or the current commercial product containing the 
API. 
   The aim of chapter 2 was to investigate the influence of hydrophilic stabilizers in 
powder compositions prepared by the spray freezing into liquid (SFL) process using 
either an emulsion feed dispersion or an organic co-solvent feed solution on enhancing 
the wetting and dissolution properties of nanostructured aggregates containing 
itraconazole.  The particles were evaluated based on degree of crystallinity, dissolution 
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rate and morphology to determine the optimum stabilizer combination for testing in an 
animal model.  The in vivo performance of the optimum micronized powder was 
compared to the itraconazole commercial product in a study performed in collaboration 
with the University of Texas Health Science Center in San Antonio highlighting the 
importance of these studies to validate these technologies for clinical use. 
 Up to this point, a majority of the particle engineering utilizing rapid freezing was 
performed with the SFL process.  A novel freezing technology was introduced to 
facilitate process scale up under commercial manufacturing conditions.  The URF process 
entails freezing an API/excipient solution drop-wise onto the surface of a solid cryogen.  
The hypothesis is that the URF process can produce powders with enhanced physico-
chemical properties leading to improvements in bioavailability of poorly water soluble 
compounds.  In order to determine if the freezing rates were sufficient to manufacture 
powders with the desired physico-chemical properties, a study was conducted to model 
the freezing rates and to determine any limiting factors that may exist.  The study 
described in chapter 3 provides an detailed explanation of how the solvent’s physical 
properties and thin film geometry influence the freezing rate and consequently the final 
physicochemical properties of URF processed powders.  Sound engineering concepts of 
heat transfer were applied to model the freezing droplet and assess the advantages of 
using this method of rapid freezing.  In addition, a novel approach to measuring the heat 
transfer between the droplet and the cryogenic substrate was performed using a high 
speed infra-red camera.  Lastly, particle performance was evaluated using in vitro tests to 
validate the URF process.   
 In subsequent studies (chapters 4 and 5), the URF process was utilized to 
manufacture enhanced compositions for immediate release of tacrolimus and modified 
release of itraconazole, respectively.  The objective of chapter 4 was to investigate the 
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effects of combinations of polymeric stabilizers on the maximum degree and extent of 
supersaturation of tacrolimus and to establish if an in vitro-in vivo correlation exists 
between supersaturation and improved pharmacokinetic parameters for orally 
administered tacrolimus.  It was hypothesized that the production of supersaturated 
solutions could enhance the transport of tacrolimus across biological membranes thereby 
enhancing the bioavailability of tacrolimus.  Differences were observed in supersaturated 
dissolution profiles of the tacrolimus compositions which correlated to differences in the 
pharmacokinetic profiles for each of the compositions.  In addition, it was found that the 
URF micronized powders showed enhanced absorption over the commercial tacrolimus 
product as a result of the improved physico-chemical properties. 
 Because of the enhanced physico-chemical properties such as rapid dissolution 
rates are associated with rapid freezing processes, these processes have traditionally been 
utilized to develop immediate release systems.  However, increased bioavailabilities can 
also be achieved through the utilization of modified drug release by controlling the 
release of the drug thereby preventing premature precipitation and recrystallization which 
can decrease drug absorption.  Amorphous solid dispersions containing enteric polymers 
could overcome these limitations by 1.) delaying dissolution until the compound enters 
the small intestines and preventing premature precipitation of the ITZ and 2.) increasing 
the apparent solubility at higher pH to increase the driving force for absorption.  The 
objective of the final study was to investigate the influence of composition parameters 
including drug:polymer ratio and polymer type, and particle structure of enteric solid 
dispersions on the release of ITZ under sink and supersaturated dissolution conditions.  
Particles were characterized by thermal methods, to determine the miscibility limits of 
itraconazole in the polymers.  Once miscibility limits were established, the dissolution 
performance of the particles under both sink and supersaturated conditions was evaluated 
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to elucidate how the release kinetics were influenced by the miscibility of ITZ within the 
polymer. 
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Chapter 2:  The Influence of Hydrophilic Stabilizer on Dissolution 
Enhancement and Oral Bioavailability of Itraconazole Nanoparticles 
Prepared by Spray Freezing into Liquid 
 
2.1  ABSTRACT 
 
The aim of this study is to investigate the influence of hydrophilic stabilizers in 
powder compositions prepared by the spray freezing into liquid (SFL) process using 
either an emulsion feed dispersion or organic co-solvent feed solutions on enhancing the 
wetting and dissolution properties of nanostructured aggregates containing itraconazole 
(ITZ).  Subsequently, an in vivo pharmacokinetic study  was conducted comparing 
powder from the emulsion feed dispersion, commercially available cyclodextrin-based 
Sporanox® oral solution, and micronized crystalline ITZ.  SFL A was manufactured from 
an emulsion feed dispersion consisting of ITZ, sorbitan monooleate (S80), poloxamer 
188 (P188), and polyethylene glycol 8000 (PEG) (1:1:2:1) in a 33:67 
dichloromethane:water emulsion.  SFL B and C were manufactured from an organic co-
solvent feed solution and consisted of ITZ, poloxamer 407 (P407) and polysorbate 80 
(T80) (1:0.75:0.75) or ITZ, polysorbate 20 (T20) and polyvinylpyrrolidone K15 
(PVPK15) (10:1:2), respectively. Examination by scanning electron microscopy of 
particles produced by the SFL process revealed porous aggregated structures, compared 
to dense aggregates with crystalline habits for the bulk micronized ITZ.  Both SFL A and 
SFL C produced powders containing nanoparticle domains containing ITZ.  BET analysis 
showed high surface areas of 15.5-20.3 m2/g for the SFL powders while x-ray diffraction 
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studies revealed a lack of crystallinity in any of the SFL processed samples.  According 
to the in vitro characterization, the SFL process created high surface area particles 
containing amorphous ITZ allowing for rapid dissolution enhancement.  The 
pharmacokinetic profiles obtained for SFL A and Sporanox® oral solution showed 
similarities between both the absorption profiles and the estimated pharmacokinetic 
parameters.  Analysis of the AUC(0-24) revealed that the SFL formulation was 84% of the 
commercially available Sporanox®, further demonstrating the similarity of performance 
of SFL A compared to the cyclodextrin-based Sporanox in vivo.  Serum levels for the 
micronized crystalline ITZ powder were not detected.  In conclusion, the SFL powder 
from an emulsion feed dispersion produced surface stabilized amorphous nanoparticle 
domains which enhanced the physico-chemical properties (wetting, surface area, particle 
size) leading to enhanced dissolution rate and in vivo oral bioavailability.  
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2.2  INTRODUCTION 
 
Diagnosis of systemic fungal infections has increased dramatically over the last 
20 years, in part due to the increasing number of immunosuppressed or 
immunocompromised patients such as those receiving chemotherapy treatment, 
transplant recipients, HIV/AIDS patients, and the elderly.[1]  Aspergillus spp. continues 
to be one of the most common and deadly invasive fungal infection responsible for 62% 
of cases.  However, first line treatment using amphotericin B deoxycholate or liposomal 
amphotericin has failed to improve mortality rates which can reach as high as 90% in 
central nervous system (CNS) patients.[2]  Likewise, case fatality rates were 99%, 86%, 
and 66% for cerebral, pulmonary, and sinus aspergillosis, respectively.[3, 4]  While 
amphotericin B has failed to show improvements in mortality rates of patients with 
aspergillosis, itraconazole (ITZ) treatment has lowered the mortality rates of patients 
more than 15% compared to amphotericin treatments.[3] 
Itraconazole, a broad-spectrum triazole anti-fungal agent developed in the early 
1980s by Janssen Research Foundation [5] is a Biopharmaceutical Classification System 
(BCS) class II drug.  Because of the solubility and dissolution rate limitations of class II 
drugs, ITZ has shown poor bioavailability in vivo.  Likewise, ITZ is a weak base 
(pKa=3.7), and has a higher water solubility at low pH, 4 µg/ml in pH = 1.0 compared to 
~1 ng/ml in de-ionized water.[6]   
In the SFL process, a poorly water soluble drug and stabilizing agent(s) are 
dissolved in a suitable solvent to create a liquid feed (solution or emulsion), atomized 
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under high pressure through a nozzle which is submerged below the surface of liquid 
nitrogen, and subsequently freeze-dried to remove any frozen solvent. Rogers et al. 
demonstrated that an emulsion feed dispersion could be used to manufacture powders 
with high danazol:polymer ratios and high solids loadings (using less organic solvents) 
while maintaining enhanced physico-chemical properties traditionally seen in co-solvent 
feeds.[7]  The focus of the Rogers et al. study was to investigate high potency danazol 
compositions surface stabilized by poloxamer 407 (P407), polyvinyl alcohol (PVA) and 
polyvinylpyrrolidone (PVP), while this study investigates the effect of different 
stabilizers to enhance the dissolution of an extremely hydrophobic API, ITZ.   
The objective of this study is to investigate the influence of hydrophilic stabilizers 
in powder compositions prepared by the SFL process using either an emulsion feed 
dispersion or organic co-solvent feed solutions on enhancing the wetting and dissolution 
properties of nanostructured aggregates containing itraconazole.  Feeds included a 
composition (SFL A) manufactured from an emulsion in which the drug, ITZ, is 
primarily localized within the organic phase of the o/w emulsion having stabilizing 
excipients on the surface.  Two other compositions were manufactured from an organic 
co-solvent feed solution.  SFL B, composed of highly wettable surfactants, poloxamer 
407 (P407) and polysorbate 80 (T80), should lead to rapid dissolution rates while SFL C, 
was a high potency composition containing a wetting agent (polysorbate 20; T20) and a 
stabilizing polymer polyvinylpyrrolidone (PVPK15).  The various excipients were 
investigated to determine their contribution to the dissolution process such as 
enhancement of wetting properties and their effect on surface characteristics such as 
morphology and surface area.  The study also investigates the in vivo release of an 
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amorphous ITZ composition prepared using SFL compared with the commercially 
available liquid Sporanox® solution and micronized crystalline ITZ. 
 
2.3  MATERIALS AND METHODS 
 
2.3.1  Materials 
 
Itraconazole (ITZ) was purchased from Hawkins Chemical (Minneapolis, MN, 
USA).  Poloxamer 407 (P407) and 188 (P188), polyethylene glycol 8000 (PEG), 
polysorbate 20 (T20) and 80 (T80) sodium lauryl sulfate (SLS), polyvinylpyrrolidone 
K15 (PVPK15), and sorbitan monooleate (S80) were purchased from Spectrum 
Chemicals (Gardena, CA, USA).  Diethanolamine and hydrochloric acid (HCl) were 
purchased from VWR International (West Chester, PA, USA).  Acetonitrile (ACN), 
dichloromethane (DCM) and methanol were purchased from EM Industries Inc. 
(Gibbstown, NJ, USA).  Methoxyflurane (Metofane®) was purchased from Pittman-
Moore Inc. (Mundelein, IL, USA). 
2.3.2  Preparation of SFL Powders 
 
SFL powders were prepared from either an emulsion feed dispersion or organic 
co-solvent feed solution.  For the SFL powder prepared from an emulsion feed 
dispersion, the organic phase was prepared by adding ITZ (0.7g) and S80 (0.7g) to DCM.  
P188 (1.4g) and PEG (0.7g) was added to purified water to make the aqueous phase of 
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the 33:67 DCM:water emulsion.  The organic phase was slowly added to the aqueous 
phase and blended using a rotor-and-stator homogenizer (Polytron 10/35 with TS 10 mm 
Generator; VWR Scientific Corporation, West Chester, PA, USA) for 90 seconds.  The 
resultant course emulsion was added to an Emulsiflex C-5 high-pressure homogenizer 
(Avestin, Inc., Ottawa, ON, Canada) and homogenized at a pressure of 18,000 PSI for ten 
cycles. For SFL powders prepared from an organic co-solvent feed solution, ITZ and the 
surfactants in their appropriate ratios according to Table 2.1 were dissolved first in a 
small amount of DCM.  ACN was slowly added to volume under constant stirring.   
During the SFL process the feed was pumped at 50 mL/min via a piston using an 
ISCO model 100DX syringe pump (ISCO, Inc., Lincoln, NE, USA) and atomized 
through 127 µm ID polyether-ether ketone (PEEK) (Upchurch Scientific, Oak Harbor, 
WA, USA) tubing below the surface of liquid nitrogen.  The atomized droplets were 
instantly frozen to produce a suspension of fine frozen particles.  The particles were 
transferred to a non-insulated container and lyophilized using a VirTis Advantage 
Benchtop Tray Lyophilizer (VirTis Corp., Gardiner, NY, USA) equipped with a liquid 
nitrogen trap to condense sublimed organic solvents.  The primary drying phase was 
performed at -60°C for 10 hours and -40°C 14 hours.  The shelf temperature was then 
ramped up at a rate of 0.9° per minute to 25°C where the secondary drying phase was 
conducted for a minimum of 12 hours.  A vacuum of 200 mTorr was maintained for the 
primary drying phase and increased to 100 mTorr for the remainder of the freeze-drying 
cycle. 
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2.3.3  Scanning Electron Microscopy (SEM) 
 
The powder samples were sputter coated using a model K575 sputter coater 
(Emitech Products, Inc., Houston, TX, USA) with gold-palladium for 35 seconds and 
viewed using a Hitachi S-4500 field emission scanning electron microscope (Hitachi 
High-Technologies Corp., Tokyo, Japan).  An accelerating voltage of 5-10 kV was used 
to view the images.  All SEMs pictured were representative of the entire sample. 
2.3.4  Contact Angle Measurements 
 
Tablets were pressed from the SFL powder samples (50mg) using a Model M 
Carver Laboratory Press (Fred S. Carver, Inc., Menomonee Falls, WI, USA) and a 
compression force of 300 kg.  A droplet of dissolution media, 0.1N HCl 0.5%w/w SLS, 
(3µL) was placed on the flat face of the tablet and the contact angle was measured using a 
Model 100-00-115 goniometer (Ramè-Hart Inc., Mountain Lakes, NJ, USA).  Each 
sample was measured in triplicate. 
2.3.5  Dissolution Testing 
 
Dissolution testing was performed on the SFL powder samples using a USP 24 
Type II paddle apparatus model VK7000 (Varian Inc., Cary, NC, USA).  An equivalent 
of 7 mg ITZ was added to 900 ml of 0.1N HCl 0.5%w/w SLS (pH 1.2) dissolution media 
and stirred at 50 rpm.  The dissolution media was maintained at 37.0 ± 0.2°C. 
Samples (5ml) were withdrawn at 2, 5, 10, 20, 30 and 60 minute time points, 
filtered using a 0.45µm GHP Acrodisc filter and analyzed using a Shimadzu LC-10 liquid 
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chromatograph (Shimadzu Corporation, Kyoto, Japan) equipped with an Alltech ODS-2 5 
µm C18 column (Alltech Associates, Inc., Deerfield, IL, USA).  A mobile phase of 
ACN:water:diethanolamine (70:30:0.05) at 1ml/min eluted the ITZ peak at 5.5 min and 
absorbance was measured at λ = 263 nm.  
2.3.6  X-Ray Diffraction (XRD) 
 
The x-ray diffraction pattern of the SFL powders were analyzed using a model 
1710 x-ray diffractometer (Philips Electronic Instruments, Inc., Mahwah, NJ, USA).  
Data were collected using primary monochromated radiation (CuKα1, λ = 1.54056 Å), a 
2θ step size of 0.05 and a dwell time of 1.0 second per step. 
2.3.7  BET Specific Surface Area Analysis 
 
Specific surface area was measured using a Nova 2000 v.6.11 instrument 
(Quantachrome Instruments, Boynton Beach, FL, USA).  Weighed powder was added to 
a 12 mm quantachrome bulb sample cell and degassed for a minimum of three hours.  
The sample was then analyzed by the NOVA Enhanced Data Reduction Software v. 2.13 
using the BET theory of surface area. 
2.3.8  Particle and Droplet Size Analysis 
 
Low angle laser light scattering using a Mastersizer S (Malvern Instruments 
Limited, Malvern, UK) was used to determine (i) droplet size of the emulsion feed 
dispersion prior to SFL processing, and (ii) the particle size distribution of aggregated 
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nanoparticles following lyophilization.  The Mastersizer S was equipped with a large 
volume flow through cell and a 300RF lens (0.1-1000µm). 
The emulsion feed dispersion was diluted by dropping into purified water in a 
large volume flow through cell to reach a laser obscuration between 10 and 25%. 
Approximately 5 mg of lyophilized SFL powder was pre-dispersed in a saturated 
water/itraconazole solution and sonicated for 30 seconds.  The pre-dispersed solution was 
added drop wise to a saturated itraconazole solution in the large volume cell to achieve a 
laser obscuration between 10 and 25%.  Median particle/droplet sizes were determined 







      (1) 
 
where D90, D50 and D10 are the cumulative particle sizes less than 90%, 50% and 10%, 
respectively. 
2.3.9  Pharmacokinetic analysis 
 
The in vivo study was conducted with approval from the Institutional Animal Care 
and Use Committee (IACUC) at the University of Texas Health Science Center at San 
Antonio.  Forty-two (42) seven week old male ICR/Swiss mice, disease and pathogen 
free (Harlan-Sprague-Dawley, Indianapolis, IN) weighing 32 g were used.  Animals were 
housed 4 per cage and allowed water ad libitum.  The mice were subdivided into 3 groups 
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of 14 to be dosed with the SFL product, the liquid Sporanox® or bulk micronized ITZ 
suspension. 
A suspension of the SFL product (2.4 mg/ml; dose equivalent of 30 mg/kg of 
itraconazole) was used for each of 14 mice (0.96 mg total).  This dose was selected as it 
had previously been reported to be the highest concentration administered orally prior to 
the onset of diarrhea.  The itraconazole formulation was delivered orally in 0.4 ml 
suspension using a curved gavage tube in a single dose.  Liquid oral Sporanox® was also 
delivered to 14 mice at the same dose equivalent of 30 mg/kg.  In addition, a suspension 
of the bulk crystalline ITZ was made with 0.01% T80 (as a wetting agent), this was 
administered at the same dose equivalent of 30 mg/kg to the mice. 
Blood samples (0.5-1 ml) were taken via cardiac puncture of anaesthetized mice 
(using methoxyflurane) at time points of 0.5, 1, 2, 4, 6, 10, 24 hrs. Mice were then 
euthanized by cervical dislocation; two mice were allocated for each time point.  Blood 
samples were placed in Monoject Samplette® capillary serum separator tubes (Kendall 
Healthcare, Mansfield, MA) and held at room temperature for 30 minutes before 
centrifugation at 2,500 rpm for 3 minutes.  The supernatant (serum sample) from each 
sample time point was collected and stored at -20°C prior to analysis. 
ITZ concentration was determined by HPLC analysis.  The HPLC system (Waters 
Inc., Miliford, MA, USA) consisted of a UV-detector (W486), pump (W510), 
autosampler (W717) and column heater, and an Altima® (Alltech Associates, Deerfield, 
IL, USA) reversed phase column (C-18 base-deactivated, 5 µm, 250 x 4.6 mm) protected 
by a guard column (C-18, 5 µm, 7.5 x 4.6 mm).  Calibration and pharmacokinetic 
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samples were analyzed using a method in which the mobile phase comprised ACN, 
deionized water and methanol (55:35:10 v/v) (flow-rate 1.0 ml/min, λ = 263 nm). 
Serum samples (250 µL) were pipetted into 0.3 N barium hydroxide / 0.4 N zinc 
sulfate heptahydrate solution (50 µL) and vortex mixed (30 seconds).  Acetonitrile (1 
mL) was added before a further vortex mixing (1 min), followed by centrifugation at 
2,500 rpm (15 min).  The supernatant was transferred to flat bottom tubes and immersed 
in a water bath (50°C) under a stream of nitrogen to dryness.  Samples were then 
reconstituted with 250 µL mobile phase and vortex mixed (1 min) before transferring to a 
micro centrifuge tubes and centrifuging at 12,500 rpm (10 min).  The supernatant was 
then transferred into HPLC injection vials with low volume inserts (250 µL). 
Pharmacokinetic parameters were analyzed using non-compartmental 
pharmacokinetic analysis:  Area under curve (AUC) between 0-24 hours was calculated 
using the trapezoidal rule; Cmax and Tmax were determined from the concentration-time 
profiles; T1/2 was calculated by using the elimination rate constant (Kd); Kd was obtained 
from the natural log of the concentration-time profile.  
2.4  RESULTS 
 
2.4.1  In vitro Characterization of SFL Processed Powders 
 
 Various compositions containing ITZ were prepared using the SFL process.  
These compositions, summarized in Table 2.1, were characterized and evaluated based on 
their in vitro attributes.  Table 2.2 summarizes the average particle size, available surface 
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area, and contact angle measurements of each of the SFL powders.  For the SFL A 
composition which was prepared from an emulsion feed dispersion, the droplet size 
distribution of the emulsion feed dispersion was determined.  The results show that the 
SFL A emulsion feed dispersion was composed of stabilized submicron droplets of DCM 
within an aqueous polymer solution.  Interestingly, the distribution of submicron droplets 
(760 nm) was found to be very narrow, as indicated by a span index of 1.39.  A slightly 
larger average particle size was determined on dried powder prepared from the emulsion 
feed dispersion after rapidly freezing and lyophilization.  SFL powders B and C, which 
were made from organic co-solvent feed solutions revealed larger average particle sizes 
of 5.82 and 6.21 µm, respectively.  In addition, the surface area of the SFL powder was 
significantly greater than that of micronized ITZ.  Surface areas for the SFL powders 
range from 15.58 to 20.25 m2/g while the micronized ITZ has a surface area of 4.22 m2/g.  
The wettability of the powders was assessed by measuring the contact angle of an 
aqueous droplet on the flat surface of a compressed tablet of the powder.  As the contact 
angle of the droplet decreases, it is assumed that the droplet is able to more completely 
wet the powder surface and therefore will have a lower surface energy between the water 
and the solid powder.  As seen in Table 2.2, all SFL powders have lower contact angles 
compared to the bulk ITZ.  Bulk ITZ is a hydrophobic compound and therefore has a 
high contact angle measuring 57.9° ± 2.4° while the SFL powders have measured contact 
angles between 7.5 and 46.5°.  A direct correlation exists between the contact angle and 
the potency of the composition with higher potency compositions having higher contact 
angles due to the hydrophobicity of ITZ .  SFL A is composed of 60% hydrophilic 
material, including P188 and PEG and therefore has the lowest contact angle of all the 
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samples.  However, SFL C, which has the highest potency, has a significantly lower 
contact angle compared to the micronized ITZ indicating that intimate mixing between 
hydrophobic ITZ and the hydrophilic polymer PVP occurred. 
The scanning electron micrographs in Fig. 2.1 confirm the particle size and 
surface area results presented in Table 2.2.  The SFL powders A-C (Fig. 2.1a-c) all show 
highly porous aggregates containing nanostructures.  Close inspection of the micrograph 
of SFL A (Fig. 2.1a) reveals many small particles about one to two microns in diameter 
appearing mostly circular in diameter.  SFL B (Fig. 2.1b), on the other hand, appears to 
contain particles with smoothed edges which have agglomerated or fused together.  This 
is most likely a result of the high level of T80 in the composition.  T80, a liquid at room 
temperature, could cause an increase in mobility of the particles causing them to fuse 
together forming the agglomerated particles.  SFL C (Fig. 2.1c) is composed of 
nanoparticles with very high surface area particles.  Lastly, the micronized ITZ appears to 
have smooth flat particle surfaces while the particles themselves appear to have a plate 
shape.  Close inspection of each of the SFL powders (Fig. 2.2a-c) reveals differences 
between the compositions.  SFL A (Fig. 2.2a) displays many individual spherical 
nanoparticles embedded within a surrounding polymer matrix.  SFL B shows 
agglomerated nanoparticles with smoothed edges as a result of the high levels of the 
liquid surfactant.  SFL C (Fig. 2.2c) reveals particles composed of aggregated 
nanoparticles (<200 nm) surrounding an inner polymer matrix most likely created from 
the small amount of liquid T20 in the composition.      
The crystallinity of the powders was measured using x-ray powder diffraction and 
the XRD patterns are shown in Fig. 2.2.  Analysis of the bulk micronized ITZ reveals the 
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many peaks associated with crystallinity however the characteristic ITZ peaks (most 
intense) used for determining crystallinity of the SFL processed samples are located at 
17.45 and 17.95 (doublet), 20.30, and 23.45  two theta degrees.  The x-ray diffraction 
pattern for SFL A reveals two crystalline peaks associated with poloxamer 407 and PEG 
(19.65 and 23.80), however, there are no peaks associated with crystalline ITZ.  The 
XRD pattern of each pure excipient revealed similar patterns with both excipients 
producing peaks around 19.6 and 23.8 two theta degrees.  Similarly, SFL B displays the 
crystalline peaks resulting from poloxamer but appears to lack the characteristic ITZ 
peaks indicating an amorphous sample.  Lastly, SFL C lacks any crystalline peaks but 
displays one broad low intensity (> 50 counts) halo and is characteristic of amorphous 
particles. 
Investigation of the dissolution properties of the SFL processed powders was 
performed under sink conditions as shown in Fig. 2.3.  Bulk ITZ had the slowest 
dissolution of all samples investigated with 20% dissolved after 10 minutes, increasing 
up to about 45% after 30 minutes and 60% after 60 minutes.  Interestingly, bulk ITZ 
showed a nearly constant dissolution rate over 60 minutes.  The dissolution rate for 
Sporanox® solution was also determined as a control for the SFL processed powders.  As 
expected, the dissolution of ITZ from the composition into the media was instantaneous, 
occurring within the first two minutes of the experiment.  Rapid dissolution was observed 
by all SFL processed powders showing greater than 90% dissolution within 20 minutes.  
However, differences were seen within the first 20 minutes between the three SFL 
processed powders.  SFL A appeared to dissolve instantaneously on contact with the 
surface of the dissolution media and shows the fastest dissolution of all SFL processed 
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powders.  From the dissolution profile, the SFL A powder is 80% dissolved within the 
first two minutes and completely dissolved within the first five minutes.  SFL B also 
wetted very well in the dissolution medium and exhibited rapid dissolution with 75% 
dissolved after five minutes and nearly completely dissolved after 10 minutes.  SFL C, on 
the other hand, did not wet well and therefore displayed the slowest dissolution rate of all 
the SFL processed powders.  Upon addition to the aqueous dissolution media, the SFL C 
powder remained on the surface and required agitation of the paddles for complete 
wetting.  As a result, a slower dissolution rate was observed for SFL C within the first 10 
minutes (40% dissolved in 5 minutes and 65% dissolved in 10 minutes).  Therefore, the 
dissolution rate rank order for the SFL processed powders was SFL A > SFL B > SFL C. 
2.4.2  In vivo Characterization 
 
 After evaluation of the in vitro performance of each SFL composition, SFL A was 
selected for testing in a mouse model.  Mice were dosed via an oral gavage of an SFL A 
aqueous suspension and the pharmacokinetic parameters were determined for a single 
dose over 24 hours.  Results were compared with the commercial product, Sporanox® 
oral solution. 
 Due to the number of samples per time point (pooling of samples) and model 
selection in previous studies examining oral delivery of ITZ solid dispersions [8-10], 
non- compartmental analysis was utilized to analyze the pharmacokinetic parameters of 
the ITZ oral dosing. ITZ serum concentration vs. time is shown in Fig. 2.5 [11].  
Absorption profiles were similar for both the SFL A and Sporanox® compositions; 
however, greater variation was seen with the SFL A composition.  From Fig. 2.5 and 
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Table 2.3 the pharmacokinetic parameters are displayed.  Pharmacokinetic parameters are 
reported for both the SFL A composition and the Sporanox® oral solution.  The ITZ 
serum levels of the micronized crystalline ITZ were below the limit of quantitation and 
therefore the pharmacokinetic parameters are not reported.  The Cmax, Tmax, elimination 
rate constant Kd, T1/2, and AUC (0-24 hr) for the Sporonox oral liquid and SFL A are 
1.59 and 1.28 µg/mL, 1.0 and 2.0 hr, 0.36 and 0.51 hr-1, 5.42 and 4.56 mg*hr/mL, 
respectively. 
2.5  DISCUSSION 
 
 Because ITZ is a BCS class II compound, absorption is dissolution rate limited 
and therefore, enhancing the dissolution should lead to overall enhanced absorption and 
improved oral bioavailability.  ITZ has extremely low solubility in neutral or alkaline 
media such as that of the upper small intestines, and it was hypothesized that complete 
dissolution and absorption of ITZ within the stomach is desirable for delivery of ITZ.  
Immediate dissolution would allow maximum time for absorption within the stomach 
before the dose is emptied into the upper small intestine, resulting in a pH shift that may 
cause precipitation of ITZ out of solution and subsequent recrystallization.  Excipients 
used in SFL A, which was produced from an emulsion feed dispersion, were chosen for 
two reasons: their ability to stabilize the emulsion feed dispersion for a sufficient period 
of time necessary to allow processing and increase the wettability and dissolution 
properties of the powder.  S80 is a sorbitan fatty acid ester with a low hydrophilic-
lipophilic balance (HLB) value of 4.3 used as the primary emulsifying agent allowing for 
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stable droplet sizes of 760 nm in diameter.  Surfactant/stabilizers P188 and PEG were 
added to the aqueous phase increase wetting of the amorphous ITZ domains after 
lyophilization as well as aid in stabilization at the droplet interface.   Excipients used in 
SFL B were chosen also to enhance the wetting of ITZ.  P407 is a block copolymer with 
an HLB value greater than 20 and was used as a wetting/stabilizing agent while T80 has 
an HLB value of 16.7. Because the powders were developed from an organic co-solvent 
feed solution, the ITZ should be either dissolved within the polymers (i.e. solid solution) 
or exist as nanostructured domains within the polymer matrix.    PVPK15 was used as a 
stabilizer to prevent recrystallization of the ITZ. However, binary mixtures of ITZ and 
PVP showed poor wetting during dissolution and therefore, T20 was added in order to 
overcome dissolution limitations associated with poor wetting. 
All three SFL processed powders were amorphous as a results of the rapid 
freezing process, regardless of the excipient composition used.  Amorphous materials are 
known to dissolve faster than their crystalline counterparts due to their lower heat of 
solution and energy required for dissolution to occur.[12]  Equally important is that an 
API in its amorphous state temporarily has a higher apparent solubility in a given solvent 
compared to its crystalline counterpart.  This leads to a higher concentration driving force 
(Cs-C) allowing for dissolution rate enhancement.[13]  Although not tested in this study, 
Vaughn et al. investigated the relationship between danazol supersaturation in vitro and 
bioavailability enhancement, and concluded that there was a direct correlation.[14]  It is 
estimated that the SFL process using liquid nitrogen as a cryogen can achieve freezing 
rates on the order of 104 K/sec.[15]  This freezing rate is sufficient to arrest the 
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recrystallization process inherent in slower freezing processes regardless of the liquid 
feed composition.   
However, the choice of feed composition is critical in controlling the particle’s 
structural characteristics.  The emulsion feed dispersion allowed for the preferential 
distribution of the stabilizer to the surface of the ITZ while the organic co-solvent feed 
solutions led to co-precipitation of the ITZ and the stabilizers.  This localization of the 
stabilizer to the particle surface leads to more efficient use of the hydrophilic stabilizers.  
Sinswat et al. further showed adsorption of the stabilizer onto the surface of the particle is 
largely dependent on the HLB value and the hydrophobicity of ITZ.[16]  Since P407 and 
PEG, which are both very hydrophilic, are less likely to adsorb to the hydrophobic 
regions of ITZ, S80, a nonionic surfactant, was added to the organic phase to reduce the 
hydrophobicity of the droplet allowing for greater adsorption of the stabilizers.  This led 
to greater physical stabilization of the emulsion as well as providing for enhanced wetting 
capabilities of the lyophilized powder.  Based on this and other high potency studies,[7, 
16, 17] it is estimated that the potency of this composition could be increased without 
sacrificing the desired wetting and dissolution characteristics of the powder.  
SFL B was produced from an organic co-solvent feed solution which is a 
homogeneous mixture of ITZ and the hydrophilic stabilizers.  As freezing occurs, 
solubility differences from temperature change result in rapid nucleation of both the ITZ 
and the stabilizers.  If freezing rates are sufficiently fast spontaneous and simultaneous 
nucleation should result in a solid solution containing both ITZ and the stabilizers.  
However, because of the intimate mixing between the ITZ molecules and the stabilizers, 
the stabilizers can exert a greater influence on the final powder characteristics.  For 
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example, Hu et al. found dramatic differences in surface areas between danazol:P407 and 
danazol:PVP compositions at equal ratios.  The surface area for the danazol:PVP was 
over 45-times greater than the surface area for the danazol:P407 composition, although 
dissolution rates were comparable.[18]   
SFL C was a high potency composition which displayed remarkable dissolution 
rate enhancement despite having higher regions of hydrophobicity compared to the other 
two compositions as indicated by contact angle studies.  Previous studies using 
technologies such as spray-drying, solvent evaporation, and melt-extrusion [19-21] to 
increase ITZ potencies in solid dispersions have, in some instances, seen a dramatic 
decrease in dissolution rate as potency is increased.  Verreck et al. found that dissolution 
rates of ITZ:HPMC solid dispersions were a function of polymer content and rates 
decreased tremendously as HPMC content decreased from 60% to 33%.       
SFL A was further investigated to determine its in vivo  performance in a mouse 
model compared to a commercially available ITZ product and micronized crystalline ITZ 
because the composition displayed the best physico-chemical properties of all the SFL 
processed powders investigated.  The SFL A powder was composed high surface area 
aggregates containing nanoparticle amorphous API domains surface stabilized with 
hydrophilic polymers.  The powder also displayed the fastest dissolution rate as a result 
of its lower potency (increased wetting agent) and enhanced physico-chemical properties.  
The improved pharmacokinetic parameters for SFL A validate the enhanced physico-
chemical properties of the composition.  Absorption of ITZ occurred rapidly most likely 
due to the enhanced wetting of the composition while the high serum levels were 
attributed to the increased absorption from improved dissolution.  The extent of ITZ 
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absorption, as indicated by the AUC, was comparable to the Sporanox® oral solution 
having about 85% relative bioavailability. The lack of an absorption profile for the 
micronized crystalline ITZ is the result of poor wetting of the ITZ preventing dissolution 
in vivo and solubility limitations resulting from the crystalline structure of the ITZ.  The 
Sporanox® oral liquid contains hydroxypropyl-β-cyclodextrin which has formed a 
complex with ITZ thereby enhancing the solubility of ITZ in both and acidic and higher 
pH (intestinal) environment.  Because Sporanox® exists as a solution, dissolution within 
the stomach is not necessary and absorption can begin immediately.  Likewise, within the 
cyclodextrin complex, ITZ should remain in solution upon entering the upper intestinal 
tract and absorption should continue.  Despite these advantages of the oral solution, the 
ITZ absorption profiles for SFL A and the Sporanox® oral liquid were similar although 
statistical analysis could not be performed due to the number of samples per time point 
(n=2).  Therefore, these studies have shown that the SFL process can create highly 
wettable high surface solid dispersions of amorphous API leading to enhanced absorption 
of poorly water soluble APIs. 
2.6  Conclusion 
 
 Three compositions were manufactured using the SFL process to investigate the 
influence of hydrophilic stabilizer on the enhancing the wetting and dissolution rate.  SFL 
A, sprayed from an emulsion feed dispersion, resulted in a solid dispersion of amorphous 
nanoparticle API domains stabilized by adsorption of stabilizing polymers on the surface.  
SFL B and SFL C were sprayed from organic co-solvent feed solutions and resulted in 
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porous structures thought to contain nanodomains of ITZ.  SFL B contained lower 
melting point stabilizers which resulted in agglomeration of the nanoparticles lowering 
the surface area.  SFL C, although having a high potency, still maintained a rapid 
dissolution rate due in part to its high surface area and amorphous nanoparticle domains.  
Studies revealed that the in vitro properties were enhanced first through the rapid freezing 
process to create amorphous ITZ.  Secondary to the process, properties were further 
enhanced by addition of the stabilizers to the surface of the amorphous ITZ using an 
emulsion feed dispersion.  This surface adsorption allowed for better wetting of the 
particles leading to enhanced dissolution.  The effect of the polymer on particle 
characteristics was much more pronounced and led to particle agglomeration in SFL B.  
Likewise, a high potency composition had a decreased dissolution rate compared to SFL 
A and SFL B and was attributed to the increased hydrophobicity of the particle from the 
ITZ.  An in vivo study proved increased efficacy of the SFL A micronized powder 
compared to the commercially available Sporanox® oral solution and micronized 
crystalline ITZ.  In conclusion, the SFL powder prepared from the emulsion feed 
dispersion produced surface stabilized amorphous ITZ nanostructured aggregates which 
enhanced the physico-chemical properties (wetting, surface area, particle size) leading to 
enhanced dissolution rate and in vivo absorption with high and rapid onset of Cmax and a 
relative bioavailability of 85% that of Sporanox® oral solution. .   
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Chapter 3:  Novel Ultra-rapid Freezing Particle Engineering Process for 
Enhancement of Dissolution Rates of Poorly Water Soluble Drugs 
 
3.1  ABSTRACT 
An ultra-rapid freezing (URF) technology has been developed to produce high 
surface area powders composed of solid solutions of an active pharmaceutical ingredient 
(API) and a polymer stabilizer.  A solution of API and polymer excipient(s) is spread on 
a cold solid surface to form a thin film that freezes in 50 ms to 1s.  This study provides an 
understanding of how the solvent’s physical properties and the thin film geometry 
influence the freezing rate and consequently the final physicochemical properties of URF 
processed powders.  Theoretical calculations of heat transfer rates are shown to be in 
agreement with infrared images with 10 ms resolution.  Danazol 
(DAN)/polyvinylpyrrolidone (PVP) powders, produced from both acetonitrile (ACN) and 
tert-butanol (T-BUT) as the solvent, were amorphous with high surface areas (~28-30 
m2/g) and enhanced dissolution rates.   However, differences in surface morphology were 
observed and attributed to the cooling rate (film thickness) as predicted by the model.  
Relative to spray freezing processes that use liquid nitrogen, URF also offers fast heat 
transfer rates as a result of the intimate contact between the solution and cold solid 
surface, but without the complexity of cryogen evaporation (Leidenfrost effect).  The 
ability to produce amorphous high surface area powders with submicron primary 
particles with a simple ultra rapid freezing process is of practical interest in particle 
engineering to increase dissolution rates, and ultimately bioavailability. 
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3.2  INTRODUCTION 
 
 A significant number of active pharmaceutical ingredients (API) being discovered 
display desirable therapeutic properties, but have undesirable physicochemical properties 
(e.g. solubility) making formulation into an effective drug product challenging. The 
Biopharmaceutical Classification System (BCS) class II APIs, which have been reported 
to account for as many as 40% of new chemical entities[1], present particular challenges 
in creating successful drug products.   For example, BCS class II compounds do not 
readily dissolve in the biological media of the digestive tract and thus exhibit poor or 
variable bioavailability.  Consequently, the major obstacle in formulating these 
compounds into successful commercialized products is the difficulty in enhancing the 
dissolution rate. 
 A number of strategies and processes have been reported to facilitate the 
dissolution of these poorly water soluble APIs.  These include particle reduction/milling, 
solution based precipitation techniques, and emulsification/precipitation, etc., as 
described extensively in reviews.[2-6]   Cryogenic technologies, in particular, have been 
shown to  enhance the dissolution rates of poorly water soluble APIs by creating highly 
porous nano-structured particles[7-10]  The processes Spray Freezing into Liquid (SFL) 
and Spray Freeze Drying (SFD) use cryogens, particularly N2, to form a solid dispersion 
or solid solution[11] composed of nanoparticle domains of API within a polymer matrix.  
The particles are produced by rapidly freezing a feed solution in a cryogenic liquid and 
removing the solvent(s) through lyophilization.  Micronized powders containing 
nanoparticles of API have been successfully manufactured with the SFL technology 
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using a variety of different types of solvents.[12, 13]  Early work utilized aqueous co-
solvent systems such as tetrahydrofuran (THF):water which has the ability to dissolve 
both a poorly water soluble API as well as hydrophilic excipients.  Subsequently, organic 
solvents such as acetonitrile (ACN) which have the unique ability to dissolve both an API 
and a hydrophilic excipient were used to increase API loading and reduce the risk of 
liquid-liquid phase separation.  However, Hu et al.[14] found that increasing API loading 
has a profound effect on the surface morphology of the processed powders.  Later, 
Rogers et al.[13] developed an oil-in-water (o/w) emulsion system in which the API and 
emulsifiers were dissolved in dichloromethane while hydrophilic stabilizers were 
dissolved in the aqueous phase.  High pressure homogenization was used to reduce the 
mean diameter of the oil droplets to less than 1 µm before freezing the sample via the 
SFL process.   
Ultra-rapid freezing (URF) was recently developed as a particle engineering 
technology designed to enhance the dissolution rates and bioavailability of poorly water 
soluble APIs.[15]  Briefly, the process involves freezing an API contained in a polymer 
solution onto the surface of a cryogenic substrate with a thermal conductivity k between 
10-20 W/(m*K), collecting the frozen particles and removing the solvent.  Because of 
rapid conductive heat transfer, resulting in high supersaturation and nucleation rates, the 
URF technology has the potential to create powders with superior physico-chemical 
properties, similar to those produced by other rapid freezing technologies. As in other 
freezing technologies, the rapid freezing of the API/polymer composition is critical in 
preventing phase separation during freezing, allowing for the active to be molecularly 
dispersed with the polymer.  Recrystallization of the active is avoided by the inclusion of 
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high glass transition temperature (Tg) polymers such as polyvinylpyrrolidone (PVP) or 
hypromellose (HPMC).   
Previously, criteria for selection of the solvent(s) suitable for the SFL process 
included sufficient solubility of the solids and the ability to remove the solvent without 
re-crystallizing the API.  These solvents generally have freezing points between 208K 
and 273K which are ideal for tray lyophilization.  Solvents with freezing points below 
208K melt during lyophilization while solvents with freezing points higher than 273K 
may freeze prematurely within the atomizing nozzle.  Because the URF technology 
applies the droplets directly onto the cryogenic substrate, premature freezing is not a 
concern and high freezing point solvents may be used.  These solvents could prove 
beneficial by reducing the lyophilization time [16] or eliminating the solvent removal 
process altogether as some of these solvents sublime at ambient conditions or higher[17].   
The objectives of this study are to introduce the URF technology as a novel 
method to manufacture pharmaceutical powders and to investigate how solvent properties 
and thin film geometry of the droplet affect the freezing rate and thus the physico-
chemical properties of the final micronized powders.  To determine the effect of the 
solvent properties, powders were manufactured from solutions from two solvents, tert-
butanol (T-BUT) and ACN.  T-BUT was selected for its higher freezing point and good 
lyophilization characteristics while ACN was selected for its good heat transfer 
properties.  Heat transfer calculations of freezing rates are compared with those measured 
by infrared imaging.  The model and results from imaging with a focal plane array 
infrared camera are complementary and are utilized to demonstrate differences in 
freezing rates between the two solvent systems.  The physico-chemical properties of the 
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processed powders were compared to the unprocessed bulk API, and co-ground physical 
mixtures to assess the potential benefit of the URF technology.  The powders were 
evaluated based on degree of crystallinity, surface area, surface morphologies, wettability 
and dissolution rate.  It is hypothesized that the URF technology can produce powders 
with enhanced physico-chemical properties, for example low crystallinity and high 
surface area, leading to faster dissolution rates which could potentially enhance in vivo 
absorption for the BCS class II compounds. 
3.3  MATERIALS AND METHODS 
 
3.3.1  Materials 
 
Micronized danazol (DAN), sodium lauryl sulfate (SLS), and 
polyvinylpyrrolidone (PVP) K-15 were purchased from Spectrum Chemicals (Gardena, 
CA, USA).  High performance liquid chromatography (HPLC) grade acetonitrile (ACN) 
was obtained from EM Science (Gibbstown, NJ, USA), and tert-butanol (T-BUT) was 
purchased from Fisher Scientific (Fair Lawn, NJ, USA). 
3.3.2  Preparation of the URF Micronized Powders 
 
 The compositions were prepared by dissolving DAN and PVP K15 at a 1:2 ratio 
and 0.55% total solids in either T-BUT heated to 313K or ACN at room temperature.  
The DAN/PVP feed solutions were processed using the URF apparatus (process 
schematic shown in Fig. 3.1).  The feed solutions were applied to a cryogenic solid 
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substrate cooled to a temperature range of 193 K to 243K, collected, and lyophilized 
using a VirTis Advantage benchtop tray lyophilizer (The VirTis Company, Inc. Gardiner, 
NY, USA).   
3.3.3  Preparation of Control Powders 
 
The bulk API was used as received while the co-ground physical mixtures were 
prepared by adding the API and excipients to a glass mortar and pestle and 
mixed/triturated using the geometric dilution technique until a uniform powder was 
achieved.  
3.3.4  Infrared Imaging of Freezing Droplets 
 
A single droplet of ACN or T-BUT was released from a pipette with a 2 mm 
diameter tip 10 cm above a cryogenically cooled surface and allowed to impinge on the 
surface of the cryogenic substrate.  An InSb focal plane array (FPA) camera (Phoenix 
digital acquisition system (DAS) camera, Indigo Systems, Santa Barbara, CA, USA) was 
positioned to acquire infrared images from above the freezing droplet on the substrate.  
The FPA camera detected 3–5 µm radiation, and the images were acquired at 100 frames 
per second (10 ms/image).  The dimensions of each frame were 256 pixels by 256 pixels 
(15 mm X 15 mm). The image spatial resolution was approximately 40 µm per pixel.  
Average intensity values were calculated using MATLAB® version 6 (20 x 20 pixel 
square within the center of the droplet) and plotted versus time to determine the time for 
the center of the droplet to reach thermal equilibrium with the substrate.  
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3.3.5  Scanning Electron Microscopy (SEM) 
 
The powder samples were sputter coated using a model K575 sputter coater 
(Emitech Products, Inc., Houston, TX, USA) with gold-palladium for 35 seconds and 
viewed using a Hitachi S-4500 field emission scanning electron microscope (Hitachi 
High-Technologies Corp., Tokyo, Japan).  An accelerating voltage of 5-15 kV was used 
to view the images.  All SEMs pictured were representative of the entire sample. 
3.3.6  Dissolution Testing 
 
Dissolution testing was performed on all powder samples using a United States 
Pharmacopeia (USP) 24 Type 2 apparatus (VanKel VK6010 Dissolution Tester with a 
Vanderkamp VK650A heater/circulator, Cary, NC, USA).    The dissolution medium 
consisted of 0.3% SLS dissolved in de-ionized water and maintained at 37.0 ± 0.2°C 
throughout the study.  Five ml samples were withdrawn at 2, 5, 10, 20, 30 and 60 minute 
time points, filtered using a 0.45µm GHP Acrodisc filter and analyzed using a Shimadzu 
LC-10 liquid chromatograph (Shimadzu Corporation, Kyoto, Japan) equipped with an 
Alltech ODS-2, 5 µm C18 column (Alltech Associates, Inc., Deerfield, IL, USA).  A 
70:30 ACN:water mobile phase at 1 ml/min eluted the DAN peak at 5 min[11].  The 
maximum absorbance was measured at λ=288 nm.  System suitability requirements were 
met (R2 ≥ 0.999, precision ≤ 2.0% RSD).  
3.3.7  X-Ray Powder Diffraction (XRD) 
 
 85
The x-ray diffraction patterns of all powder samples were analyzed using a Philips 
1710 x-ray diffractometer with a copper target and nickel filter (Philips Electronic 
Instruments, Inc., Mahwah, NJ, USA).  The leveled powder was measured from 5 to 45 
2θ degrees using a step size of 0.05 2θ degrees and a dwell time of one second. 
3.3.8  Surface Area Analysis 
 
Specific surface area was measured using a Nova 2000 v.6.11 instrument 
(Quantachrome Instruments, Boynton Beach, FL, USA).  A known weight of powder was 
added to a 12 mm Quantachrome bulb sample cell and degassed for a minimum of three 
hours.  The sample was then analyzed (n=3) by the NOVA Enhanced Data Reduction 
Software v. 2.13 via the Brunauer, Emmett, and Teller theory of surface area[18]. 
3.3.9  Contact Angle Measurement 
 
 A 50 mg aliquot of sample powder was compacted with a Model M Carver 
laboratory press (Fred S. Carver, Inc., Menomonee Falls, WI, USA) using a compaction 
force of 500 kg to form a smooth surfaced tablet.  A 3 µl drop of purified water was 
added to the surface of the tablet and the contact angle was quantitated using a 
goniometer (Ramè-Hart Inc., Mountain Lakes, NJ, USA) by measuring the tangent to the 
curve of the droplet on the surface of the tablet. 
3.3.10  Statistical analysis 
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One-way analysis of variance (ANOVA) was used to determine statistically 
significant differences between results. Results with P values < 0.05 were considered 
statistically significant.  Post-hoc comparisons using Tukey’s test were made to 
determine differences between the URF compositions and the controls. 
3.4  RESULTS 
 
3.4.1  Infrared Measurements of Cooling Droplets on Cryogenic Plate 
 
An infrared (IR) camera was used to quantitate the amount of IR energy radiated 
from the spread droplet over time on a cryogenic plate.  The IR camera outputs intensity 
values assigned on a grayscale with white having a high intensity and black having a low 
intensity in relation to the amount of radiant energy emitted from the droplet.  A thermal 
equilibrium was established when the intensity value was constant over time, indicating 
that the rate of heat transfer approached zero.  It is estimated that at thermal equilibrium, 
the temperature of the droplet is near the temperature of the cryogenic substrate and 
confirmed via direct thermocouple measurement using a surface measuring probe.  As the 
droplets enter the field of view, they appear white for both ACN and T-BUT.  Figures 3.2 
and 3.3 contain time lapse IR photographs for ACN and T-BUT, respectively.  For ACN, 
complete spreading of the droplet occurred within the first 10 ms interval indicating that 
the time of droplet spreading, tspreading, was much less than the freezing time, tfreeze..  
Therefore, t=0 was defined as the first frame in which impingement was observed.  When 
dropped from a height of 10 cm, the diameter for the spread ACN droplet as measured by 
a ruler and confirmed by IR camera was 1.9 cm.  At t=20 ms, the droplet began to 
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visually darken evenly throughout the entire droplet.  Since IR radiation between 3 and 5 
microns is not readily absorbed by either ACN or T-BUT, it is believed that the initial 
darkening is a result of the cooling of the solvent near the droplet-surface interface.  
Between 20 and 70 ms, a cooling front is observed moving radially inward as the 
remaining droplet freezes.  After 70 ms a slight fluctuation in intensity is observed before 
thermal equilibrium around 2280 intensity units is established.  Figure 3.4a is a plot of 
the average intensity at the center of the ACN droplet as a function of time.  After a rapid 
decrease in intensity is initially observed in which the bottom of the solvent immediately 
freezes, the rate begins to slow slightly until a minimum intensity value of 2280 is 
reached at 70 ms. 
With a melting point near room temperature (296-298 K), the T-BUT samples 
were heated to 313 K to prevent premature freezing before spreading of the droplet on the 
cryogenic surface.  As in the case of the ACN droplet, impingement and complete 
spreading of the T-BUT droplet also occurred within the first 10 ms interval.  When 
dropped from a height of 10 cm, the spread diameter for the frozen T-BUT droplet 
measured 0.8 cm, less than half that of the ACN droplet.   At 150 ms, the appearance of a 
black ring around the edge of the droplet appears indicating that the cooling rate is faster 
near the edge of the droplet (Fig 3.3b).  As cooling continues, the cooling front proceeds 
radially inward towards the center of the droplet and has much greater contrast than 
observed with the ACN droplet.  At 400 ms, IR intensity throughout the droplet was 
decreased (Fig. 3.3c) and at 1000 ms thermal equilibrium was established (Fig. 3.3d).  
Similar to the case for the ACN droplet, the first few frames indicate a sharp decrease in 
intensity as the liquid in contact with the cryogenic surface immediately cools (Fig. 3.4b).  
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After the initial drop in intensity where the droplet freezes instantaneously at the solid 
liquid interface, the rate of intensity decrease begins to slow and becomes much slower 
than for the ACN droplet.  Since solidification occurs in the axial direction according to 
this model, the resulting solid solvent and solid API/polymer particles act as an insulating 
layer[19] decreasing the rate of heat transfer.  Ultimately, the droplet thermally 
equilibrates around 2030 at around 1000 ms.    
3.4.2  Physico-chemical Properties and Dissolution Rates of URF Processed Powders 
 
DAN powders were produced using the URF technology, and the physico-
chemical properties were compared to the bulk API and the physical mixture.  The 
characteristic crystalline peaks for DAN were found at 15.90 and 19.15 2θ degrees with a 
doublet peak around 17.30 2θ degrees, as seen in the bulk DAN and physical mixture 
samples in Fig. 3.5.  The physical mixture sample showed a reduction in crystalline 
intensity due to the dilution of PVP in the sample.  Both URF processed powders lacked 
the characteristic crystalline peaks and therefore were considered to contain amorphous 
DAN.  This is attributed to the rapid freezing occurring during the URF process and the 
ability of PVP to inhibit crystal growth.       
As seen in Table 3.1, high specific surface areas (SSA) were reported for both the 
URF processed powder from T-BUT, with values of 29.3 and 25.9 m2/g, respectively.  
The SSA was 50-60X greater than that of the micronized bulk DAN and about 40X 
greater than that of the physical mixture.      
 Differences between the two URF processed powders are evident in the surface 
morphology.  The URF processed powder from ACN showed compacted aggregates of 
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uniform nanoparticles with diameters of about 100 nm or smaller (Fig. 3.6a) in all areas 
of the sample.  The surface morphology of the 1:2 DAN:PVP composition dissolved in 
T-BUT and processed by URF indicated regions of nanoparticles with similar particle 
sizes (Fig. 3.6b); however, particle sizes were not as uniform as those present from 
powders produced from ACN.  Likewise, other areas of the powder exhibited very thin 
plate-like domains.   
Dissolution rates for the processed powders are compared in Fig. 3.7 with those of 
the bulk DAN and the physical mixture. Samples processed from URF revealed rapid 
dissolution with at least 85% API dissolved within 10 minutes and showed statistically 
greater release than the bulk DAN and the physical mixture (p<0.05).  The URF 
processed powders produced from both T-BUT and ACN had nearly identical dissolution 
profiles (p>0.05).  The similar profiles may be rationalized by the observation that both 
compositions were amorphous and had similar and very high surface areas.  These factors 
produced very rapid dissolution rates.  Inclusion of PVP in the physical mixture increased 
the dissolution only slightly, relative to pure danazol indicating that the low surface area 
and crystallinity of DAN limited the dissolution rate.   
ANOVA statistical analysis revealed that significant differences in contact angle 
existed between the four sample groups (F > Fcrit).  Contact angle measurements for both 
the processed powders and the physical mixture of 1:2 DAN:PVPK15 showed a 
statistically significant (p < 0.05) decrease in contact angle (30.5°-39.5°) compared to the 
bulk DAN (64.0°) indicating better wettability of the powders as seen in Table 3.1.  
There were no significant differences between the two URF processed powders (e.g. 
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85.35.2 <=−− ACNBUTT XX ) but there were differences between the URF processed 
powders and the physical mixture.  This is most likely due to the intimate mixing of PVP 
and DAN during the process allowing for a more homogenous distribution of the PVP 
throughout the powder. 
3.5  DISCUSSION 
 
3.5.1  Theoretical Modeling 
 
 The phenomena of droplet spreading and solidifying/freezing for an impinging 
droplet on a solid substrate have been studied extensively by many research groups.[19-
32]  The fluid dynamics and heat transfer can be coupled requiring a numerical solution.  
However, in our IR imaging studies the heat transfer was much slower than the droplet 
spreading.  Thus the model can be solved analytically to describe the cooling rate in 
URF.[33]  The validity of the model will be evaluated by comparison to the experimental 
IR data for ACN and T-BUT. 
In the model it is first assumed that droplet spreading after impact occurs on a 
much shorter time scale than heat transfer. Consequently, significant heat transfer does 
not occur until spreading is complete.  The second assumption is that the droplet spreads 
to form a thin cylindrical disk.  Because of the small height of the disk relative to the 
diameter, the third assumption is that only one-dimensional heat transfer is present in the 
z direction.  Conduction in the radial direction through the thin disk parallel to the surface 
may be neglected.  The final assumption is that the thermal diffusivity α is constant over 
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the entire temperature range and remains unchanged during the phase change of freezing.  
Given the above assumptions the transient heat transfer equation through the cylindrical 
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where the temperature T is a function of time t and x is the distance into the disk from the 
top surface of the thin film exposed to air.  The thermal diffusivity of the spread droplet is 
defined as pCk ∗= ρα / , where k is the thermal conductivity, ρ is the density, and Cp is 
the heat capacity.   
The first boundary condition for Equation 1 assumes that heat transfer through the 
top surface of the disk exposed to the air is negligible.  Therefore, the air is assumed to 
act as an insulator.  The second boundary condition assumes the cryogenic plate 
temperature, plateT , remains constant during the cooling process with negligible heat 
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 92
Here x = L is the bottom surface of the disk in contact with the plate.  The initial 
condition assumes that the droplet temperature is uniform before impact and is defined 
as: 
 
 iTxT =)0,(  (4) 
 
where iT  is the initial solvent temperature.  Equation 1 is then solved analytically for a 
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where L  is the disk thickness.  Cooling times are then determined by calculating the 
time, t, it takes for the surface of the solvent film at x = 0 with thickness L to reach a 
given temperature T using the software MATHCAD® version 11.   
The spread droplet thickness was easily determined with the assumption that the 
droplet impacting on the cold substrate deformed into a cylinder with an equivalent 
volume to the original droplet volume before impact.  Droplet volume was determined by 
dropping 100 droplets into a graduated cylinder and measuring the total volume.  Frozen 
spread droplet diameters were measured with a ruler across two directions and averaged 
for 10 droplets.  Droplet thicknesses were then calculated from the known volume of the 
falling droplet and the diameter of the frozen spread droplet and were 109±10 µm and 
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403±32 µm for ACN and T-BUT, respectively.  Modeling the frozen spread droplet as a 
thin cylindrical disk has been used in many previous models [20-22, 25, 34] and has been 
experimentally justified when the Weber number, γρ /2 DVWe =  (inertial to interfacial 
forces), of the impacting droplet is >>1 [26] where V  is the impact velocity, D  is the 
droplet diameter, and γ  is the droplet interfacial tension.  The impact velocity, V  was 
calculated from the free-fall equation in a gravitational field, 2/1)2( gHV = [34] where the 
falling height, H , of the droplet was 10 cm resulting in an impact velocity of 1.4 m/s.  
The densities and interfacial tensions for each solvent were determined using the DIPPR 
database (Brigham Young University, Provo, UT) at the initial temperatures of 298 K and 
313 K for ACN and T-BUT, respectively.  The resulting We numbers were 207 and 274 
for the ACN and the T-BUT droplets, respectively, which supports the assumption that 
the impinging droplets deform into thin cylindrical disks.[26]  The thermal diffusivity, 
α , used for each solvent in this model was determined by first taking the average of each 
property in the definition of α evaluated between the initial droplet temperature to the 
freezing temperature of each solvent.(Table 3.2).  The α for each solid solvent was not 
determined since thermal conductivity values were not available for each solvent in solid 
form. 
The calculation of cooling times for each solvent was based on the time it takes 
for the top of the spread droplet at x = 0 to reach a given temperature, T.  The cooling 
time to reach the freezing point of each solvent was calculated first.  Fig. 3.8a is the 
calculated temperature profile for an ACN spread droplet.  After 72 ms the top of the 
spread droplet defined at x = 0 reaches the freezing point of ACN, 230 K.  For T-BUT 
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(Fig. 3.8b) the cooling time to reach the freezing temperature of 299 K was 483 ms.  
Since the freezing points of each solvent are greater than the surface temperature of the 
solid substrate, 213 K, the spread droplet will continue to cool below the freezing point 
until an equilibrium temperature is reached.  Therefore, a cooling time was calculated for 
the droplet to reach an arbitrary temperature of 225 K, which is approximately 5% greater 
than the cryogenic substrate temperature.  These times were 86 and 3037 ms for ACN 
and T-BUT, respectively. 
3.5.2  Comparison of ACN IR data to calculated cooling times 
 
To evaluate the accuracy of the predictions of the proposed model, the calculated 
cooling times were compared to the IR images.  The initial intensity of 2783 for time t = 
0 ms correlated to the initial ACN temperature of 25ºC (Fig. 3.4a).  Due to the small 
thickness of the spread droplet it is reasonable to assume that the equilibrium intensity of 
2280 at the top surface of the spread droplet is close to the temperature of the cryogenic 
substrate (213 K).  The calculated cooling times to reach the freezing point, 230 K, and 
225 K were 72 and 86 ms, respectively.  The similarity in these times is consistent with 
the small difference in temperature between the freezing temperature and 225 K.  The 
calculated cooling time is located at the bottom of the initial steep descent for the 
experimental curve in Fig. 3.4a.  The calculated equilibrium cooling time occurs shortly 
thereafter at the beginning of the flat part of the intensity curve.  The abrupt change in 
slope of the intensity curve near 70 ms may be an indication of ACN changing from the 
liquid to solid phase.  The discontinuity in the slope of the intensity curve was confirmed 
when the experiment was repeated a second time.  The good agreement between the 
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calculated cooling times and the shape of the intensity curve supports the assumption that 
the heat transfer time is considerably slower, and essentially uncoupled, from the rapid 
spreading of the droplet on impact.  Frame by frame analysis of the impinging ACN 
droplet showed that complete spreading occurred in less than 10 ms.  Furthermore, the 
spreading diameter on the cryogenic substrate was similar to that on the same substrate at 
room temperature, indicating that cooling and freezing of the droplet did not inhibit 
spreading.  Although the model calculates cooling times that are consistent with 
experimental IR data, it does not account for the radial cooling front observed during the 
latter stages of cooling of the spread ACN droplet.  In spite of the radial cooling front 
observed during cooling, the calculated cooling times do not vary significantly from the 
experimental cooling times. 
3.5.3  Comparison of T-BUT IR data to calculated cooling times 
 
The cooling behavior was substantially different for T-BUT compared to ACN.  
As shown in Fig. 3.3, cooling along the radial direction of the spread T-BUT droplet 
appeared to be significant.  Also, after the T-BUT droplet impacted the cryogenic 
substrate the final spread droplet diameter was only 0.8 cm which was significantly 
smaller compared to the 1.9 cm formed on the same substrate at room temperature.  The 
smaller spread diameter corresponds to a frozen spread droplet thickness 4X greater than 
ACN.  The calculated cooling time to freezing (299 K) for T-BUT was 483 ms starting 
from an initial droplet temperature of 313 K.  In (Fig. 3.4b) the approximate intensity 
value at t = 483 ms was 2185 which was slightly above the asymptotic equilibrium 
intensity (~213 K) of 2016, but well below the initial intensity of 3227 correlated to 313 
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K.  The intensity curve reaches equilibrium at approximately t = 1000 ms which is 
assumed to correlate to an approximate spread droplet surface temperature of 213 K.  The 
calculated time for the top droplet surface to reach the defined equilibrium temperature of 
225 K was 3037 ms which is about 3 fold the experimental value of 1000 ms.  However, 
the model correctly predicted that the experimental observation that the cooling was 
much slower than for ACN. 
Various factors may contribute to the faster cooling in the experiments versus the 
model.  The difference cannot be explained by cooling of the droplet during free fall.  
The free fall cooling effect on droplets, initially at 313 K, according to the model of 
Bennett and Poulikakos,[34]  would produce an insignificant change of less than 1K.  The 
more rapid cooling for the experimental measurements may be the result of radial cooling 
as the droplet spread, and even after spreading.  The movement of the radial cooling front 
was about 30X slower for T-BUT than for ACN.  Thus radial cooling appeared to play a 
greater role for T-BUT, which is consistent with the thicker disk for T-BUT, which 
corresponds to a greater cross-sectional surface area for radial conduction, and a smaller 
surface area for axial conduction.     
The effect of radial cooling was shown for molten metal droplets impinging on a 
cold substrate by other research groups.[19, 32]  It was determined that significant heat 
transfer can occur during spreading of the droplet after impact.[19, 32]  Zhao et al. 
described that the radial cooling front occurs because during impaction high temperature 
solvent is continuously supplied to the center region of impact while the spreading front 
cools at a faster rate by contacting the low temperature surface of the substrate.[32]  
Fukai et al. determined that the spreading diameter of droplets can be arrested on a cold 
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substrate as the edges freeze.[19] It is likely that the spreading diameter was reduced for 
T-BUT by freezing of the droplet edge, since the temperature difference from the initial 
droplet temperature (313 K) to freezing point (299 K) is only 14 K versus 68 K for ACN. 
The effect of radial cooling and partial cooling before complete spreading led to an 
overestimation by the model; however, it gave a reasonable result that was instructive for 
explaining the slower cooling for T-BUT versus ACN. 
3.5.4  Influence of solvent system on powder properties 
 
Even though there are substantial differences in the freezing characteristics of 
each solvent, both solvents produced powders comprising DAN and PVP with similar 
physico-chemical properties indicating sufficient cooling rates in both solvents.  The 
URF technology was used to manufacture micronized powders containing DAN and 
PVPK15 in a 1:2 ratio using both ACN and T-BUT as the solvent system. 
The rapid freezing of the URF technology produced powders with amorphous 
characteristics which can enhance dissolution rates through increasing the solubility 
driving force[35] and lowering the heat of solution of the API[36].  According to the 
contact angle measurements, wetting of the DAN was improved through the use of the 
hydrophilic polymer PVP which also acts as a stabilizer to prevent recrystallization of 
DAN.  Statistical differences was seen between the contact angles for the processed 
powders and the physical mixtures at the current ratios, while even higher potency 
powders produced from URF (not published) or SFL[11, 14] have also shown significant 
differences in wetting compared to their physical mixture counterparts.  Despite the 
similar surface areas for both URF micronized powders, the particle morphologies were 
 98
very different.  Both processed powder SEMs revealed discrete nanoparticle domains 
containing DAN.  However, flat plate-like regions were also observed throughout the 
powder sample in Fig. 3.6b for T-BUT.  This is attributed to a difference in cooling rates 
between the two solvents.[28, 29]  The temperature decrease over time at the top of the 
droplet (x=0) is much slower for the T-BUT droplet which drops 17 degrees Kelvin in 
600 ms compared to the ACN which drops 75 degrees Kelvin within 70 ms.   The slower 
cooling for T-BUT provided time for growth to occur, forming the plate-like regions.  
The growth may have been non-uniform, as more time for growth was available closest 
to the air surface where the temperature was the highest. However, the freezing rates 
appeared to be sufficiently fast in both solvents to produce high surface area powders 
with low crystallinity.  Differences in surface morphology could also be attributed to 
possible differences in solubility within the solvent based on the temperature-composition 
phase diagram of the API/polymer solution.[37, 38]  However, these diagrams were not 
determined and therefore, the extent of this phenomenon on the particle morphology is 
not known at this time. 
3.6  CONCLUSIONS 
 
 Sample powders were prepared by URF technology from two different solvents 
with different thermal and physical properties, T-BUT and ACN.  The differences in the 
thermal properties of the solvent and droplet dimensions had a dramatic effect on the 
cooling rate of the droplets as evidenced by the heat transfer model and IR studies. An 
axial heat transfer model for the spread droplets indicated ACN droplets cooled in 72 ms 
while T-BUT droplets required a much greater time of 483 ms.  The much longer cooling 
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time for T-BUT was also observed by IR imaging.  However, it was found that the rate of 
cooling was sufficiently rapid in both solvents to produce amorphous powders with high 
surface areas on the order of 25.9-29.3 m2/g and high wettability.  Relative to physical 
mixtures, the URF processed powders had much more rapid dissolution profiles, which 
were attributed to nano-structured amorphous API domains, and the improved surface 
areas and wettability.  The surface morphology of the powders was different for the two 
processing solvents, despite the similar surface areas.   The primary particles in powders 
produced from ACN were spherical and uniform in size as a result of the more rapid and 
uniform cooling of the droplet relative to T-BUT.  The use of ACN as a solvent allows 
for high heat transfer rates, which is beneficial for producing small rapidly dissolving 
particles, however, its low melting point can cause loss in particle surface area prior to 
solvent removal.  T-BUT, on the other hand, has a lower (but sufficient) heat transfer rate 
compared to ACN, but is less susceptible to melting at ambient conditions prior to 
solvent removal.. As a result of fast cooling rates and thus high supersaturation, the URF 
technology is a viable and robust process for producing high surface area nano-structured 
powders of poorly water soluble APIs with rapid dissolution rates, which will likely lead 
to enhanced bioavailability in vivo.  
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Chapter 4:  Effect of Stabilizer on the Maximum Degree and Extent of 
Supersaturation and Oral Absorption of Tacrolimus Made By Ultra-
Rapid Freezing 
 
4.1  ABSTRACT 
 
 Supersaturated solutions are known to enhance transport across biological 
membranes by increasing the concentration driving force.  Amorphous nanoparticles 
containing tacrolimus (TAC) in a solid dispersion with the ability to form supersaturated 
solutions in aqueous media were prepared using the Ultra-rapid Freezing (URF) process.  
Maximum supersaturation levels (C/Ceqmax), defined as the ratio of the highest 
instantaneous TAC concentration C to the equilibrium solubility of crystalline TAC 
(Ceq), and extent of supersaturation, as measured by the area under the supersaturation 
curve (AUC), were used to assess the performance of the URF compositions.  The 
stabilizers included poly(vinyl alcohol) (PVA), poloxamer 407 (P407), and sodium 
dodecyl sulfate (SDS)..  The correlation between in vitro supersaturation and in vivo 
absorption enhancement in rats was investigated for various URF compositions of TAC.  
Dissolution studies were conducted at supersaturated conditions in both acidic media 
(0.2% NaCl in 0.1N HCl) for 24 hours and at delayed release conditions (USP 25 enteric 
test method A; with acid to base pH change) to better simulate intestinal transit.  The rank 
order of C/Ceqmax in the dissolution studies at acidic conditions was URF-P407 
(TAC:P407) > URF-SDS (TAC:SDS) > Prograf® (PRO) > URF-PVA:P407 
(TAC:PVA:P407).  For C/Ceqmax under delayed release (enteric) conditions, the order 
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was URF-SDS > PRO > URF–PVA:P407 > URF-P407, and for the extent of 
supersaturation (AUC) in acidic and pH shift conditions it was URF-SDS > PRO > URF-
PVA:P407 > URF-P407.  However, analysis of the pharmacokinetic data suggests URF-
P407 had the greatest absorption having statistically higher Cmax and a 1.5-fold increase 
in AUC (p>0.05) compared to PRO.  All URF compositions had a significantly shorter 
Tmax (p<0.05) compared to PRO, as well.  High standard deviations in the 
pharmacokinetic data (e.g. Cmax, AUC0-24) are attributed to various biological 
interferences such as enzymatic degradation or P-glycoprotein efflux associated with oral 
absorption of TAC, making in vitro-in vivo correlations difficult.  The nanostructured 
powders containing various stabilizing polymers formed by the URF process offer 
enhanced supersaturation characteristics leading to increasing oral absorption of TAC.  
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4.2  INTRODUCTION 
 
 Tacrolimus (TAC) is a hydrophobic macrolide antibiotic (MW 822.1 kDa) that 
has shown promise as a potent immunosuppressive agent.[1] Clinical and 
pharmacokinetic studies revealed that TAC may have superior immunosuppressive 
properties compared to cyclosporine A (CsA), but similar erratic absorption properties 
have limited its potential.[2-4]  Mean oral bioavailability is reported to be 25% and 
ranges from 4-93%.[5, 6]  Various strategies have been employed to increase the 
bioavailability of TAC including compounding TAC as an oral liquid [7], solid 
dispersions [8], complexation with cyclodextrins [9, 10], and incorporation into 
liposomes for oral [11, 12] and pulmonary [13] delivery.   
The formation of a supersaturated state with solid dispersions and solid solutions 
may increase oral bioavailability of active pharmaceutical ingredients (APIs) which 
suffer from poor/erratic bioavailability.  In fact, it was proposed that increasing the 
solubility greater than two-fold through polymorphism can have a significant increase in 
biopharmaceutical activity.[14-16]  Mechanistically speaking, APIs in a polymorph with 
a higher thermodynamic activity  form a supersaturated solution with a apparent 
solubility above the equilibrium solubility and therefore have an increased driving force 
for transport across biological membranes such as the epithelial membrane within the GI 
tract.[17]  Another challenge, however, is to maintain the supersaturated state and prevent 
precipitation of the API out of solution.  Stabilizing polymers such as 
hydroxypropylmethyl cellulose (HPMC), which are known to form hydrogen bonds with 
the API preventing precipitation [18, 19], can be incorporated into the composition. 
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HPMC and polyvinylpyrrolidone (PVP) have been shown to be two of the best polymers 
for maintaining supersaturation of poorly water soluble APIs by preventing precipitation 
of the API into solution.  However, the ability of other polymers/surfactants to stabilize 
supersaturated solutions and prevent precipitation is largely unknown. 
Rapid freezing processes such as the Spray Freezing into Liquid (SFL) [20-22] 
and Ultra-rapid Freezing (URF) [23, 24] have been shown to produce particles with 
enhanced dissolution rates for biopharmaceutical classification system (BCS) class II 
active pharmaceutical ingredients (API).  Recently, in vivo studies have shown that 
nanostructured danazol particles produced from SFL have increased oral absorption in 
mice [21] and nanostructured itraconazole particles from SFL have improved both oral 
and pulmonary absorption in mice compared to the commercial product[25].  The URF 
process utilizes a cryogenic surface to rapidly freeze the API/polymer solution to produce 
nanostructured powders characterized by their high surface area, increased wettability, 
amorphous API structure, and rapid dissolution rates.  Briefly, the process involves 
freezing an API/polymer solution directly onto the surface of a cryogenic substrate with a 
thermal conductivity k between 10-20 W/(m*K), collecting the frozen particles and 
removing the solvent via lyophilization. 
  However, determining an in vivo-in vitro correlation with amorphous particles 
can be problematic as supersaturation levels in the GI tract may not correlate with levels 
in the dissolution vessel.  Premature precipitation of the active following oral 
administration can decrease the overall absorption of the API by decreasing the driving 
force for transport across the biological membrane and limiting the time available for 
absorption.  Although the mechanism for inhibition of recrystallization in supersaturated 
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solutions has not been established [26], it is believed that adsorption of polymer onto the 
hydrophobic surface of crystals inhibit growth of embryo that nucleate from metastable 
solutions [27] and suspensions [28].  Recently, Raghaven et al. have proposed hydrogen-
bonding as a mechanism to inhibit or retard crystal growth of hydrocortisone acetate in 
supersaturated solutions containing HPMC.[18, 29]  Therefore, inclusion of polymers 
such as HPMC and PVP which have a number of hydrogen-bonding acceptor and donor 
sites have been shown to maintain supersaturation of TAC, hydrocortisone acetate, and 
an experimental poorly water soluble compound RS-8359 for up to 24 hours.[8, 19, 30]  
However, the effectiveness of the polymer stabilizer is API dependent as illustrated for 
HPMC, which is known to maintain a supersaturated solution of hydrocortisone acetate 
for up to 72 hours.  However the supersaturation of an oestradiol solution decreased 60% 
after only six hours [26]. 
The objective of this study was to assess the effects of combinations of polymeric 
stabilizers on the maximum degree and extent of supersaturation of TAC, and attempt to 
establish if an in vitro-in vivo correlation exists between supersaturation and improved 
pharmacokinetic parameters for orally dosed TAC.  The selected polymers were partially 
hydrolyzed polyvinyl(alcohol) (PVA) which has been shown to increase drug 
concentration in vitro [31] and poloxamer 407 (P407) which has been shown to alter 
surface properties of crystals [32].  Sodium dodecyl sulfate (SDS), a non-polymeric 
anionic surfactant, may be expected to facilitate wetting and dissolution rates, but 
supersaturation of pharmaceuticals with SDS has not been reported below the critical 
micelle concentration.  TAC/stabilizer particles were manufactured using the Ultra-rapid 
Freezing Process (URF) and the physico-chemical properties were compared  with those 
 111
of the bulk API, as well as the commercially available amorphous solid dispersion of 
TAC and HPMC.[33]  The maximum degree and extent of supersaturation in vitro was 
established for each TAC/excipient composition in both acidic media (for 24 hours) and 
under shifting pH conditions according to United States Pharmacopoeia (USP).  
Pharmacokinetic analysis of orally administered TAC compositions in a single dose study 
design was conducted to determine the performance of the compositions. 
4.3  MATERIALS AND METHODS 
 
4.3.1  Materials 
 
Bulk tacrolimus (TAC) and Prograf® (PRO) capsules (5 mg and 1 mg, Fujisawa) 
were generously donated by the  Dow Chemical Company (Midland, MI, USA).  
Poly(vinyl) alcohol (PVA, Mw 13,000-23,000, 87-89% hydrolyzed) and sodium dodecyl 
sulfate (SDS) were purchased from Sigma-Aldrich (St. Louis, MO, USA).  Poloxamer 
407 (P407), Mw 9,800-14,600) was purchased from Spectrum Chemicals (Gardena, CA, 
USA).  Sodium phosphate tribasic (Na3PO4) was purchased from Fisher Scientific 
chemicals (Fair Lawn, NJ, USA).  High performance liquid chromatography (HPLC) 
grade acetonitrile (ACN) was obtained from EM Science (Gibbstown, NJ, USA). 
4.3.2  Preparation of the URF Micronized Powders 
 
 The URF compositions investigated in this study are described in Table 4.1.  The 
compositions were prepared by dissolving TAC and hydrophilic excipients at a 1:1 
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API/excipient ratio and 1.0% solids in a 60/40 mixture of ACN and water.  The 
TAC/excipient feed solutions were processed using the URF apparatus.  The feed 
solutions were applied to a cryogenic substrate cooled to a temperature of -150°C, 
collected, and lyophilized using a VirTis Advantage benchtop tray lyophilizer (The 
VirTis Company, Inc. Gardiner, NY, USA).  Micronized powders were stored at room 
temperature and under desiccant until characterized. 
4.3.3  Scanning Electron Microscopy (SEM) 
 
The powder samples were sputter coated using a K575 sputter coater (Emitech 
Products, Inc., Houston, TX, USA) with gold-palladium for 35 seconds and viewed using 
a Hitachi S-4500 field emission scanning electron microscope (Hitachi High 
Technologies Corp., Tokyo, Japan).  An accelerating voltage of 5-10 kV was used to 
view the images.  All SEM fields of view were representative of the entire sample. 
4.3.4  Supersaturated Dissolution Testing Under Acidic Conditions 
 
Supersaturated dissolution testing was carried out on PRO and all URF 
micronized powder samples using a small volume dissolution apparatus equipped with a 
paddle stirring mechanism (VanKel VK6010 Dissolution Tester with a Vanderkamp 
VK650A heater/circulator, Varian Inc., Cary, NC, USA).  The small volume vessels were 
filled with 100 mL of deaerated (via He sparge) 0.2% NaCl in 0.1N HCl (Japanese 
Pharmacopeia XIX, JP first media) and heated and maintained at 37.0 ± 0.2°C throughout 
the dissolution study.  Amounts of drug compositions were weighed out corresponding to 
28X the aqueous solubility of TAC (7 mg TAC/vessel) and added to the vessels.  The 
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paddle speed was set to 200 RPM and a 3 mL aliquot of sample was taken manually at 
10, 20, 30, 60, 120, 240, and 1440 minutes, with no medium replacement.  This aliquot 
was filtered first through a 0.45 µm GHP Acrodisc syringe filter (Pall, East Hills, NY, 
USA) and then through a 0.02 µm Whatman Anotop 25 membrane filter (Maidstone, 
UK).  A 0.75 mL portion of the filtered solution was transferred to a 1.5 mL HPLC vial 
and diluted with 0.75 mL ethanol, vortexed and analyzed using a modified method 
developed by Nishikawa et al [34].  A Shimadzu LC-10 liquid chromatograph (Shimadzu 
Corporation, Kyoto, Japan) equipped with an Alltech Inertsil ODS-2 5 µm C18 column 
(Alltech Associates, Inc., Deerfield, IL, USA) maintained at 60°C was used to quantitate 
the TAC.  A 70:30 ACN:water mobile phase at 0.9 mL/min eluted the TAC peak at 8.5 
min.  The maximum absorbance was measured at wavelength λ=214 nm.  System 
suitability requirements were met (R2 ≥ 0.999, precision ≤ 2.0% RSD).  
4.3.5  Supersaturated Dissolution Testing Under pH Shift Conditions 
 
 All dissolution conditions were maintained as described in section 4.3.4 except 
that the dissolution medium was changed during the dissolution test.  Using the USP 
enteric test (method A) conditions as a guide, 75 mL of 0.1N HCl was added to the small 
volume dissolution vessels and heated to 37.0 ± 0.2°C.  All dissolution media was 
deaerated via He sparge.  Sample powders were added to the vessels stirred at 200 RPM.  
After 2 hours, 21 mL of 0.2 M Na3PO4 (1:3 v/v buffer:acid ratio observed) was added to 
increase the pH to 6.8 for the remainder of the study.  Samples were taken  at the 
 114
following time points: 15, 30, 60, 120, 135, 150, 240, and 1440 minutes; then filtered, 
diluted, and analyzed by HPLC as stated above. 
4.3.6  X-Ray Powder Diffraction (XRD) 
 
The x-ray diffraction pattern of all powder samples were analyzed using a Philips 
1710 x-ray diffractometer with a copper target and nickel filter (Philips Electronic 
Instruments, Inc., Mahwah, NJ, USA).  The leveled powder was measured from 5 to 45 
2θ degrees using a step size of 0.05 2θ degrees and a dwell time of one second. 
4.3.7  Surface Area Analysis 
 
Specific surface area was measured using a Nova 2000 v.6.11 instrument 
(Quantachrome Instruments, Boynton Beach, FL, USA).  Weighed powder was added to 
a 12mm Quantachrome bulb sample cell and degassed for a minimum of three hours.  
The sample was then analyzed (n=3) by the NOVA Enhanced Data Reduction Software 
v. 2.13 via the Brunauer, Emmett, and Teller theory of surface area [35]. 
4.3.8  In Vivo Oral Absorption Studies 
 
 An animal study was designed and approved by the University of Texas at Austin 
Institute of Animal Care and Use Committee (IACUC).  Four groups of six pre-
catheterized male Sprague-Dawley rats (300 g) were dosed with 5 mg/kg tacrolimus in 
size 9 gelatin capsules (Torpac Inc., Fairfield, NJ, USA) followed by administration of 
0.4 mL water via oral gavage.  An aliquot of 300 µl of blood was withdrawn at 0.5, 1, 
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1.5, 2, 3, 4, 6, and 24 hours and replaced with 6 units/µl heparinized normal saline 
solution.  Fifty µl of the whole blood sample was analyzed by the PRO-TracTM II FK-506 
ELISA assay (Diasorin Inc., Stillwater, MN) to quantitate amount of tacrolimus.[36]  
Whole blood samples were diluted when necessary with the calibrator 0 provided with 
the PRO-TracTM kit in order to fit within the specified standard curve range (0.3-30 
ng/mL).  Pharmacokinetic parameters were determined using a non-compartmental 
analysis in WinNonlin Professional version 2.1 (Pharsight Corporation, Mountain View, 
CA, USA).  
4.3.9  Statistical Analysis 
 
 One-way analysis of variance (ANOVA, α = 0.05) was used to determine 
statistically significant differences between results. Results with p-values<0.05 were 
considered statistically significant.  Post- hoc analysis using Tukey’s honestly significant 
difference (HSD) test was performed after analysis to determine individual differences 
between compositions.  Mean differences greater than the HSD were deemed statistically 
significant. 
 
4.4  RESULTS 
 
4.4.1  In vitro Characterization of URF Micronized Powders 
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 The micronized powders were analyzed using SEM to observe the surface 
morphology.  Bulk TAC in Fig. 4.1a displays a plate-like shape with particle sizes 
ranging from a few microns to over 20 microns in diameter.  The particle surfaces appear 
to be smooth with few pores.  In contrast, the URF micronized powders (Fig. 4.1b-d), are 
a highly porous network of nanostructured aggregates.  URF-SDS powder (Fig. 4.1b) is 
composed of discrete nanoparticles measuring less than 200 nm in diameter.  URF-
PVA:P407 powder (Fig. 4.1c) appears to be a combination of agglomerated or fused 
nanoparticles with smoothed edges.  The size of the fused particles appears to be larger 
than those in Fig. 4.1a but still appear to be less than one micron in diameter.  Lastly, 
URF-P407, (Fig. 4.1d) appears to have few submicron domains.  A magnified view 
reveals large agglomerated nanoparticles which have fused to create a porous 
macrostructure.   
 Figure 4.2 shows the XRD results for bulk TAC which has a characteristic 
doublet peak at 19.10 and 19.95 2θ degrees and a secondary crystalline peak at 23.45 2θ 
degrees.  All compositions of the URF micronized powders lack any characteristic 
crystalline peaks of TAC.  URF-P407 contains two crystalline peaks at 19.4 and 23.6 2θ 
degrees and is associated with the P407 in the composition, which is partially crystalline 
after lyophilization as has been observed in rapidly frozen or melt compositions[20, 37, 
38].  Likewise, these two peaks are seen to a lesser degree in the URF-PVA:P407 
composition due to a decrease in P407 in the composition.   
 In vitro supersaturation dissolution studies were conducted in acidic media for 24 
hours for each of the URF micronized powders, as well as the control, the PRO powder, 
as shown in Fig. 4.3 and summarized in Table 4.3.  Sample powders were added to the 
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dissolution media at approximately 28-times the equilibrium solubility of TAC in the 
media as measured by HPLC.  The degree of supersaturation is defined as the 
concentration (C) of TAC in the media divided by the equilibrium solubility (Ceq) of 
crystalline TAC within the medium, C/Ceq.  All URF micronized powders had rapid 
dissolution rates reaching their maximum supersaturation within 2 hours.  URF-SDS 
displayed a high C/Ceqmax with an extended supersaturation that produced the highest 
AUC of all compositions investigated.  URF-PVA:P407 displayed the lowest C/Ceqmax at 
14.5-times equilibrium solubility, and precipitated out to 3.5-times equilibrium solubility 
after 24 hours.  URF-P407 had the fastest dissolution rate and the highest maximum 
supersaturation of all powders examined with a C/Ceq of 22.8-times equilibrium solubility 
at 1 hr.  However, URF-P407 rapidly precipitates to 6.3-times equilibrium solubility at 6 
hours and was the only one of the three URF processed powders investigated to reach 
equilibrium solubility at 24 hrs.  PRO powder, which is composed of equal ratios of 
amorphous TAC and HPMC[33], showed a slower dissolution rate reaching its maximum 
supersaturation level (17-times) after 6 hours.  However, for PRO TAC,  a 
supersaturation at 11-times equilibrium solubility was still present after 24 hours. 
 Because the powders were to be administered orally, supersaturated dissolution 
was also investigated using an enteric dissolution test method to more accurately 
represent the pH conditions encountered during transit from the acidic environment in the 
stomach to the basic environment in the upper small intestine (Fig. 4.4; parameter 
summary in Table 4.3).  TAC is known to have pH independent solubility over the pH 
range 1-9 [39] and therefore has the same solubility in acidic media as in the pH 6.8 
buffer (2.2 µg/mL) [8].  Upon a pH shift from pH 1.2 to 6.8 at 2 hours, URF-SDS was the 
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only composition with an increase in supersaturation level reaching its C/Ceqmax 15 
minutes after the pH shift occurred.  After 15 minutes, TAC precipitated out from 
solution and after 24 hours had 2-times equilibrium solubility in the basic dissolution 
media.  Both URF-PVA:P407 and URF-P407 had similar supersaturation profiles 
reaching their maximum supersaturation before precipitation occurred.  PRO, however, 
began to precipitate out of solution immediately after the pH shift occurred.  As a result 
of the pH shift, PRO was not able to achieve the level of supersaturation observed in the 
acidic media.  After the pH shift occurred, a high level of supersaturation was not 
maintained.  PRO precipitated to only 2.5-times equilibrium solubility after 24 hours, 
unlike the case in acid conditions where supersaturation was extended at high levels. 
 Both URF-SDS and URF-P407 had significantly higher (p<0.05) maximum 
supersaturation ratios (C/Ceqmax) in acidic medium while only URF-SDS had a 
significantly higher (p<0.05) C/Ceqmax when tested with the pH shift dissolution 
conditions compared to PRO.  The URF micronized powders reached their C/Ceqmax 
within one to two hours in acidic media while PRO reached its C/Ceqmax at 6 hours.  All 
URF compositions reached their C/Ceqmax before PRO under acidic conditions indicating 
the rapid wetting that occurs with URF micronized powders.  .However, both URF-
PVA:P407 and URF-P407 had lower extents of supersaturation (AUC) compared to 
PRO, while URF-SDS had better AUC than PRO under acidic and pH shift conditions, 
respectively. 
4.4.2  In Vivo Characterization of URF Micronized Powders 
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Whole blood samples were analyzed using a commercially available immuno-
assay kit and the TAC whole blood concentrations vs. time are plotted in Fig. 4.5.  The 
absorption profiles for the URF compositions indicate faster absorption and higher TAC 
blood levels during the absorption phase.  From these profiles, non-compartmental 
analysis, as discussed by Arima et al.[10], was performed to determine the appropriate 
pharmacokinetic parameters for each of the compositions tested and are summarized in 
Table 4.4.  One-way ANOVA revealed that there were significant differences (p<0.05) 
between the four compositions in regards to Cmax and Tmax while there were no statistical 
differences (p>0.05) regarding the tacrolimus half-life (T1/2), the elimination rate constant 
(Kel), or the AUC.  All URF micronized powders had higher Cmax values ranging from 
65.2-138 ng/mL as compared to the PRO powder which had a Cmax of 51.5 ng/mL.  
However, only URF-P407 powder had a significantly higher Cmax compared to PRO 
while URF-SDS and PVA:P407 powders were not statistically differently (p>0.05).  The 
measured Tmax for each URF micronized powder was between 0.5 and 0.67 hr while the 
PRO powder had a measured Tmax of 1.3 hours.  All powders had similar Kel while PRO 
had the lowest at 0.094 hr-1 and URF C had the highest Kel at 0.106 hr-1.  Consequently, 
URF-P407 had the fastest clearance of TAC and therefore had the fastest half-life at 
T1/2=6.9 hrs.  Lastly, URF-P407 had the highest AUC(0-24) at 450.6 ng*hr/mL.  Despite 
having a 1.5 fold increase in AUC compared to PRO, this was not statistically significant 
(p>0.05).  URF-PVA:P407 had the next highest AUC at 319.8  ng*hr/mL followed by 
PRO at 298.8 ng*hr/mL.  URF-SDS had the lowest AUC at 223.6 ng*hr/mL.  Therefore, 
the pharmacokinetic parameters assessed in the study were enhanced by the URF 
compositions (Cmax, Tmax, T1/2, and AUC) as compared to PRO.  The average relative 
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bioavailability for URF-SDS, URF-PVA:P407, and URF-P407 are 77.1%, 105.6%, 
144.2%, respectively. 
4.5  DISCUSSION 
 
 In the present study, nanostructured aggregate powders containing TAC and 
excipients, manufactured by the URF process were characterized in order to better 
understand the mechanism of supersaturation stabilization.   Furthermore, an attempt is 
made to identify the effect of supersaturation on increasing the bioavailability of TAC. 
In vitro characterization of the URF micronized powders revealed that they were 
composed of nanoparticle domains containing amorphous TAC.  URF-P407 displayed 
the lowest surface area at 7.73 m2/g.  Similar results were reported by Hu et al. [20] who 
produced binary mixtures containing danazol and a hydrophilic polymer by another rapid 
freezing process, spray freezing into liquid.  The surface area of danazol:P407 was 5.5 
m2/g, while danazol:PEG and danazol:PVP powders had surface areas of 12.0 and 89.8 
m2/g, respectively.  In a similar study by McConville et al., low surface areas were 
attributed to incorporation of high levels (>30%) of a liquid surfactant, polysorbate 
20.[38]  In that study, it was hypothesized that surface area reduction occurred during the 
lyophilization process.   During lyophilization, compositions containing excipients, which 
exist in a liquid state at ambient conditions, have more molecular mobility than those 
containing solid excipients with high glass transition temperatures (e.g. PVP).  With the 
greater mobility, the particles may coalesce to reduce the surface area, as has been 
observed for polysorbate 20.   However, all polymers used in this study are solids at room 
temperature and should provide greater rigidity compared to liquid surfactants during 
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lyophilization and gave much higher surface areas than polysorbate 20.  The modestly 
lower surface area for P407, relative to the other formulations in Table 4.2, may reflect its 
much lower Tg. 
Specifically regarding TAC supersaturation studies, Yamashita et al. investigated 
the performance of HPMC, PVP, and polyethylene glycol (PEG) on maintaining the 
supersaturation of TAC.[8]  While all samples had reached the same C/Ceqmax, only 
HPMC was able to maintain at least 95% of the maximum supersaturation over 24 hours 
in acidic medium.  To date, the mechanism by which they maintain supersaturation of 
dissolved drug has not been delineated.   
Apart from their particle formation properties, polymers also play an important 
role in enhancing dissolution rates through wettability, and at supersaturated conditions, 
maintaining API supersaturation.  Both SDS and P407 are known to increase wetting due 
to their high hydrophilic-lipophilic balance (HLB) values, while PVA is used as a 
stabilizing agent and has been reported to enhance supersaturation.[31]  Suzuki and 
Sunada report that although PVA maintained supersaturation to a lesser degree than 
HPMC or PVP, dissolution supersaturation was enhanced by more than 20-times 
compared to the crystalline API.  The present supersaturation studies indicate that P407 is 
not able to maintain supersaturation for extended periods of time of up to 24 hours, but 
the enhanced wetting properties of the polymer allow for high supersaturation levels at 
short times.  Inclusion of PVA into the composition decreases the level of supersaturation 
but allows for slightly slower precipitation rates in the acidic media after six hours.  SDS, 
although not a polymer, was able to maintain supersaturation of TAC at a similar level to 
HPMC under both supersaturated dissolution conditions tested.  It is important to note 
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that the concentrations of SDS present in the medium reached only 10% of the critical 
micelle concentration in aqueous media (conc. SDSdisso = 2.5 x 10-4 M and SDSCMC = 2.8 
x 10-3 M) containing a salt as calculated by Dutkiewicz and Jakubowska.[40]  SDS 
dissociates in the electrolyte medium to produce a hydrogen-bonding acceptor site.  In 
addition, the interaction between the hydrophobic tail of a surfactant molecule and the 
hydrophobic surface of the API molecule, and a second complimentary interaction 
between the sulfate group of the surfactant molecule with an adjacent hydrogen bonding 
donor site on the API may facilitate solvation of the drug in water.  The same type of 
mechanism may take place for the polymeric stabilizers with hydrophobic moieties and 
hydrogen bonding sites.   Furthermore, it is likely that, other SDS molecules will adsorb 
with tails oriented onto the surface of embryo crystals of TAC with the head groups 
extending into water. The anionic sulfate groups on the adsorbed surfactant will provide 
electrostatic repulsion inhibiting particle growth from coagulation.      
In solution, the polymers may adsorb onto the surface of small embryo particles 
and inhibit crystal growth by blocking active surface and providing steric stabilization.  
In addition, hydrogen bonding between TAC and the stabilizers may complement 
hydrophobic interactions between these species to help maintain supersaturation. 
Structurally, HPMC has many hydroxyl groups which are both hydrogen bond donors 
and acceptors for the TAC.  Investigation of the TAC structure (Fig. 4.6) reveals four 
possible H-bond acceptor sites indicated by circles along with three possible donor sites 
indicated by triangles.  PVA has one H-bond donor and acceptor per monomer unit while 
P407, on the other hand, has one donor site per polymer unit.   
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PRO maintained supersaturation under acidic conditions to a similar extent as 
SDS, as shown in Table 4.3.  The less effective stabilization by PVA and P407 may 
reflect weaker adsorption on the surfaces of the embryo particles and thus less steric 
stabilization against particle growth.  In addition P407 with only one H-bonding donor 
sight per chain may not have interacted strongly enough with hydrogen bond acceptor 
sites on TAC to inhibit crystallization.  PVA:P407 was slightly better than P407 alone, 
perhaps indicating that the addition of hydrogen bond donor sites in PVA provided 
beneficial interactions with TAC.  
The shift in media pH at 2 hours during the supersaturation dissolution studies 
dramatically affected the physical stability of the supersaturated solutions even though 
the solubility of the API in aqueous media without stabilizers is independent of pH.  
While URF-PVA:P407 and URF-P407 began precipitating before the pH shift occurred 
the PRO composition immediately began precipitating after the pH was increased. This 
precipitation may produce a loss in bioavailability as a result of decreased absorption in 
the small intestine.  Interestingly, the degree of supersaturation for URF-SDS increased 
for at least 15 minutes after the pH shift occurred before it then decreased.  However, the 
rate of precipitation out of solution over the next 21 hours was much more pronounced 
than under acidic conditions in Figure 4.3 indicated by the supersaturation level at 24 
hours.  This trend was seen for all compositions investigated at pH 6.8 compared to the 
acidic media and could be the result of bonding strength changes from the presence of 
inorganic salts.[41]  Khutoryanskiy et al. suggests that the presence of inorganic salts 
such as Na3PO4 (in particular, the divalent and trivalent phosphates) in the dissolution 
media can alter the ionic strength or thermodynamic properties of the solution and salt 
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out the API.  Introduction of inorganic salts can cause collapse of the polymer chains on 
the surface of embryo API particles.  This collapse will weaken steric stabilization and 
may lead to precipitation of the API out of solution, particularly with P407 in the 
presence of NaCl and Na3PO4.[42] 
Both the acidic and enteric in vitro supersaturation test condition studies reveal 
that the URF micronized powders rapidly wet and dissolve resulting in solutions with 
high C/Ceqmax.  The in vivo absorption profiles also indicate rapid wetting and dissolution 
as evidenced by the rapid Tmax for all URF compositions leading to rapid absorption 
times.  This rapid dissolution could be a combination of both the polymer characteristics 
(i.e. wetting enhancement) as well as the rapid freezing process which create amorphous 
nanoparticle domains of API.  Because the powders were dosed within a size #9 hard 
gelatin capsule by oral gavage, the powders were not pre-wetted by aqueous solution 
containing a surfactant.  Therefore, the powders must rely on the gastric fluid and on the 
enhanced powder wetting properties (i.e. polymer/surfactant wettability, and available 
surface area) to wet, disintegrate, and dissolve the particles.  It is clear from both the in 
vitro and in vivo data that the URF micronized powders are wetted more effectively than 
PRO leading to enhanced absorption profiles early in the absorption phase.  While 
numerous studies have reported increases in bioavailability as a result of API being in a 
supersaturated state, rapid dissolution and supersaturation could prove counter 
productive, especially for examples in which the API can precipitate during transit when 
the pH increases from the stomach to upper small intestine.  Absorption of the API can be 
compromised in instances when all of the powder is dissolved in the stomach but not 
fully absorbed through the stomach lining.  As the API moves into the upper small 
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intestine, the solution begins to precipitate arresting absorption.  While it is true that the 
measured pharmacokinetic parameters for the URF micronized powders were superior to 
those of PRO, premature precipitation while in transit could have prevented the powders 
from achieving their full potential.  This is evidenced by URF-P407 which showed a high 
C/Ceqmax in vitro under acidic conditions and also had the highest Cmax in vivo.  In this 
case, URF-P407 probably completely dissolved into a supersaturated solution leading to 
excellent absorption initially but rapid precipitation limited further absorption.    
Absorption of TAC within the small intestine is also affected by a number of 
biological processes making further in vitro-in vivo correlations difficult.  TAC is 
reported as a substrate for p-glycoprotein (P-gp), a plasma protein involved with efflux 
pumps and responsible for multi-drug resistance.[43] In addition, TAC is known to 
degrade enzymatically within the GI lining from CYP3A metabolic enzymes further 
lowering its absorption potential.  However, recent studies have suggested that within the 
rat and mouse small intestine, the CYP3A enzymes play a larger role in limiting TAC 
absorption rather than P-gp as previously thought.[44-46]  Saitoh et al. showed via an in 
situ intestinal loop technique that when TAC was administered with a specific CYP3A 
inhibitor (clotrimazole) the TAC AUC increased seven fold.[47]  Food effects can also 
cause changes in TAC absorption.  Kagayama et al. showed that rats receiving TAC in a 
fasted state can have twice the AUC of rats who received the same dose of TAC in a fed 
state.[48]  Regardless, these barriers to TAC absorption are well documented in rats [48] 
and because there is a fair correlation between mammal species regarding intestinal 
absorption [49], this animal model is valid for preliminary pharmacokinetic analysis of 
the URF micronized compositions containing TAC.  
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4.6  CONCLUSION 
 
 The relationship between supersaturation behavior, measured during dissolution, 
and in vivo absorption enhancement was investigated for various compositions of TAC 
prepared by the URF process.  The ability of two polymers, PVA and P407, and one low 
molecular weight surfactant, SDS, to provide sufficient supersaturation levels (C/Ceqmax) 
and to maintain supersaturation under acidic and pH shifted conditions was determined.  
The supersaturation for URF-SDS was equal to or better than PRO under acidic and pH 
shift conditions, respectively, even though the levels of SDS were well below the CMC in 
the medium.  It is hypothesized that SDS was able to maintain supersaturation of TAC 
through adsorption onto the surface of tiny embryo particles to inhibit growth and 
precipitation.   For URF-PVA:P407 and URF-P407, maintenance of supersaturation in 
vitro was poorer than for PRO.  URF-P407 was the only composition where the 
concentration decayed to the equilibrium value after 24 hours in acidic medium.  URF-
PVA:P407 and URF-P407 both began to precipitate while still in acid,  while PRO began 
to precipitate immediately after the shift.  Although TAC solubility and chemical stability 
are independent of pH, the rate of precipitation was more extensive at pH 6.8 than in 
acidic media possibly as the result of changes caused by the presence of inorganic salts in 
the buffer.  In vivo results in a rat model reveal enhanced Cmax and Tmax for all URF 
micronized compositions and higher AUC in URF-PVA:P407 and URF-P407 resulting 
from enhanced dissolution properties (e.g. rapid onset of supersaturation) of the 
processed powders.  Based on the pharmacokinetic parameters and supporting in vitro 
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supersaturation data, it is concluded that the enhanced physico-chemical properties of 
URF micronized powders led to enhanced in vivo absorption enhancement over PRO. 
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Chapter 5:  Solid Dispersions of Itraconazole and Enteric Polymers 
Made by Ultra-Rapid Freezing 
 
5.1  ABSTRACT 
 
 The primary objective of the study is to investigate the influence of degree of 
miscibility of a dispersion of ITZ and an enteric polymer, either hydroxypropylmethyl 
cellulose phthalate (HP-55) or Eudragit® L100-55 (L100-55), prepared by Ultra-rapid 
Freezing (URF), on enhanced dissolution of ITZ in pH 6.8 dissolution media.  
Bioavailability can be increased for drugs that form supersaturated solutions in the small 
intestine allowing for maximum area for absorption.  Delayed release until the drug 
reaches the upper small intestine prevents premature precipitation and subsequent 
recrystallization for compounds which display higher solubility in acidic conditions such 
as itraconazole (ITZ).  Furthermore the effect of composition parameters (e.g. ITZ 
potency, enteric polymer type, and total solids loading) on dissolution rates at both sink 
and supersaturated conditions was studied.  Modulated differential scanning calorimetry 
(MDSC) was utilized to define the level of ITZ miscibility with each polymer. The 
compositions were completely miscible at 60% ITZ for both polymers and as high as 
70% in HP-55.  High potency composition glass transition temperatures (Tg) correlated 
with predicted Tg’s from the Gordon-Taylor equation, however, recrystallization 
exotherms revealed pure amorphous regions indicating that phase separation occurred 
during particle formation.  Furthermore, in vitro studies including x-ray powder 
diffraction (XRD), scanning electron microscopy (SEM), surface area analysis (BET), 
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and dissolution were performed to determine differences between low potency 
(completely miscible) and high potency (partially miscible) compositions.  Dissolution 
studies on low potency ITZ compositions revealed that miscibility plays an active role in 
ITZ release under sink conditions, and t1/2 diffusion through the enteric polymer is 
observed.  In dissolution studies at supersaturated conditions, high potency compositions 
had maximum saturation levels (C/Ceqmax) between 10.6 and 8-times (X) equilibrium 
solubility, but with higher cumulative extents of supersaturation, compared to low 
potency compositions which had C/Ceqmax values between 15-19.6X.  However, these 
low potency compositions tended to rapidly precipitate leading to significantly lower 
AUCs (p<0.05).  The change in the miscibility of the solid dispersion had a pronounced 
effect of drug release (sink) while differences in potency influenced supersaturated 
dissolution profiles.  
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5.2  INTRODUCTION 
 
 Itraconazole (ITZ) is a broad spectrum triazole antifungal with pH dependent 
solubility.  It is a weak base (pKa1 = 3.7) and is more soluble in the gastric environment 
of the stomach compared to the more neutral pH of the other parts of the small 
intestine.[1]  Intuitively, it may appear that the likely site of absorption would be in the 
acidic environment of the stomach.  However, variable gastric emptying times can lead to 
variable absorption rates, while food effects can alter the pH leading to further variability.  
Likewise the surface area (SA) of the stomach available for absorption is small relative to 
other absorption sites in the GI tract.  In fact, investigation of the stomach lining reveals 
epithelial layers which continually shed cells limiting absorption.[2]  However, the 
intestinal surface is composed of microscopic finger-like projections known as villi and 
microvilli which increase the absorptive surface area of the small intestine 600-fold (> 
170 m2)[3] making it an excellent site for absorption.  However, as ITZ enters the small 
intestines, the change in pH has the potential to precipitate ITZ that was dissolved in the 
stomach, slowing the absorption process and decreasing bioavailability.  In addition, any 
undissolved particles would remain insoluble with a pH above the pKa.  Amorphous solid 
dispersions containing enteric polymers could overcome these limitations by 1.) delaying 
dissolution until the compound enters the intestines preventing premature precipitation of 
the ITZ and 2.) increasing the apparent solubility at higher pH to increase the driving 
force for absorption.  Amorphous drugs can achieve a supersaturated state due to their 
low heat of fusion.[4]  Hancock and Parks have shown that amorphous indomethacin has 
a 2.5X increase in apparent solubility compared to its crystalline counterpart [5] while up 
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to a 25X increase in solubility has been reported for tacrolimus and 
diacetylmidecamycin.[6, 7]  However, these supersaturated solutions are 
thermodynamically unstable and will precipitate and return to the equilibrium state over 
time.  Therefore, a stabilizing polymer must be included to extend the time the compound 
remains supersaturated.  These polymers are able to prevent recrystallization or particle 
growth in solution through hydrogen-bonding [8, 9] or adsorbing on the surface of solid 
particles blocking the addition of other solute onto the surface[10-12]. 
 Modified release systems including delayed release systems are used to target 
delivery of the API within a specific section of the GI tract or when gastric degradation 
can severely limit the effectiveness of the API.  One common approach is to coat the 
surface of the delivery system (microspheres, tablets, beads/pellets, etc.) with a gastro-
resistant polymer, which often displays pH dependent solubility.  These polymers 
typically contain functional groups which ionize at specific pH values, allowing for 
targeted delivery of the API to certain sections of the GI tract and are often referred to as 
enteric polymers.  Hasagawa et al. were the first to develop solid dispersions comprising 
a binary mixture of a poorly water soluble API, nifedipine, and an enteric polymer.[13]  
A variety of technologies have been employed to develop these enteric solid dispersions 
such as traditional melt dispersion [14], hot melt extrusion/spheronization[15, 16], anti-
solvent precipitation[17], solvent evaporation[18, 19], and spray drying[20].  A novel 
technique based on the aerosol flow reactor has also been used to produce solid 
dispersions [21].  Oral absorption of poorly-water soluble compounds has been achieved 
using these enteric solid dispersions [18, 22] particularly since they can delay dissolution 
and supersaturation until the API reaches the upper small intestine[19].  To date, high 
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potency compositions with desirable delayed release properties have not been achieved as 
a result of miscibility limitations between the API and the enteric polymer.  
 The objective of the study is to investigate the influence of composition 
parameters including drug:polymer ratio and polymer type, and particle structure of 
enteric solid dispersions on the release of ITZ under sink and supersaturated dissolution 
conditions.  Solid dispersions containing ITZ and an enteric polymer were produced 
using the Ultra-rapid freezing (URF) process.  The URF process is shown to create 
amorphous API allowing for supersaturation, while the enteric polymer protects the ITZ 
from premature dissolution in the acidic environment and prevents particle growth in 
higher pH environments.  Since drug release for modified release systems is dependent 
on the polymer release characteristics, the degree of miscibility may be expected to play a 
key role on dissolution.  To define the level of ITZ miscibility with the enteric polymers, 
MDSC was performed on varying ITZ potency URF micronized powders.  Once ITZ 
miscibility limits were established, the effects of ITZ potency, enteric polymer type, and 
% total solids in the feed on in vitro dissolution were assessed.         
 
5.3  MATERIALS AND METHODS 
 
5.3.1  Materials 
 
Itraconazole (ITZ) was purchased from Hawkins Chemical (Minneapolis, MN, 
USA).  The enteric polymers hydroxypropylmethyl cellulose phthalate NF (HP55) and 
Eudragit L100-55 (L100-55) were purchased from Shin Etsu Chemical (Tokyo, Japan) 
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and Röhm GmbH (Darmstadt, Germany), respectively. Histological grade 1,4-dioxane, 
99%+, was purchased from Sigma-Aldrich (St. Louis, MO, USA).  HPLC grade 
Acetonitrile (ACN) was purchased from EMD chemicals (Gibbstown, NJ, USA).  
Diethanolamine, hydrochloric acid and tribasic sodium phosphate was purchased from 
Fisher chemicals (Fair Lawn, NJ, USA).  Polysorbate 20 was purchased from Spectrum 
Chemical (Gardena, CA, USA). 
5.3.2  Preparation of URF Powders 
 
ITZ and the pH-dependent polymer were dissolved in an appropriate amount of 
1,4-dioxane and rapidly frozen using the URF apparatus.  The API/polymer solutions 
were applied to a cryogenic solid substrate cooled to -60°C, collected, and lyophilized 
using a VirTis Advantage benchtop tray lyophilizer (The VirTis Company, Inc. Gardiner, 
NY, USA). 
5.3.3  Modulated Differential Scanning Calorimetry (MDSC) 
 
Samples in the range of 8-10 mg of processed and bulk powders were added to 
crimp sealed aluminum pans and measured on a TA Instruments model 2920 MDSC 
(New Castle, DE, USA).  Samples were heated at a rate of 2°C/min from 30 – 200°C at a 
modulating oscillatory frequency of 0.21°C/min.  Samples were purged with nitrogen gas 
at 150 mL/min. Glass transition temperatures were measured at the midpoint of the step 
transition.  The MDSC was calibrated using an indium standard. 
 141
5.3.4  True Density measurements 
 
 True density was measured using the true density of the pure amorphous ITZ and 
enteric polymer was determined using helium pycnometry (Micrometrics AccuPyc 1330 
pycnometer; Norcross, GA). URF processed pure components were immediately tested 
after removal from the lyophilizer to limit water adsorption and placed in a sample cup 
and purged twenty times at 19.85 psi followed by six analytical runs at 19.85 psi. The 
equilibration rate was 0.0050 psi/minute.  Measurements were performed in triplicate. 
5.3.5  Scanning Electron Microscopy (SEM) 
 
The powder samples were sputter coated using a model K575 sputter coater 
(Emitech Products, Inc., Houston, TX, USA) with gold-palladium for 35 seconds and 
viewed using a Hitachi S-4500 field emission scanning electron microscope (Hitachi 
High-Technologies Corp., Tokyo, Japan).  An accelerating voltage of 5 kV was used to 
view the images.  All SEMs pictured were representative of the entire sample. 
5.3.6  Sink Dissolution Testing 
 
Dissolution testing was performed on the URF powder samples using a USP 25 
Type II paddle apparatus model VK7000 (Varian Inc., Cary, NC, USA).  An equivalent 
of 1 mg ITZ was pre-wetted with 0.075% Polysorbate 20 in de-ionized water and added 
to 900 mL of 0.1N HCl (pH 1.2) dissolution media.  The dissolution media was 
maintained at 37.0 ± 0.2°C and the paddle speed was maintained at 100 rpm throughout 
the testing period. 
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Samples (5 mL) were withdrawn at 15, 30, 45, 60, 90 and 120 minute time points, 
filtered using a 0.20µm Whatman nylon filter (Clifton, NJ, USA), diluted with HPLC 
grade ACN, and analyzed using a Shimadzu LC-10 liquid chromatograph (Shimadzu 
Corporation, Kyoto, Japan) equipped with an Alltech ODS-2 5 µm C18 column (Alltech 
Associates, Inc., Deerfield, IL, USA).  A mobile phase of ACN:water:diethanolamine 
(70:30:0.05) at 1 mL/min eluted the ITZ peak at 5.5 min and absorbance was measured at 
wavelength λ = 263 nm.  
 
5.3.7  Supersaturation Dissolution Testing 
 Dissolution testing was performed on the URF powder samples using a USP 25 
dissolution apparatus model VK7000 (Varian Inc., Cary, NC, USA).  Dissolution was 
conducted according to USP enteric test method A for delayed release dosage forms 
using 100 mL glass dissolution vessels and stirred with appropriate small paddles.  An 
equivalent of 8.8 mg ITZ (20X ITZ equilibrium solubility) was pre-wetted with 5 mL 
0.008% Polysorbate 20 in 0.1N HCl and added to 70 mL 0.1N HCl (75 mL total).  The 
dissolution media was maintained at 37.0 ± 0.2°C and the paddle speed was maintained at 
50 rpm throughout the testing period.  After 2 hours, 0.2M tribasic sodium phosphate 
(Na3PO4) containing 0.28% sodium dodecyl sulfate was equilibrated to 37.0 ± 0.2°C and 
added to the dissolution vessels.  Therefore, the final SDS concentration was 0.07% 
which was determined to give equal equilibrium solubilities of ITZ in both pH 
environments.  For each time point, 3 mL of medium was withdrawn and filtered using a 
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0.20µm nylon filter, diluted with HPLC grade ACN, and analyzed according to the 
HPLC method outlined above. 
5.3.8  X-Ray Diffraction (XRD) 
 
The x-ray diffraction pattern of the SFL powders were analyzed using a model 
1710 x-ray diffractometer (Philips Electronic Instruments, Inc., Mahwah, NJ, USA).  
Data were collected using primary monochromated radiation (CuKα1, λ = 1.54056 Å), a 
2θ step size of 0.05 and a dwell time of 1.0 second per step. 
5.3.9  BET Specific Surface Area Analysis 
 
Specific surface area was measured using a Nova 2000 v.6.11 instrument 
(Quantachrome Instruments, Boynton Beach, FL, USA).  Weighed powder was added to 
a 12 mm Quantachrome bulb sample cell and degassed for a minimum of three hours.  
The sample was then analyzed by the NOVA Enhanced Data Reduction Software v. 2.13 
using the BET theory of surface area. 
5.3.10  Statistical Analysis 
 
One-way analysis of variance (ANOVA, α = 0.05) was used to determine 
statistically significant differences between results. Results with p-values<0.05 were 
considered statistically significant.  Post- hoc analysis using Tukey’s honestly significant 
difference (HSD) test was performed after analysis to determine individual differences 
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between compositions.  Mean differences greater than the HSD were deemed statistically 
significant.  
5.4  RESULTS 
 
5.4.1  ITZ miscibility in URF Micronized Powders 
 
 MDSC was used to determine the level of ITZ which could be added to the 
mixture before reaching phase separation and partial miscibility.  Fig. 5.1a shows the 
MDSC profiles for increasing levels of ITZ in HP-55 (every 10% up to 80% ITZ) 
prepared via the URF process from a feed solution of 2.0%.  Pure amorphous ITZ 
manufactured by the URF process was also included as a reference.  To investigate if the 
nucleation process during rapid freezing and particle formation can enhance the 
miscibility of ITZ and HP-55, MDSC was also performed on the ITZ:HP-55 URF 
powders from 0.2% total solids loading.  Profiles for the 0.2% loading were identical to 
those presented in Fig. 5.1b, however, the data is not shown.  For samples with ITZ lower 
than 60% ITZ, no melting endotherms were detected and only a single glass transition 
(Tg) was detected while the  Tg decreased with increasing ITZ potency.  Upon increasing 
the ITZ potency to 70%, a slight melting endotherm was detected, while increasing the 
ITZ potency to 80% caused a large melting endotherm for both feed concentrations.  
Interestingly, only one single Tg was detected at 70% ITZ and two Tg’s were detected at 
80% ITZ (2% only).  The melting point for the 70% and 80% ITZ compositions were 
measured at 158.4°C and 162.7°C, respectively, which are lower than the melting point 
of micronized crystalline ITZ (166.8°C) which was measured separately (data not 
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shown).  The slight melting point depression is thought to occur from the polymer HP-55, 
which is estimated to melt at 150°C.  Figure 5.1b shows the MDSC profiles for the 
ITZ:L100-55 binary mixtures manufactured from the URF process.  Increasing levels of 
ITZ in L100-55 (every 10%) were analyzed to determine if phase separation occurs.  Just 
as in the previous figures, a melting endotherm was detected for ITZ potencies greater 
than or equal to 70%.  In addition, only a single Tg was detected for all potencies and 
decreased with increasing levels of ITZ.  
 Compositions containing 70% ITZ or greater displayed a recrystallization 
exotherm when analyzing total heat flow MDSC profiles.  Examples of these 
recrystallization exotherms can be seen in Fig. 5.2.  Compositions containing 70% ITZ in 
HP-55 showed a slight melting endotherm, but did not produce the recrystallization 
exotherm associated with pure amorphous ITZ.   The recrystallization endotherm is 
present when the potency is increased to 80%.  For the ITZ:L100-55, a small 
recrystallization endotherm appears at 70% ITZ and increases as potency increases.  
Likewise, as the recrystallization endotherm increases, the melting endotherm increases 
as a result of the melting amorphous ITZ. 
The Gordon-Taylor equation is used to predict the Tg’s for binary mixtures (Tg12) 
of polymers and has also been applied to estimate the Tg for API (small molecule) and 
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where ρ1 and ρ2 are the true densities of the pure amorphous components.  The measured 
Tg’s for the increasing potencies of ITZ were plotted against the estimated Tg’s from the 
Gordon-Taylor equation for each of the ITZ:polymer binary mixtures as depicted in Fig. 
5.3a and 5.3b.  The predicted Tg’s values were constructed by first measuring the Tg’s 
and true density of the pure amorphous components using MDSC and helium 
pycnometry, respectively.  The measured Tg’s for amorphous ITZ, HP-55, and L100-55 
are 59°C, 147°C, and 128°C, respectively.  The true densities were measured at 1.37, 
1.75, and 1.32 g/cm3, respectively, and agree closely with literature values.[23]  Fig. 5.3a 
plots the Tg’s for the ITZ:HP-55 binary mixtures from both the 2.0% and 0.2% total 
solids feed solutions.  Interestingly, all potencies revealed a very close correlation with 
the predicted Tg.  At 80% ITZ, two Tg’s exist for the 2.0% total solids loading (as stated 
above) and the measured values are 74.7°C and 60.5°C, the latter in good agreement with 
pure amorphous ITZ at 59°C.  Measured Tg values for the powders produced from a 0.2% 
feed solution also closely agreed with the predicted values at all potencies.  In Fig. 5.3b, 
the measured Tg’s for the ITZ:L100-55 binary mixtures are shown.  Again, measured Tg’s 
for all potencies up to 90% ITZ were very close to Tg’s predicted by the Gordon-Taylor 
equation. 
5.4.2  In Vitro Analysis of Low and High Potency URF micronized Binary Mixtures 
 
In order to determine the effect of ITZ potency on the in vitro performance of the 
powders, low (1:4 ITZ:polymer ratio) and high potency ITZ (4:1 ITZ:polymer ratio) 
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compositions were manufactured via the URF process.  For compositions containing HP-
55, two total solids feed solution concentrations (0.2% and 2.0%) were examined.  
Compositions containing L100-55 were manufactured from 0.2% total solids feed 
solutions due to solubility limitations of this polymer in the feed solvent.  For 
convenience, the compositions will be referred to by the ITZ:polymer ratio (1:4 or 4:1), 
followed by the polymer type (HP55 or L100-55) and concluding with the % total solids 
in the feed (2% or 0.2%) 
The crystallinities of URF processed powders were examined using XRD and the 
profiles are depicted in Fig. 5.4.  From the diffraction profile, the characteristic ITZ peaks 
(most intense) used for determining crystallinity of the URF processed samples are 
located at 17.45 and 17.95 (doublet), 20.30, and 23.45 two theta degrees.  XRD profiles 
for the all URF micronized powders lacked the diffraction peaks associated with 
crystalline ITZ implying the samples contained amorphous ITZ.   
Scanning electron micrographs were taken to determine the surface morphology 
of each of the URF micronized compositions at 30,000x magnification (Fig. 5.5a-f).  
Both 4:1HP55(2%) and 1:4HP55(2%) (Fig. 5.a-b) are composed of a porous matrix while 
4:1HP55(0.2%) and 1:4HP55(0.2%) (Fig. 5.c-f) are composed of aggregated 
nanoparticles.  For compositions containing HP-55, dramatic differences in surface 
morphology were observed when comparing the solids loadings with 2% solids loadings 
forming a porous matrix while 0.2% loadings forming disrete nanoparticle domains.  ITZ 
potency also had a dramatic effect on the surface morphologies of compositions 
containing HP-55.  The morphology of 4:1HP55(2%) in Fig. 5.5a is a porous matrix 
composed of both macropores on the order of 800 nm and embedded micropores (> 50 
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nm) making the surface appear rough.  1:4HP55(2%) (Fig. 5.5b) is composed of pores 
ranging from 50-200 nm in diameter; however, the matrix surface appears smooth and 
flat.  Likewise, 4:1HP55(0.2%) which contains a high level of ITZ (80%) appears 
different from 1:4HP55(0.2%) which contains low levels of ITZ (20%).  4:1HP55(0.2%) 
appears to display smooth thread-like structures over a majority of the particle surface, 
while spherical nanoparticles filled in the rest of the areas.  A few of these nanoparticle 
regions can be seen on the left side and bottom region of the SEM.  1:4HP55(0.2%) 
revealed regions of clearly defined nanoparticles (~100 nm in diameter) but also 
displayed larger particles (> 600 nm) with smooth surfaces.  Finally, both 4:1L100-
55(0.2%) and 1:4L100-55(0.2%) which were composed of ITZ and L100-55 both 
displayed nanoparticles which appear to be > 100 nm in diameter. From these SEM it 
appears that the % total solids in the feed had a substantial effect on particle formation 
dictating whether nanoparticles or a porous matrix would result. 
The specific surface areas of the URF micronized powders (Table 5.1) were very 
high and ranged from 19.12-122 m2/g.  4:1HP55(2%) which was composed of a highly 
porous matrix with both macro- and micro-sized pores had a measured surface area of 
54.2 m2/g while its lower potency counterpart 1:4HP55(2%) had a measured surface area 
of 19.1 m2/g.  While this value was lower than those of all other compositions, it still 
represents a 4.5-fold increase in surface area over micronized ITZ.  The compositions 
which displayed nanoparticles in the SEM also had high surface areas of greater than 
57.3 m2/g with 1:4L100-55(0.2%) having the highest measured surface area of 122 m2/g.  
Interestingly, both compositions containing L100-55 had larger surface areas compared 
to the compositions containing HP-55 (4:1HP55(0.2%) and 1:4HP55(0.2%)). 
 149
Sink dissolution studies in 0.1N HCl were performed to investigate the effect of 
potency on drug release.  All URF micronized powders were compared to crystalline 
micronized ITZ which was 65% dissolved after 2 hours.  The dissolution profiles in Fig. 
5.6a-c show that as potency increases, the rate and cumulative release increases, with 
4:1HP55(2%) having the most ITZ (68.8%) released after two hours.  In the first 30-45 
minutes the slope is particularly large for the high potency samples.  Here localized 
regions of pure amorphous ITZ could exist and be exposed to the dissolution medium 
creating a burst effect.  After 45 minutes the ITZ release reaches an asymptote.  Although 
all URF micronized powders lacked any crystalline ITZ according to XRD, the total 
amount of ITZ released was never higher statistically than for crystalline ITZ, despite the 
amorphous morphology and considerably higher surface areas.  Low ITZ potency 
compositions released very little ITZ into solution ranging from 12.9 to 27.5% dissolved 
ITZ after two hours.  The dissolution data were modeled using the simplified Higuchi 
model to describe diffusional drug release kinetics.  Figure 5.7a and 5.7b show the 
Higuchi plots for the low potency and high potency compositions, respectively.  Qt is the 
amount of ITZ dissolved per unit area based on the surface area of the powders.  In 
addition, the correlation coefficients (R2), Higuchi dissolution constants (Kh), and the 
diffusion coefficients (D) for the low potency compositions are listed in Table 5.2. 
Dissolution studies were also performed under supersaturated conditions (20-
times the crystalline ITZ equilibrium solubility) to determine the maximum 
concentrations, and the cumulative supersaturation, which depends both upon dissolution 
of the powder and the ability of the enteric polymers to inhibit precipitation of ITZ.  The 
dissolution studies were conducted according to the USP XXV enteric test method A, and 
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the results are given in Table 5.3.  After two hours in acidic media, aliquots were 
removed and the ITZ concentrations were determined.  Table 5.3 also lists the percentage 
of total ITZ added which dissolved within the first two hours.  All values were lower than 
those which were calculated under sink conditions with 4:1HP55(2%) having the highest 
release (23.8%; 6.6-times) and 1:4L100-55(0.2%) having the lowest % release (5.3%; 
1.4-times).  Upon addition of the buffer an increase in supersaturation was observed for 
all compositions as the enteric polymer dissolved and released the amorphous ITZ within 
the polymer.  It was also observed that the degree of supersaturation increase was 
strongly dependent on the level of polymer in the composition.  After the buffer was 
added, the enteric polymer immediately dissolved leading to the maximum extent of 
supersaturation (C/Ceqmax) for all URF compositions.  Low potency ITZ compositions 
had the highest C/Ceqmax 15 minutes after the buffer was added with 1:4HP55(2%) 
having the highest measured C/Ceqmax value of 19.7X.  For high potency ITZ 
compositions, the supersaturation increased after addition of the buffer, with 
4:1HP55(2%) having the highest measured C/Ceqmax value at 10.7-times equilibrium 
solubility. However, the supersaturation levels were not as high as those of the low 
potency compositions.  
The supersaturation profiles also indicate that the compositions which achieved a 
high C/Ceqmax were also subject to greater subsequent losses in supersaturation, 
regardless of the stabilizing polymer.  In addition, for compositions with a smaller 
C/Ceqmax, smaller amounts of subsequent precipitation were observed.  To place the 
results in further perspective, the cumulative extent of supersaturation (AUC) was 
calculated as the area-under-the-supersaturation-curve, as listed in Table 5.3.  High 
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potency URF compositions had significantly higher (p<0.05) AUCs ranging from 33.1 to 
38.0 mg*min/mL compared to the low potency URF compositions which had AUCs 
ranging from 17.6 to 22.9 mg*min/mL.  Further analysis revealed that there were also 
significant differences in AUC versus the total solids loading for both high and low 
potencies.  The 1:4L100-55(0.2%) sample has a significantly higher (p<0.05) AUC than 
1:4HP55(0.2%) indicating that L100-55 is able to maintain supersaturation of ITZ longer 
than HP-55.   
5.5  DISCUSSION 
 
5.5.1  ITZ Miscibility in pH Dependent Polymer Binary Mixtures 
 
 For immediate release systems, Craig et al. described the mechanism for API 
release from solid dispersions containing water-soluble polymers [24].  They concluded 
that when the API was dispersed within the polymer on a molecular level (i.e. solid 
solution) API release was carrier mediated.  However, if localized regions of pure API 
existed (i.e. solid dispersion) and were sufficiently large, dissolution of the API may also 
be API mediated.  In addition, Six et al. investigated the effect of ITZ miscibility within 
water-soluble polymers to determine the effect of miscibility on dissolution rate.[25, 26] 
The results suggest that for immediate release systems, ITZ miscibility within a polymer 
carrier is not critical to achieve rapid dissolution rates.  In fact, both the carrier, in this 
case, Eudragit® E100, and the physical state of the ITZ contribute to the dissolution rate.  
In other words, the E100 dissolves immediately into solution (within the media) while 
aiding wetting of any immiscible ITZ domains.  Additionally, having the ITZ in an 
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amorphous state contributes to the dissolution process by largely removing the crystalline 
heat of fusion and raising the solubility.  However, a carrier is needed along with the 
amorphous API in order to achieve delayed release, sustained release or extended release.  
Consequently, if an API is only partially miscible in an enteric solid dispersion, localized 
regions of API near the particle surface could dissolve rendering the delayed release 
preference unfavorable.  Therefore, it is critical to determine the effect of API miscibility 
on these modified release systems. 
 MDSC analysis for the URF micronized powders revealed Tg’s which correlated 
very closely to predicted Tg’s estimated from the Gordon-Taylor equation for all ITZ 
potency levels, solids loadings, and polymer type.  Thus the API domains are too small to 
produce a separate Tg peak.  The API may be molecularly dispersed with the polymer or 
the domains may be smaller than about 50 nm.  Rapid freezing technologies can produce 
powders with nanoparticle domains as small as 20 nm in diameter.[27]  The rapid 
freezing arrested particle growth and inhibited phase separation. 
A variety of methods exist to assess miscibility limits within polymers [21, 28, 
29].  For nanoparticles produced using the aerosol flow reactor method, Eerikäinen et al. 
determined the level at which a crystalline melting endotherm was observed for the APIs 
ketoprofen and naproxen.  The endotherm indicates that the API solubility limit within 
the polymer was exceeded.[21, 30]  Because this process involved heat to evaporate 
solvent, evaporation rates could be sufficiently slow to allow crystallization of the API 
during phase separation.  Since no melting endotherms were observed for samples with 
60% ITZ potency or lower, ITZ miscibility within both HP-55 and L100-55 is at least 
60%.  The experimental miscibility limit of ITZ in L100-55 was unexpected since ITZ 
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miscibility levels with a structurally similar polymethacrylate polymer, Eudragit® E100, 
was measured at 13%.[25]  In addition, Six et al. investigated the miscibility of ITZ with 
the hydrophilic polymer Eudragit® E100 and found that “cold crystallization”, a 
recrystallization exotherm at about 133°C was indicative of regions of pure amorphous 
ITZ.  Investigation of total heat flow profiles for the URF powders greater than 60% ITZ 
revealed recrystallization exotherms indicating cold crystallization into pure itraconazole 
for compositions 80% ITZ and greater.  Therefore it is determined that for URF 
micronized powders containing ITZ and either HP-55 or L100-55, the partial miscibility 
of the ITZ occurs between 60-80%, more likely occurring between 70-80% ITZ.   
Six et al. investigated phase separation as a function of Tg by comparing the 
measured Tg of the solid dispersion to that of the predicted Gordon-Taylor equation.  
Deviations from the predicted value indicate possible partial miscibility.  Also, multiple 
Tg’s indicate phase separation or partial miscibility is occurring. For instance, the 
composition 4:1HP55(2%) showed a slight transition at 60.3°C (Tg near pure ITZ) and a 
larger transition at 74.7°C providing further evidence of partial miscibility at 80% ITZ 
potency. 
5.5.2  Modeling kinetics of compositions under sink and supersaturated conditions 
 
In acidic media, the enteric polymer is insoluble and ITZ release can only occur 
via diffusion through the polymer, assuming the system is completely miscible and no 
cracks or pores within the polymer exist.  Therefore, the dissolution release kinetics were 
modeled using the simplified Higuchi model which describes drug release as a diffusion 
process based on Fick’s law resulting in t1/2 dependence.[31]  It was assumed that the 
 154
system was planar and the matrix was homogeneous, since ITZ was completely miscible 
with the polymer at low concentrations.  The release is described by [32]: 
sst CCADtQ )2( −=      (3) 
where Qt is the amount of ITZ released in time t per unit area, D is the diffusion 
coefficient, A is the total amount of drug present in the matrix per unit volume, and Cs is 
the solubility of the drug in the matrix substance.  Eq. 3 can be expressed as the 
simplified Higuchi equation: 
2/1tKQ ht =       (4) 
where Kh is the Higuchi diffusion-related parameter.  The linear fit of the data suggested 
that the mechanism of diffusion through the polymer matrix is consistent with the data.  
Other kinetic models such as zero-order release and first order release gave poor fits of 
the data.  Only the Higuchi square root model for diffusion through the matrix offered 
acceptable correlation coefficients (R2>0.99) for ITZ release under acidic conditions.  
Eerikäinen et al. was able to accurately predict diffusional drug release of ketoprofen 
from an enteric solid dispersion using the Higuchi square root model.  Total ketoprofen 
release was estimated based on calculating the diffusion penetration depth in a 100 nm 
particle and the concentration of ketoprofen from within the nanoparticle.[21] 
 The plots based on the Higuchi square root model in Fig. 5.7b reveal  much less 
accurate fits for the high potency compositions (R2<0.94) indicating a release mechanism 
other than diffusion through the matrix occurs during the initial phase of dissolution.  
Based on the MDSC data it is predicted that the ITZ within the high potency 
compositions existed in a partially miscible state having domains rich in ITZ, and also a 
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significant amount of ITZ at the miscibility limit dissolved within the polymer.  The 
MDSC data confirmed the possibility of ITZ rich regions by revealing recrystallization 
exotherms.  Amorphous ITZ rich domains could readily dissolve within the acidic media 
because of their lower heat of solution and higher apparent solubility resulting in higher 
drug release rates during the initial phase of dissolution.  The dissolution of the ITZ rich 
domains could also create pores and channels for additional dissolution of ITZ rich 
domains within the core of the particle leading to higher percentages of ITZ dissolved.  
This possibility is supported by the dissolution profiles since they showed faster release 
rates in the first 45 minutes compared to the final hour and 15 minutes.  After dissolution 
of the ITZ rich domains, diffusion of ITZ from the polymer could continue to cause drug 
release, but at a slower rate as observed.   
5.6  CONCLUSION 
 
 Particles composed of ITZ and enteric polymer were manufactured using the ultra 
rapid freezing process to determine the importance of composition parameters such as 
ITZ:polymer ratio, enteric polymer type, and particle structure on modified drug release 
systems.  MDSC data revealed the ITZ solubility/miscibility limit within the enteric 
polymers HP-55 and L100-55 and were between 60-70% ITZ.  Completely miscible low 
potency (20% ITZ) and partially miscible high potency (80% ITZ) high surface area 
powders, prepared using the URF process, were found to be amorphous.  Compositions 
from 2% solids loading appeared to be a highly porous matrix structure while 0.2% solids 
loading created nanostructured domains.  For dissolution studies conducted at sink 
conditions in acid (i.e. non-eroding polymer condition), the matrix diffusion of ITZ in 
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completely miscible low potency powders showed Higuchi square root kinetics,  while 
partially miscible high potency powders exhibited additional diffusional mechanisms.  
Supersaturation dissolution studies, following USP guidelines for enteric release, were 
highly complimentary to the sink dissolution studies.  All low potency compositions 
produced very high C/Ceqmax ranging from 15-times to 19-times the equilibrium value, 
but the high saturation driving force produced rapid precipitation.  Relative to these 
compositions, the lower C/Ceqmax levels for all high potency compositions produced less 
precipitation, as shown in the greater cumulative supersaturation over time.  The behavior 
of the dissolution, under both sink and supersaturated conditions for these enteric solid 
dispersions is strongly influenced by the ITZ:polymer ratio, and to a lesser extent, the 
degree of polymer -API miscibility.   
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Table 2.1:  Summary of compositions and feed systems used to manufacture SFL 
processed powders 
Composition API (A) Exipient(s) (E) A:E ratio 
(A:E1:E2:E3) 









SFL B ITZ P407:T80 1:0.75:0.75 Organic co-
solvent (0.5% 
DCM in ACN) 
40% 0.9% 
SFL C ITZ T20:PVPK15 10:1:2 Organic co-
solvent (0.5% 




Table 2.2:  Mean particle size, specific surface area, and contact angle measurements for 
SFL processed compositions compared to micronized crystalline ITZ 






SFL A Feed Emulsion 0.76* 1.39 --- --- 
SFL A Powder 0.94 3.54 20.25 7.5 ± 0.5 
SFL B Powder 5.82 2.92 15.58 25.5 ± 2.5 
SFL C Powder 6.21 2.64 18.76 46.5 ± 3.5 
Micronized crystalline 
ITZ 
4.22 2.16 4.22 57.9 ± 2.4 
 
* Indicates average droplet size of feed emulsion 
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Sporanox® oral solution 1.59(0.03) 1.0 0.36 1.94 5.42 
SFL A 1.28(0.35) 2.0 0.51 1.36 4.56 
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Table 3.1:  Surface area and contact angles of the URF compositions investigated 
Composition Surface Area (m2/g) 
Contact Angle 
(°) 
URF 1:2 DAN:PVPK15 (in ACN) 25.93 30.5 ± 0.5 
URF 1:2 DAN:PVPK15 (in T-BUT) 29.33 32.5 ± 0.5 
Phys. Mix. 1:2 DAN:PVPK15 0.69 39.5 ± 4.5*,† 
Bulk DAN 0.52 64.0 ± 3.0*,† 





*=statistically different from URF 1:2 DAN:PVPK15 in ACN 
†=statistically different from URF 1:2 DAN:PVPK15 in T-BUT 
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Table 3.2:  Thermal and physical properties used to calculate tfreeze for ACN and T-BUT.   
Property ACNa T-BUTb 
k (W/m-K) 0.218 0.121 
ρ (g/cm3) 0.811 0.774 
Cp (J/g-K) 2.182 3.057 
α (cm2/s) 0.0012 0.00051 
Estimated tfreeze (ms) 61 483 
Measured tequil (ms) 70 1000 
a For ACN, the average values calculated at Tfreeze=229K and Ti =298K.   
b For T-BUT, the average values calculated at Tfreeze=298K and Ti=313K 
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Table 4.1:  Tacrolimus compositions produced using the URF process 
URF 
Composition 






URF-SDS  TAC SDS 1:1 1.00 
URF-PVA:P407  TAC PVA:P407 1:0.5:0.5 1.00 
URF-P407  TAC P407 1:1 1.00 
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Table 4.2:  Specific surface area of URF micronized compositions 
Composition Surface Area (m2/g) 
URF-SDS  54.96 
URF-PVA:P407  43.68 
URF-P407  7.73 
Bulk TAC 0.53 
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Table 4.3:  Maximum supersaturation and AUC ratios of URF micronized compositions compared to PRO for in vitro 
dissolution in acid media and dissolution according to USPXXV enteric test method A involving 0.1N HCl for 














Area Ratio to 
Prograf® 
(enteric) 
URF-SDS  20.9 ± 0.3 120 1.04 21.8 ± 2.7 135 1.18 
URF-PVA:P407  14.5 ± 3.3 60 0.45 12.0 ± 0.8 60 0.34 
URF-P407  22.8 ± 0.3 60 0.38 11.0 ± 1.2 60 0.32 
Prograf® 17.0 ± 1.7 240 1.00 13.8 ± 0.6 120 1.00 
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Table 4.4:  Pharmacokinetic parameters for URF micronized compositions and the commercially available tacrolimus product  
Composition Cmax 
(ng/mL) 







URF-SDS  65.2 ± 43.4 0.67 ± 0.4 7.5 ± 1.8 0.096 ± 0.0  223.6 ± 102.7 254.8 ± 113.3 77.1 
URF-PVA:P407  67.9 ± 11.7 0.5 ± 0.0 7.5 ± 1.4 0.095 ± 0.0 319.8 ± 138.2 348.6 ± 141.4 105.6 
URF-P407  138.5 ± 69.1 0.6 ± 0.2  6.9 ± 2.3 0.106 ± 0.0 450.6 ± 188.1 476.1 ± 187.1 144.2 
Prograf® 51.5 ± 19.8 1.3 ± 0.4 7.7 ± 1.8 0.094 ± 0.0 298.8 ± 83.2 330.2 ± 84.9 - 
AUC = area under the curve 
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Table 5.1:  Specific surface area for URF micronized powders containing ITZ and an 
















Bulk ITZ 4.22 
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Table 5.2:  Diffusion modeling correlation and diffusion coefficients for dissolution of 
URF micronized powders 







 Calculated Diffusion Coeff. (Dm) 
from Simplified Higuchi model (1 x 
10-13 cm2/min) 
1:4HP55(2%) 0.982 0.118 1.88 
1:4HP55(0.2%) 0.991 0.045 0.273 
1:4L100-55(0.2%) 0.990 0.011 0.017 
4:1HP55(2%) 0.939 - - 
4:1HP55(0.2%) 0.922 - - 
4:1L100-55(0.2%) 0.837 - - 
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Table 5.3:  Supersaturation data for URF micronized powders containing ITZ and enteric 
polymer 
Composition % Dissolved After 2 Hours in Acidic Mediaa 
C/Ceqmax AUCss 
(mg*min/mL)b 
1:4HP55(2%) 14.62 ± 0.63 19.67 17.58 ± 1.31 
1:4HP55(0.2%) 14.14 ± 1.63 17.45 22.41 ± 1.21 
1:4L100-55(0.2%) 5.26 ± 0.62 15.20 22.93 ± 3.21 
4:1HP55(2%) 23.85 ± 0.99 10.68 33.11 ± 2.02 
4:1HP55(0.2%) 14.49 ± 1.09 8.44 37.97 ± 1.08 
4:1L100-55(0.2%) 14.94 ± 1.14 9.27 35.45 ± 2.50 
a - Percent of total ITZ dissolved in gastric medium after two hours under supersaturated 
conditions (based on weight added) 
b – Area under curve at supersaturated conditions calculated via trapezoidal rule 
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Table A.1:  Compositions of URF feed solutions 
Active [A] Excipient 1 [E1] Excipient 2 [E2] Ratio [A:E1:E2] % Total Solids Solvent(s) 
DAN P407 PVPK30 4:3:3 0.5, 2.00 T-BUT 
DAN P407 PVPK30 6:2:2 0.5, 2.00 T-BUT 
DAN P407 PVPK30 9:0.5:0.5 2.00 T-BUT 
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Table A.2:  Surface area of the URF compositions investigated 
Composition URF (m2/g) Physical Mixture (m2/g) 
4:3:3 DAN:P407:PVPK30 23.69 1.24 
6:2:2 DAN:P407:PVPK30 30.87 1.34 
9:0.5:0.5 DAN:P407:PVPK30 27.59 1.53 
Bulk DAN - 0.52 
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Table A.3:  Contact angle of the URF compositions investigated 
Composition Contact Angle Processed Powder (°) 
Contact Angle Physical 
Mixture (°) 
4:3:3 DAN:P407:PVPK30 24.0 ± 1.0 26 ± 1.0 
6:2:2 DAN:P407:PVPK30 24.0 ± 1.0 26.5 ± 0.5 
9:0.5:0.5 DAN:P407:PVPK30 27.0 ± 0.75 39.5 ± 2.5 
Bulk DAN - 64.0 ± 3.0 
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Table B.1:  Analysis of extraction solvent in lyophilization/evaporation step using of 
spiked sample at a concentration of 2.2 µg/ml in JP1 medium (n=3) 
Reconstitution Solvent Average Total TAC 
Recovered 
Acetone 83.38% ± 0.85% 
75/25 (v/v) ACN/water 89.20% ± 2.64% 
50/50 EtOH/DCM 92.67% ± 3.26% 
Chloroform 83.06% ± 5.35% 
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Table B.2:  Analysis of extraction mixing method during lyophilization/evaporation step 
using spiked sample at a concentration of 2.2 µg/ml in JP1 medium 
extracted with EtOH/DCM (n=3) 
Extraction mixing method Average Total TAC Recovered 
1 washing aliquot 79.94% ± 7.11% 
3 washing aliquots 94.00% ± 1.08% 
Vortex 1 min 97.18% ± 5.81% 
Sonicate 5 min 98.04% ± 2.65% 
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Table B.3:  Effect of SPE cartridge packing and amount of recovery of TAC spiked 
sample at 2.2 µg/ml (n=3) 
SPE Cartridge % Total Recovered in 
1st mL 
Average Total  TAC 
Recovered 
DSC-18 (100 mg, C18) 95.14% 98.14% ± 7.58% 
JT-18 (100 mg, C18) 91.81% 95.28% ± 6.29% 
JT-8 (500 mg, C8) 81.15% 93.38% ± 3.09% 
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Table B.4:  Total recovery of high and low concentration spiked samples using DSC-18 
SPE cartridge (n=3) 
Spiked Concentration Average Total TAC 
Recovered 
2.2 µg/ml 100.66% ± 12.27% 
1.1 µg/ml 114.40% ± 1.68% 
0.22 µg/ml 71.18% ± 18.22% 
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Ratio Potency (%) % Total Solids Solvent(s)
Aqueous Work 
Up
1 Tacrolimus HPMC E5 1:1 50.00% 2.00% ACN:water (60/40) N
2 Tacrolimus HPMC E5:SDS 1:0.5:0.5 50.00% 2.00% ACN:water (60/40) N
3 Tacrolimus HPMC E5:SDS 1:0.8:0.2 50.00% 2.00% ACN:water (60/40) N
4 Tacrolimus HPMC E5:Polox 407 1:05:0.5 50.00% 2.00% ACN:water (60/40) N
5 Tacrolimus PVPK30:Polox 407 1:0.75:0.75 40.00% 2.00% ACN:water (60/40) N
6 Tacrolimus Lactose:SDS 1:05:0.5 50.00% 1.50% ACN:water (60/40) N
7 Tacrolimus Mannitol SDS 1:05:0.5 50.00% 1.50% ACN:water (60/40) N
12 Tacrolimus PVA 1:1 50.00% 1.00% ACN Y; PVA
13 Tacrolimus PVA:SDS 1:0.5:0.5 50.00% 1.00% ACN Y; PVA
14 Tacrolimus PVA:Polox407 1:0.5:0.5 50.00% 1.00% ACN Y; PVA
15 Tacrolimus NaCMC:Polox407 1:0.5:0.5 50.00% 1.00% ACN Y; NaCMC
16 Tacrolimus HPMC E5:SDS 1:0.5:0.5 50.00% 1.00% ACN Y, HPMC E5
17 Tacrolimus Docusate Na 1:1 50.00% 2.00% Acetone Y
18 Tacrolimus Docusate Na:Polox 407 1:0.5:0.5 50.00% 2.00% Acetone Y; Polox 407
19 Tacrolimus HPMC E5:Docusate Na 1:0.5:0.5 50.00% 2.00% Acetone:water (50/50) Y
20 Tacrolimus HPMC E5:Docusate Na 1:0.5:0.5 50.00% 2.00% Acetone:water (50/50) Y;HPMCE5
21 Tacrolimus NaCMC:Docusate Na 1:0.5:0.5 50.00% 2.00% Acetone:water (50/50) Y; NaCMC
22 Tacrolimus NaCMC:SDS 1:0.5:0.5 50.00% 2.00% ACN:water (60/40) Y; NaCMC
23 Tacrolimus NaCMC:PVPK30 1:0.5:0.5 50.00% 2.00% ACN:water (60/40) Y; NaCMC
24 Tacrolimus PVA 1:1 50.00% 1.00% ACN:water (40/60) N
25 Tacrolimus PVA:Polox 407 1:0.5:0.5 50.00% 1.00% ACN:water (40/60) N
26 Tacrolimus PVPK30:Polox407 1:0.75:0.75 40.00% 2.00% ACN:water (60/40) N
27 Tacrolimus PVPK30:PVA 1:0.5:0.25 57.14% 1.00% ACN:water (40/60) N
28 Tacrolimus PVPK30:Polox407:PVA 1:0.25:0.25:0.25 57.14% 1.00% ACN:water (40/60) N
29 Tacrolimus Lactose:SDS:PVA 1:0.25:0.25:0.5 50.00% 1.00% ACN:water (40/60) N
30 Tacrolimus SDS:PVA 1:0.1:0.4 66.67% 1.00% ACN:water (40/60) N





Table C.2:  Advantages and disadvantages of polymers/stabilizers considered for use in URF 
micronized powders containing tacrolimus 
Polymer/Stabilizer Advantages Disadvantages 
HPMC E5 LV •   Proven supersaturation 
•   High Tg 
•   Hydrophilic polymer 
•   Slow dissolver, 
swelling 
•   Patent protected 
PVP K30 •   Proven supersaturation 
•   High Tg 
•   Hydrophilic polymer, good 
wetting 
•   Hydroscopic 
(stability) 
•   Patented in dependent 
claim 
Poloxamer 407 •   Excellent wetting 
agent/surfactant 
•   Low Tg 
SDS •   Excellent wetting 
agent/surfactant 
•  High Tm and Tg 
•   Dissolved too quickly 
for comparable 
formulation 
Docusate Na •   Excellent wetting 
agent/surfactant 
•   High Tm and Tg 
•   Dissolved too quickly 
for comparable 
formulation 




•   Good stabilizer, High Tg 
•   Can slow down dissolution 
rate 
•   No mention in patents 
•   Unknown 
supersaturation 
Na CMC •   Good stabilizer, High Tg 
•   Can slow down dissolution 
rate 
•   Soluble only in water 
(aqu-workup only) 
•   Cellulose derivative 
(patent protected?) 
Lactose, Mannitol •   Hydrophilic, rapid 
dissolution 
•   Pore forming agent 
•   High Tm 
•   Wets too well 












Figure 1.1:  Nanoparticulate delivery systems for drugs within a core matrix 




Figure 1.2:  Dissolution profiles for: (◊) un-milled commercial NIF; (♦) NIF/HPMC, 10:1 
(w/w) physical mixture (mortar); (□) spray-dried formulation A (no 
milling); (■) spray-dried formulation A (Turrax® milling); (○) spray-dried 
formulation A (HPH milling); (●) Spray-dried formulation B (HPH milling).  
With permission from (Hecq et al., 2005) 
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Figure 1.3:  Effect of solid particle diameter on solubility for hypothetical examples (S: 
solubility at the surface of the particle; S0: intrinsic solubility).  With 
permission from (Kipp, 2004) 
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Figure 1.4:  Differences between nanoparticle (A) and microparticle (B) adsorption 
isotherms with corresponding adsorption models.  With permission from 
(Ponchel et al., 1997) 
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Figure 1.5:  For poorly-water-soluble compounds, the particle size of the drug crystals 
can affect bioavailabity.  The graph shows the plasma concentration time 
curve of a poorly-water-soluble discovery compound.  The compound was 
administered orally at an identical dose to fasted dogs as nanoparticles or as 
cruder dispersions.  The only variable was the mean particle size of each 
dispersion: 100 nm (♦); 500 nm (●); 2 microns (■); and 5 microns (   ).  






Figure 1.6:  a) Effects of sizes of polystyrene microspheres on the superoxide release 
from alveolar macrophages. Polystyrene microspheres with diameters of ♦, 
0.2; ◊, 0.5;▲, 1.0; ○, 6.0; ∆, 10.0 µm and ●, PBS- (control) were added to 
macrophages.  b) Effects of functional groups existing on the polystyrene 
microsphere surfaces on the superoxide release from alveolar macrophages. 
Polystyrene microspheres having ◊, primary amine; , sulfate;▲, hydroxyl; 
∆, carboxyl groups on their surfaces; ●, unmodified polystyrene 
microspheres, and ○, PBS- (control) were added to macrophages. With 











Figure 2.1:  Electron micrograph of SFL A (a), SFL B (b), SFL C (c), micronized 
crystalline ITZ 
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a.)          b.) 
 
c.)  
























Figure 2.4:  Dissolution of amorphous itraconazole prepared using the SFL process: 
Sporanox® oral solution ( ), SFL A (♦), SFL B ( ) SFL C (▲), micronized 























Figure 2.5:  Pharmacokinetic profiles of Sporanox® oral solution ( ), SFL A ( ), 





















Figure 3.2:  IR photographs of ACN droplet impinging and freezing on -60°C surface at 




a.)        b.) 
   
c.)        d.) 
 
Figure 3.3:  IR photographs of T-BUT droplet impinging and freezing on -60°C surface 










































Figure 3.4:  IR droplet intensity vs. time for ACN (a) and T-BUT (b)
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Figure 3.5:  X-ray diffraction patterns of URF processed DAN:PVP compositions 
compared to bulk DAN 
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a.)        b.) 
 
Figure 3.6:  SEM micrographs of URF processed 1:2 DAN:PVPK15 in ACN (a), URF 

























Figure 3.7:  Dissolution profile for URF processed 1:2 DAN:PVPK15 in ACN (●), URF 
processed 1:2 DAN:PVPK15 in T-BUT (■), 1:2 DAN:PVPK15 Physical 
mixture (○), Bulk DAN (X) 
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Figure 3.8:  Theoretical temperature profile of ACN droplet (a) on a cryogenic surface at 
10 ms (x), 20 ms (+), 30 ms (⁪), 40 ms (◊), 50 ms (○), 60 ms (…), 70 ms (_).  
Theoretical temperature profile of T-BUT droplet (b) on a cryogenic surface 




   
a)      b) 
 
   
c)      d) 
 





Figure 4.2:  X-ray powder diffraction of amorphous TAC compositions prepared using 
















Figure 4.3:  Supersaturated dissolution of tacrolimus in acidic dissolution medium: URF-




































Figure 4.4:  Supersaturated dissolution of tacrolimus under enteric conditions: URF-SDS 






Figure 4.5:  Mean whole blood absorption levels of TAC compositions produced using 
the URF process compared to the commercially available tacrolimus product.  Powders 
were given an gelatin capsule containing 1.5 mg equivalent TAC (5 mg/kg) dosed via 
oral gavage to a rat model: URF-SDS (■), URF-PVA:P407 (▲), URF-P407 (●), PRO (♦)
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Figure 4.6:  Possible hydrogen-bonding sites for tacrolimus: hydrogen-bond donor (∆), 







Figure 5.1:  Reverse heat MDSC profile for increasing potencies of URF micronized 
compositions containing a.) ITZ:HP-55 manufactured from 2.0% total solids 
feed b.) ITZ:L100-55 manufactured from  0.2% total solids feed.  Heat flow 




Figure 5.2:  Total heat flow MDSC for high potency URF micronized ITZ:HP-55 (2%) 









































Figure 5.3:  Measured glass transition (Tg) temperatures for increasing potencies of URF 
micronized compositions plotted vs. theoretical Tg calculated from Gordon 
Taylor equation, a.) ITZ:HP-55 from 2.0% feed (■); 0.2% feed (▲); 





Figure 5.4:  X-ray diffraction profiles for URF micronized powders containing binary 
mixtures of ITZ and a enteric polymer (% total solids in feed): (Bulk ITZ) 
bulk ITZ, (A) 4:1HP55(2%), (B) 1:4HP55(2%), (C) 4:1HP55(0.2%), (D) 
1:4HP55(0.2%), (E) 4:1L100-55(0.2%), (F) 1:4L100-55(0.2%)  
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a.)         b.) 
       
c.)         d.) 
       
e.)         f.) 
Figure 5.5:  Scanning Electron Micrographs of URF micronized powders containing 
binary mixtures of ITZ and a enteric polymer: (a) 4:1HP55(2%), (b) 
1:4HP55(2%), (c) 4:1HP55(0.2%), (d) 1:4HP55(0.2%), (e) 4:1L100-











































































Figure 5.6:  Sink dissolution profiles of URF micronized powders containing binary 
mixtures of ITZ and enteric polymer conducted in 0.1N HCl: a.) 
4:1HP55(2%) (♦), 1:4HP55(2%) (◊), bulk crystalline ITZ (X)  b.) 
4:1HP55(0.2%) (■), 1:4HP55(0.2%) (□), bulk crystalline ITZ (X)  c.)  









































Figure 5.7:  Higuchi square root diffusion model fitting of URF micronized powders a.) 
1:4HP55(2%) (◊), 1:4HP55(0.2%) (□), 1:4L100-55(0.2%) (∆); b.) 







Figure 5.8:  Supersaturation dissolution profiles of URF micronized powders containing 
binary mixtures of ITZ and enteric polymer conducted in 0.1N HCl for two 
hours and addition of 0.2M Na3PO4 with SDS (final SDS Conc. = 0.07%; 
USP enteric test method A): a.) 4:1HP55(2%) (♦), 1:4HP55(2%) (◊), 




Figure A.1:  X-ray diffraction patterns of processed DAN:P:407:PVP compositions 
compared to bulk DAN and the physical mixtures 
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Figure A.2:  Stability of processed DAN:P:407:PVP compositions after 6 months and 1 
year at 25C/60%RH in open containers 
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a.)               b.) 
        
c.)              d.) 
 
e.) 
Figure A.3:  SEM micrographs of URF processed powders from 2.0% total solids in feed: 
4:3:3 DAN:P407:PVPK30 (a), 6:2:2 DAN:P407:PVPK30 (b), 9:0.5:0.5 
DAN:P407:PVPK30 (c); SEM micrographs of URF processed powders 





















Figure A.4:  Dissolution profile for URF processed 9:0.5:0.5 DAN:P407:PVPK30 (●), 
URF processed 6:2:2 DAN:P407:PVPK30 (■), URF processed 4:3:3 
DAN:P407:PVPK30 (▲),9:0.5:0.5 DAN:P407:PVPK30 physical mixture 
(○),6:2:2 DAN:P407:PVPK30 physical mixture (□),4:3:3 











































Figure A.5 - Dissolution profile for URF micronized powders: a.)  4:3:3 
DAN:P407:PVPK30: Powder from 0.5% total solids loading in t-butanol 
(♦), Powder from 2.0% total solids loading in t-butanol (■), Physical blend 
(X). b.)  6:2:2 DAN:P407:PVPK30: Powder from 0.5% total solids loading 
in t-butanol (♦), Powder from 2.0% total solids loading in t-butanol (■), 























Figure B.1:  Dissolution profiles for enhanced URF micronized powders compared to 
Prograf® having 2 mg TAC equivalent in 900 mL JP1 medium: 1:0.75:0.75 
TAC:PVP:poloxamer 407 (■), 1:0.5:0.5 TAC:PVA:P407 (▲), 1:0.5:0.5 
TAC:LAC:SDS (●), Prograf® 5 mg powder (X) 
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1:0.5:0.5 TAC:Lactose:SDS (no aqu WU) 1:0.5:0.5 TAC: HPMC E5:SDS (no aqu WU)

























1:0.5:0.5 TAC:PVA:P407 (no aqu WU) 1:1 TAC:PVA 1:1 TAC:PVA (no aqu WU)





























1:0.5:0.5 TAC:NaCMC:PVPK30 1:0.5:0.5 TAC:NaCMC:P407
1:0.5:0.5 TAC:NaCMC:Docusate Na 1:0.5:0.5 TAC:NaCMC:SDS
 
c.) 
Figure C.1:  Dissolution studies conducted at non-supersaturated conditions organized by 






































Figure C.2:  Schematic of URF process with aqueous work-up post process 
 226
Appendix A:  Investigation of Increasing Potency Danazol Compositions 
Prepared by Ultra-rapid Freezing 
A.1  PURPOSE 
 
The purpose of this study was to investigate the effects of increasing danazol 
(DAN) potency on the physico-chemical properties and stability of URF micronized 
powders.  Compositions contained increasing API:polymer ratios while maintaining 
equal weight ratios of polyvinylpyrrolidone (PVP):poloxamer 407 (P407). 
A.2  MATERIALS AND METHODS 
 
A.2.1  Materials 
 
 Micronized danazol (DAN), sodium lauryl sulfate (SLS), poloxamer 407 (P407) 
and polyvinylpyrrolidone (PVP) K-15 were purchased from Spectrum Chemicals 
(Gardena, CA).  High performance liquid chromatography (HPLC) grade acetonitrile 
(ACN) was obtained from EM Science (Gibbstown, NJ), and tert-butanol (T-BUT) was 
purchased from Fisher Scientific (Fair Lawn, NJ). 
 
A.2.2  Preparation of URF Micronized Powders 
 
 The method for preparation of the URF micronized powders was outlined in 
section 3.3.2. 
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A.2.3  Scanning Electron Microscopy (SEM) 
 
 The method for scanning electron microscopy was outlined in section 3.3.5. 
A.2.4  Dissolution Studies 
 
 The method for dissolution testing was outlined in section 3.3.6. 
A.2.5  X-Ray Diffraction (XRD) 
 
 The method for X-ray diffraction was outlined in section 3.3.7. 
A.2.6  Surface Area Analysis (BET) 
 
 The method for surface area analysis was outlined in section 3.3.8. 
A.2.7  Contact Angle Measurement 
 
 The method for contact angle measurement was outlined in section 3.3.9. 
A.3  RESULTS 
 
Sample compositions included the non-ionic surfactant polymer P407 which has 
been shown to increase wetting of poorly water soluble APIs as well as PVPK30 to 
maintain physical stability of the samples.  Because of the high solubility of DAN in T-
BUT, the total solids content was increased to 2.0%.  The composition parameters can be 
seen in Table A.1.  Samples processed using the URF technology did not show any 
characteristic crystalline peaks for DAN indicating amorphous DAN present throughout 
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the sample as seen in Fig. A.1. These compositions were compared to the crystalline bulk 
DAN as well as physical mixtures of each of the compositions.  Peak intensities of the 
physical mixtures were reduced as each composition was diluted with the hydrophilic 
excipients.  As with the DAN:PVP compositions, sufficiently rapid freezing rates 
occurred, preventing crystallization of the API during the particle formation process.  
Long term stability was performed on the powders to determine the effectiveness of the 
polymers on preventing recrystallization of the DAN.  Samples were stored at 
25°C/60%RH and XRD was performed at 6 months and 12 months.  The 9:0.5:0.5 
DAN:P407:PVPK30 showed revealed crystalline DAN within 6 months while the 4:3:3 
and 6:2:2 DAN:P407:PVPK30 powders maintained their physical stability for at least 6 
months before crystalline DAN was observed after 1 year stability.   
Surface areas for all the URF processed powders are summarized in Table A.2 
and were considerably higher compared to the physical blends and the bulk DAN.  
Surface areas for the processed powders ranged from 22.94 m2/g to 30.25 m2/g and SSA 
improved 18 to 24 fold, respectively, compared to the physical mixture counterpart. 
However, the lower SSA for the higher potency samples was attributed to an increase in 
DAN loading in the feed solution leading to faster growth rates.  This is reasonable since 
a clear trend can be seen as SSA decreases as DAN loading increases.  Since all potencies 
of the URF processed powders maintained a 2.0% total solids loading, a substantial 
decrease in SSA was not seen as DAN potencies increased. 
While the SSA was high for all potencies, differences were seen in the surface 
morphology for all DAN:P407:PVP compositions.  For both the 40 and 60% DAN 
potency URF compositions (Fig. A.3a and A.3b, respectively), the surface morphology 
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consists of interconnected particles forming a larger highly porous aggregate.  However, 
for the 6:2:2 DAN:P407:PVPK30 composition, more necking and discrete particle 
formation was observed.  The micrograph of the 9:0.5:0.5 DAN:P407:PVPK30 processed 
powder (Fig. A.3c)  revealed less necking but included substantially more areas were 
discrete nanoparticles were formed. 
Dissolution studies of the URF processed powders revealed enhanced dissolution 
rates, even for the 90% DAN potency composition as seen in Fig A.4.  While the 
9:0.5:0.5 DAN:P407:PVPK30 composition had rapid wetting with nearly 95% of the 
powder dissolved after 2 minutes, all compositions were statistically similar after 5 
minutes with 100% DAN dissolved.  Physical mixture compositions revealed a slight 
increase in wetting compared to the bulk DAN.   The close proximity of hydrophilic 
polymers, P407 and PVP were able to further decrease the surface tension of the 
dissolution medium allowing for better solid-liquid interface between the medium and the 
hydrophobic regions of DAN.  Comparison of dissolution profiles of compositions 
manufactured from 0.5% and 2.0% total solids loading are seen in Figs. A.5a and A.5b 
for 4:3:3 and 6:2:2 DAN:P407:PVPK30, respectively.  Differences were observed in 
surface areas and surface morphologies for the compositions manufactured from the 
different solids loadings.  However, there were no differences observed in the dissolution 
profiles for these compositions. 
Contact angles for the DAN:P407:PVPK30 compositions are shown in Table A.3.  
The 40% and 60% DAN potency URF processed powders showed slight improvement in 
wetting compared to their respective physical mixtures with contact angles of 24.0° and 
24.0°, respectively.  However, the 90% potency DAN composition showed a reduction in 
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contact angle from 39.5° for the physical mixture to 27.0° for the URF processed powder 
compared to the physical mixture.  This is a statistically significant improvement 
(p<0.05) and helps support the improvement in dissolution rate for the high potency 
composition. 
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Appendix B:  Development of Solid Phase Extraction (SPE) Method for 
Analysis of Tacrolimus using High Performance Liquid 
Chromatography (HPLC-UV) 
 
B.1  PURPOSE 
 
  
The purpose of this study was to develop a technique for the analysis of 
dissolution rates of enhanced compositions of TAC at concentrations below the limit of 
quantitation (LOQ) such as under sink conditions using traditional analytical techniques 
such as UV spectrophotometry.  Dissolution studies performed under sink conditions are 
defined as addition of total amount of analyte to a given volume of medium is between 
10-33% of the equilibrium solubility of the analyte within the medium[1].  Performance 
under sink conditions is important for Biopharmaceutics Classification System (BCS) 
class II compounds to maintain a driving force for dissolution which is concentration 
independent.  Unfortunately, at sink conditions, the total concentration of TAC is below 
the LOQ for UV spectrophotometry due to the lack of chromophores in the TAC 
molecule.  Therefore, a concentration step must be incorporated to analyze TAC at lower 
concentrations.  In addition, transfer losses must be kept to a minimum to ensure 
accuracy.  Two concentration steps were developed, a lyophilization/concentration step 
and a solid phase extraction  (SPE) step.  Spiked samples at low (0.22 µg/mL) and high 
(2.2 µg/mL) concentrations were prepared.  Optimization of the 
lyophilization/concentration step included investigating various extraction solvents, as 
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well as mixing techniques.  Optimization of the SPE step included investigation of 
various SPE cartridges and extraction solvents. 
 
B.3  Materials and Methods 
 
B.3.1  Materials 
 
 Bulk crystalline tacrolimus and Prograf® (1 mg and 5 mg capsules, Fujisawa, 
Japan) were kindly provided by the Dow Chemical Company (Midland, MI, USA). 
Concentrated hydrochloric acid (HCl) and sodium chloride (NaCl) was purchased from 
Fisher Scientific Chemicals (Hampton, NH, USA).  Methanol (MeOH), acetone, 
dichloromethane (DCM), chloroform, and acetonitrile (ACN) were purchased from EM 
Industries Inc. (Gibbstown, NJ, USA).  200 proof ethanol, USP grade (EtOH) was 
purchased from Sigma-Aldrich (Milwaukee, WI, USA). All other solvents were of HPLC 
grade. 
B.3.2  Spiking of TAC 
 
A known amount of TAC was dissolved in acetonitrile and a known volume was 
added to Japanese First Media, 0.2% NaCl in 0.1N HCl (JP1).  Final spiked sample 
concentrations were between 0.22 µg/mL and 2.2 µg/mL (the estimated equilibrium 
solubility of tacrolimus) in JP1 medium[2]. 
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B.3.3  Lyophilization/concentration Procedure 
 
Spiked solution at a concentration of 2.2 µg/mL TAC in 5 mL JP1 medium at 
37°C was filtered using 0.45 µm filter GHP Acrodisc syringe filter (Pall, East Hills, NY, 
USA) into a 15 mL scintillation vial.  Samples were rapidly frozen by submersion into 
liquid nitrogen and lyophilized at -20°C for 24 hours, ramping to 25°C over 12 hours and 
held at 25°C for 12 hours at 100 mTorr.  After lyophilization, an extraction solvent was 
added to dissolve the TAC and transferred to 1.5 mL conical vial where the solvent was 
evaporated to dryness using pure nitrogen heated to 25°C.  Investigated extraction 
solvents were acetone, chloroform, 75/25 acetonitrile/water, and 50/50 
ethanol/dichloromethane (EtOH/DCM).  In addition, an extraction mixing method was 
investigated to determine an optimum extraction procedure based on percent total 
theoretical recovered.  These methods included single washing or three washing aliquots 
of 5 mL EtOH/DCM, vortexing a single washing aliquot of EtOH/DCM, or sonicating 15 
mL EtOH/DCM for 5 minutes. 
B.3.4  SPE procedure 
  
Spiked or dissolution samples were heated to 37°C and added to a pre-
conditioned SPE cartridge (Supleco, Bellefonte, PA, USA; (DSC); JT Baker, 
Phillipsburg, NJ, USA; (JT)).  Preconditioning was performed on new SPE cartridges by 
pulling and vacuum on the cartridge, adding 1 mL HPLC grade MeOH, allowing the 
liquid to drain, and repeated with 1 mL de-ionized water.  Without letting the cartridge 
come to complete dryness, the spiked sample was added to the cartridge.  The sample 
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was partially drawn through the substrate, allowed to sit for five minutes in order to allow 
the analyte to bind to the substrate, and then the solution was then collected under 
vacuum.  Two x 0.5 mL aliquots of ACN were added to the cartridge and drawn through 
at a rate of approximately one drop/second and collected in a 1.5 mL centrifuge vial 
(repeated twice).  Collected samples were evaporated to dryness under pure nitrogen at 
room temperature (TAC degrades at high temperatures) and reconstituted with 150 µL 
filtered 70:30 ACN:water.  The reconstituted samples were vortexed for 30 seconds and 
transferred to a HPLC 200 µL vial insert and analyzed according the method described in 
4.3.4.    
B.3.5  Sink dissolution testing 
 
 
Dissolution testing was performed on the TAC compositions, both Prograf® and 
URF micronized powders using a USP 24 Type II paddle apparatus model VK7000 
(Varian Inc., Cary, NC, USA).  An equivalent of 2 mg ITZ was added to 900 ml of 0.1N 
HCl containing 0.2% NaCl (JP1) dissolution media and stirred at 100 rpm.  The 
dissolution media was maintained at 37.0 ± 0.2°C.  Samples (5ml) were withdrawn at 30, 
60, 120 and 240 minute time points, filtered using a 0.45µm GHP Acrodisc filter, 
concentrated using the lyophilization/concentration step and the TAC was extracted with 
three washings of EtOH/DCM each vortexed for one minute.  These aliquots were 
transferred to a 1.5 mL conical vial and dried using nitrogen gas.  The residue was 
reconstituted with mobile phase and analyzed according the method described in 4.3.4. 
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B.4  RESULTS 
 
B.4.1  Optimization of Lyophilization/concentration step 
 
 The lyophilization/concentration step was developed as a simple and reproducible 
method for investigating dissolution profiles of TAC in which TAC was dissolved at 
concentrations below the LOQ of HPLC-UV.  Table B.1 shows differences in total TAC 
recovery of spiked samples of different extraction solvents.  It was shown that 
EtOH/DCM had sufficient TAC recoveries (>90%) while 75/25 ACN/water was very 
close with 89.20% TAC recovered.  TAC solubilities are higher in acetone (561 mg/mL) 
and chloroform (573 mg/mL) compared to EtOH (355 mg/mL) [3]; however, recoveries 
from acetone where lower because of poor peak resolution (absorbance of residual 
acetone at low wavelengths) and chloroform is a known carcinogen.  EtOH/DCM was 
chosen as the extraction solvent because of its higher recovery and its ability to dissolve a 
wider range of excipients used in URF processed solid dispersions, although, 75/25 
ACN/water could also be used when excipients are water soluble.   
 The extraction mixing method was also investigated to optimize the time for TAC 
recovery when many samples need to be analyzed; results are shown in Table B.2.  It is 
clear that multiple washings lead to higher recoveries; however, this method of extraction 
can be time consuming when many samples need to be analyzed.  Sonication can also 
lead to very high TAC recovery, but sonication also loosens the NaCl around the walls.  
High amounts of NaCl can lead to phase separation of ACN and water after reconstitution 
and was observed in the sonicated samples and proven experimentally.  Only the ACN 
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phase was collected via pipette and analyzed on HPLC.  In addition, 15 mL of 
EtOH/DCM were required to completely cover the lyophilized residue in the scintillation 
vials.  However, sonication is advantageous since many samples can be sonicated at one 
time and sonication only needs to be performed once in order to obtain high TAC 
recoveries.  Therefore, it was determined that vortexing multiple washings was preferred 
when few samples (> 20 samples) were analyzed while sonication is preferred when 
many samples (>20 samples) require analysis. 
B.4.2  Optimization of SPE concentration step 
 
 SPE is a useful step for concentration and purification of liquid samples which 
need to be analyzed either qualitatively or quantitatively.  In this study, C18 and C8 were 
selected as the SPE cartridge packing because of their effectiveness at binding to poorly 
water soluble compounds.  From Table B.3, it can be seen that both C18 and C8 are 
effective packing substrates since all samples have high average total TAC recovered 
(>90%).  Allowing for maximum binding of the TAC to the hydrophobic packing and 
slow addition of the extraction solvent allowed for high recoveries of TAC for all 
samples.  However, greater recoveries of TAC within the first mL of extraction solvent 
were seen from extraction using 100 mg packing cartridges.  It is unknown if these 
differences were attributed to the amount of packing or the packing substrate since 
cartridges containing 100 mg of C8 were not available for analysis.  Elution solvent 
(ACN) was not investigated since this solvent was recommended by the SPE cartridge 
manufacturers as an acceptable elution solvent for TAC.  However, recovery of both high 
and low concentration spiked samples were investigated to determine reproducibility of 
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the method at low concentrations to simulate early dissolution time points.  Aliquots of 5 
mL of 1.1 µg/ml spiked samples (total TAC = 5.5 µg) were recovered fully from the SPE 
cartridge while lower concentration spiked samples (0.22 µg/ml) were not fully 
recovered.  This is most likely due to the small fraction which could not fully be 
extracted from the cartridge before evaporation of the elution solvent occurred thereby 
trapping the residual TAC in the SPE cartridge.  Since this fraction is larger in the low 
concentration sample, lower percent recoveries are observed.  Future SPE studies should 
examine higher loadings of sample solution (10 mL to 15 mL) in order to reduce the 
fraction of TAC remaining in the SPE cartridge. 
B.4.3  Dissolution of Prograf® and URF micronized powders at low TAC loadings 
 
 An example of dissolution profiles for Prograf® and URF micronized powders 
can be seen in Fig. B.1.  Enhanced dissolution rates were observed for the URF 
micronized powders while Prograf® powder had a slower dissolution rate.  While not at 
sink conditions (2 mg TAC in 900 mL = 2.2 µg/mL = equilibrium TAC solubility), these 
dissolution profiles represent the ability to reproducibly analyze dissolution samples at 
concentrations below the LOQ for UV analysis. 
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Appendix C:  Performance of URF micronized powders containing a 
variety of stabilizers/surfactants for the dissolution enhancement of 
tacrolimus 
 
C.1  PURPOSE 
 
 The purpose of this study was to asses the performance of URF micronized 
powders using various stabilizers/surfactants to enhance the physico-chemical properties 
of compositions containing tacrolimus.  URF screen compositions were assessed based 
on dissolution profiles compared to Prograf® and to be selected for further analysis. 
C.2  MATERIALS AND METHODS 
 
C.2.1  Materials 
 
  Bulk crystalline tacrolimus, Prograf® (1 mg and 5 mg capsules, Fujisawa, Japan) 
and HPMC E5 LV were kindly provided by the Dow Chemical Company (Midland, MI, 
USA).  Polyvinylpyrrolidone (PVP), poloxamer 407 (P407), sodium 
carboxymethylcellulose (NaCMC), docusate sodium (DOC), lactose (LAC), and 
mannitol (MAN) were purchased from Spectrum chemical (Gardena, CA).  Poly(vinyl) 
alcohol (PVA, Mw 13,000-23,000, 87-89% hydrolyzed), hydroxypropyl cellulose (MW 
100,000; HPC) and sodium dodecyl sulfate (SDS) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). 
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C.2.2  Preparation of URF Micronized Powders 
 
 The process for manufacturing the URF micronized powders is outlined in section 
4.3.2.  Compositions which were manufactured are listed in Table C.1.  Briefly, TAC and 
the stabilizers (polymers) were dissolved in the solvent at the listed TAC:polymer ratio 
and % total solids loading.  The feed solutions were applied to a cryogenic solid substrate 
cooled to a temperature of -155°C, collected, and lyophilized using a VirTis Advantage 
benchtop tray lyophilizer (The VirTis Company, Inc. Gardiner, NY).  Compositions 
which underwent the aqueous-work-up method were applied to the solid substrate cooled 
to -155°C.  The frozen matter was added to a stirred water bath cooled to 2°C.  If a 
polymer was added to the cooled water bath, it was listed under the aqueous work-up 
column in Table C.1.  After addition of the frozen matter, the bath continued to stir while 
a dry nitrogen stream facilitated evaporation of the organic solvent.  After 30 minutes, the 
aqueous slurry was rapidly frozen in liquid nitrogen and lyophilized. 
C.2.3  Dissolution Testing 
 
 The dissolution studies were performed according to Japanese Pharmacopoeia 
(JPXIII) method 2 (paddle) for dissolution testing using a dissolution paddle apparatus 
model VK7000 (Varian Inc., Cary, NC, USA).  An equivalent of 5 mg TAC was added to 
900 mL of 0.005% HPC aqueous dissolution medium pH adjusted to 4.5 using H3PO4.  
The dissolution media was maintained at 37.0 ± 0.2°C and the paddle speed was 
maintained at 50 rpm throughout the testing period. 
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Samples (5 mL) were withdrawn at 30, 60, 90, 120 and 240 minute time points, 
filtered using a 0.20 µm Whatman nylon filter (Clifton, NJ, USA).  Subsequent 
concentration was performed using solid phase extraction according to section B.3.4 and 
analyzed using the HPLC method described in section 4.3.4.  
C.3  Results 
 
A complete search was conducted in order to determine optimum stabilizers 
which could enhance the dissolution profile for TAC while preventing the compositions 
from reading on any existing patents.  Possible stabilizers are listed in Table C.2 along 
with their advantages and disadvantages for dissolution enhancement.  Screen 
compositions containing various ratios and combinations of the stabilizers with 
tacrolimus were manufactured using the URF process with or without the aqueous work-
up method and are listed in Table C.2.   Dissolution studies were performed to assess the 
effect of the stabilizer combination on dissolution enhancement.  Dissolution profiles in 
Fig. C.1a contain compositions with SDS and all exhibit rapid dissolution except for 
1:0.4:0.1 TAC:PVA:SDS which has the lowest ratio of SDS of all the compositions.  Fig. 
C.1b contains dissolution profiles for URF compositions containing PVA.  Compositions 
with surfactants such as the block-copolymer P407 displayed rapid dissolution while 
compositions without surfactants showed poor wetting and slower dissolution profiles.  In 
addition, the effect of the aqueous work-up method was investigated using 1:1 TAC:PVA 
composition.  PVA was added either in the feed solution or in the cooled water bath and 
will be referred to TAC:PVA (no aq-wu) and TAC:PVA (aq-wu), respectively.  The 
dissolution rate for TAC:PVA (no aq-wu) was faster than TAC:PVA (aq-wu) as seen in 
Fig. C.1b.  PVA is widely known to be a stabilizing polymer having poor wetting 
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properties.  By incorporating the PVA into the aqueous work-up method, the PVA was 
added to the surface of the TAC domains.  This led to overall decreased wetting of the 
composition.  Fig. C.1c displays the dissolution profiles for URF compositions containing 
NaCMC.  Only compositions containing hydrophilic surfactants P407 or SDS had 
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